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Abstract 
Liver disease is a prevalent clinical challenge caused by a variety of factors including viral 
infections and xenobiotic overdose. Improving our mechanistic understanding of disease 
development will lead to an improved stratification of patients and ultimately a better 
prognosis. This thesis addresses the role of metabonomics in providing insight into a variety 
of preclinical models and a clinical study. The metabolic phenotype of preclinical models of 
paracetamol (APAP) and methotrexate (MTX) toxicity were characterised, together with the 
study of clinical samples from decompensated cirrhosis, acute on chronic liver failure (ACLF) 
and acute liver failure (ALF) patients. A comparative metabonomic approach was applied to 
study the metabolic consequences following administration of APAP and its non-hepatotoxic 
isomer; N-acetyl-m-aminophenol (AMAP), in mice. The analysis revealed an APAP-induced 
hepatotoxicity through mitochondrial dysfunction which was characterized by an 
upregulation of glycolysis as well as the inhibition of beta-oxidation and the Krebs cycle. The 
metabolic and toxic effects of MTX were investigated in healthy rats and in a model of non-
alcoholic steatohepatitis (NASH; as modelled by the methionine choline deficient diet). MTX 
was shown to have an enhanced toxicity in the context of NASH, which was associated with 
unique metabolic changes. The clinical work revealed that the serum metabolic phenotypes 
of clinical decompensated cirrhosis, ACLF and ALF patients were also each characterized by 
unique metabolic perturbations. The ALF phenotype was associated with the most metabolic 
changes and consisted of markers of oxidative and energetic stress, as well as markers of 
amino acid metabolism dysfunction. Subsequently, the novel serum metabolic profiling of the 
hepatic vein, hepatic portal vein and peripheral artery of patients during liver transplantation 
aimed to characterize the hepatic disease microenvironment, which was discovered to mainly 
consist of a perturbed amino acid metabolism. 
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Liver and liver disease 
The liver is a vital organ responsible for the metabolism of a vast number of lipid and water 
soluble molecules and consequently is the most metabolically active organ. In addition to its 
function as an important source of metabolites for organs, it also possesses a significant array 
of enzymes responsible for the detoxication and chemical modification of xenobiotic 
compounds. It is a very vascular organ which can receive up to a quarter of cardiac output 
through the hepatic artery (30 %) and the hepatic portal vein (70 %) (Abdel-Misih and 
Bloomston, 2010).  The hepatic portal vein also transports the products of digestion directly 
from the gastrointestinal (GI) tract to the liver, before they are transported to the rest of the 
body. As a result of its functions, the liver has a critical role in preserving homeostasis, either 
through supporting other organs or through the processing of potentially harmful 
compounds, including foreign compounds such as xenobiotics. A diagrammatic 
representation of the functional unit of the liver, the hepatic lobule, centred on the hepatic 
vein is presented in Figure 1.1. The hepatic lobule consists of the periportal (outer) region 
which is specialized for oxidative reactions including gluconeogenesis and β-oxidation, the 
midzonal (transitional) region, and the centrilobular (inner) region which has the lowest 
concentration of oxygen and contains the highest concentration of xenobiotic metabolizing 
enzymes, including the cytochrome P450 (CYP) enzymes (Thoolen et al., 2010). 
A dysfunctional liver can lead to severe health complications and even death. Therefore it is 
important to understand the underlying mechanisms of various liver diseases in order to 
improve our prognostic and diagnostic capabilities, as well as treatment efficacy and safety. 
There is a vast spectrum of liver diseases covering a variety of aetiologies, timescales and 
severities, all of which affect the metabolic capability and function of the liver to a different 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
25 
PhD thesis  Michael Kyriakides 
extent. According to the office of National Statistics, the incidence of liver disease has almost 
tripled in the past four decades, while liver disease was repsonsible for approximately 16,000 
deaths in 2008 in the UK alone, revealing a 4.5 % increase per annum. 
 
Figure 1.1: The structural units of the liver are depicted. The arrangement of the hepatic lobules within 
the liver is shown in A. The organization of the blood vessels and the oxygenation zones in each hepatic 
lobule is presented in B. 1 – 3 represent the periportal, midzonal and centrilobular zones respectively, 
as well as the relative extent of oxygenation in each zone. The periportal zone is the most oxygenated 
region while the centrilobular zone is the least oxygenated region. 
This thesis is focused on characterizing the metabolic phenotype arising from the underlying 
mechanisms of different liver conditions, as well as investigating the mechanism of drug 
induced liver injury, in healthy and disease-compromised livers. More specifically, the liver 
conditions relevant to this thesis are non-alcoholic steatohepatitis, decompensated cirrhosis, 
acute liver failure and acute on chronic liver failure, while the drug induced liver toxicities 
caused by paracetamol and methotrexate were also characterized. 
Non-alcoholic steatohepatitis 
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that is increasingly 
recognized as a significant health issue in the modern world. It is generally characterized by 
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hepatic fat accumulation (steatosis) and insulin resistance, while Type 2 Diabetes Mellitus 
(T2DM) is also present in many cases. NAFLD is a condition comprising of many different 
stages that can range from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, 
cirrhosis and hepatocellular carcinoma (Ali and Cusi, 2009, Nseir and Mahamid, 2013, Larter 
and Yeh, 2008). Its prevalence is estimated to be ~30 – 40% in the USA population (Ali and 
Cusi, 2009), while another study has reported that this disease affects ~ 27% of the Japanese 
adult population (Jimba et al., 2005). There are several risk factors associated with the 
development of NAFLD, including ethnicity, family history, as well as conditions such as T2DM, 
gut microbe activity and obesity, which are thought to double the likelihood of disease 
development and progression (Ali and Cusi, 2009, Farrell and Larter, 2006, Miele et al., 2013).  
NASH, first described by Ludwig et al., is a severe form of NAFLD whose main pathological 
characteristics include lobular inflammation, hepatocyte injury steatosis,  macrovesicular 
steatosis, hepatocyte ballooning (resulting from the accumulation of intracellular fluid) and 
insulin resistance (Ludwig et al., 1980, Leamy et al., 2013, Farrell and Larter, 2006, Larter and 
Yeh, 2008). The most accurate method of diagnosing NASH is by histological examination of 
hepatic tissue following liver biopsy and determining the presence of fibrosis, as well as using 
the recently developed NAFLD Activity Score (NAS), which consists of a scoring system of 14 
histological features. However, it is important to note that liver biopsies are associated with 
a significant health risk to the patient (Sanyal and American Gastroenterological, 2002). Other 
diagnostic tests include imaging techniques or inflammation tests can also be employed but 
it is difficult to distinguish between steatosis, NASH and cirrhosis through imaging, while 
clinical markers such as alanine aminotransferase (ALT) are not always reliable (Farrell and 
Larter, 2006). Even though NASH was originally considered to be primarily a disease of the 
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“West”, affecting around 8% of the USA population (McCullough, 2007, Farrell and Larter, 
2006), it is increasingly diagnosed in other parts of the world (Farrell and Larter, 2006). If left 
untreated, it can progress to cirrhosis in up to 15% of patients (Cheng et al., 2012) and a study 
has reported that NASH might account for ~13% cases of hepatocellular carcinoma (Adams 
and Angulo, 2005). The link between hepatocellular carcinoma and NASH is thought to lie 
primarily on the extent of the systemic metabolic disturbance and not the actual fibrotic 
physiological state of the liver. Furthermore, the importance of the systemic metabolic 
disturbance present in NASH was highlighted by a study which reported that NASH recurrence 
was detected after liver transplantation (Farrell and Larter, 2006).  
The exact mechanism by which NASH is developed has not been characterized yet but it is 
understood to be multifaceted.  A popular model for NASH development is the “two hit 
hypothesis”, first proposed by Day and James (Day and James, 1998, Leamy et al., 2013). It 
proposes that NASH develops after a first hit which is the result of an imbalanced fat 
metabolism and a second hit that involves the metabolic and oxidative stress resulting from 
the response of the cells (Day and James, 1998, Day, 2002). The imbalance in fat metabolism 
is linked to the fat accumulation in myocytes and the visceral adipose tissue, primarily 
because of obesity, which has been reported to lead to the release of adipocytokines that 
cause inflammation and also promote free fatty acid (FFA) synthesis and accumulation in the 
liver (Figure 1.2). FFA accumulation can be counteracted in the cell by incorporating FFAs in 
triglyceride molecules which would consequentially lead to an elevation of liver triglycerides, 
which is a characteristic of NAFLD (Schaffer, 2003). This is thought to be a protective 
mechanism of dealing with and disposing of excess FFAs, and studies have shown that an 
elevation of triglycerides is only associated with minimal liver injury (Leamy et al., 2013). 
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However, this solution might only apply to unsaturated FFAs (UFAs) since saturated fatty acid 
(SFA) molecules are less efficiently incorporated into triglyceride molecules (Leamy et al., 
2013). Previous experiments have revealed that the inhibition of an enzyme responsible for 
desaturating SFAs, stearoyl-coenzyme A desaturase-1 (SCD-1), led to a reduction in hepatic 
triglyceride content and a higher sensitivity to palmitate induced apoptosis (Li et al., 2009). 
This reaffirms that FFA triglyceride incorporation might protect against apoptosis and 
suggests that SFA molecules need to be desaturated before being used for triglyceride 
synthesis.  
A potential accumulation of SFAs in the liver is thought to have many detrimental effects, 
including hepatic insulin resistance. The proposed underlying mechanism involves the 
activation of protein kinase C which would impair the tyrosine phosphorylation that is 
required for physiological signalling of insulin receptors (Farrell and Larter, 2006). Other 
effects of SFA accumulation include endoplasmic reticulum (ER) and mitochondrial stress 
which have been observed in the livers of clinical patients suffering from NASH (Farrell and 
Larter, 2006, Sharma et al., 2008, Sanyal et al., 2001). Mitochondrial dysfunction is a hallmark 
in the development of NASH (Pessayre and Fromenty, 2005) and evidence for this include 
decreased amounts of hepatic mitochondrial DNA (Kawahara et al., 2007) and a drop in 
mitochondrial activity (Perez-Carreras et al., 2003, Fromenty et al., 2004). A resulting 
disturbance to the ER structure can affect its functionality, which involves the correct folding 
of proteins (Borradaile et al., 2006). In NASH, ER dysfunction is thought to be caused by the 
deposition of SFAs in the ER membrane, which primarily consists of unsaturated 
phosphatidylcholine (Deguil et al., 2011, Leamy et al., 2013). Finally, the disruption of 
mitochondria and the ER is also linked to an upregulation of C-Jun-N-terminal kinase (JNK) 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
29 
PhD thesis  Michael Kyriakides 
signalling which can lead to the assembly of the activator protein-1 (AP-1) complex, a family 
of pro-apoptotic transcription factors that bind to the AP-1 DNA binding site, leading to 
apoptosis (Cazanave et al., 2009). A summary of the effects of SFAs is presented in Figure 1.2. 
 
Figure 1.2: The two hit hypothesis and the role of FFAs in NASH. Fat metabolism imbalances, together 
with metabolic and oxidative stress, are thought to be the two hits that lead to NASH development. 
The proposed mechanism by which SFAs contribute to NASH development is also presented. FFA – 
free fatty acid; UFA – unsaturated fatty acid; SFA – saturated fatty acid; NASH – non-alcoholic 
steatohepatitis; pkC – protein kinase C; ER – endoplasmic reticulum. 
Apart from the health risk imposed by NAFLD and NASH, it is important to appreciate the 
potential effect of these conditions on drug biotransformation, clearance and transport 
(Fisher et al., 2009), which can lead to adverse drug reactions (ADRs). More specifically, drugs 
that are known to cause type A (predictable) ADRs might have a different effect when the 
pre-existing background of the liver reveals NAFLD or NASH (Hardwick et al., 2011, Wooten, 
2010). Previous investigations have demonstrated that general hepatic gene expression in the 
presence of NAFLD and NASH is altered (Rubio et al., 2007, Younossi et al., 2005), while gene 
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expression changes specific to ADME have also been observed in clinical studies (Lake et al., 
2011). Furthermore, other clinical studies have revealed changes in the activity and 
expression of enzymes that are important for xenobiotic metabolism. These include changes 
in the activity of hepatic CYP enzymes (Fisher et al., 2009), changes in the activity and mRNA 
levels of glutathione transferase (GST) enzymes (Hardwick et al., 2010), together with changes 
in the mRNA of efflux transport proteins (Hardwick et al., 2011). Any effects on the 
cytochrome P450 system are very important because of their involvement in 
biotransformation  and ability to create reactive metabolites, including the CYP450 mediated 
metabolism of paracetamol (Miner and Kissinger, 1979). Additionally, a decline in GST activity 
would compromise the cell’s capability to detoxify electrophilic reactive species through the 
conjugation with glutathione, which could result in hepatotoxicity. 
Non-alcoholic steatohepatitis and the methionine choline deficient diet 
Due to the significant prevalence of NASH and its potential effect on liver function, it is 
frequently the subject of investigations in in-vivo rodent studies (Tilg and Diehl, 2000, Kamada 
et al., 2007, Larter and Yeh, 2008).  There are several proposed NASH models that can be used 
for such investigations, including the use of hepatotoxins, promoting physical inactivity and 
dietary or genetic models (Romestaing et al., 2007, Xu et al., 2010, Larter and Yeh, 2008, 
Rinella et al., 2008). However, it has proven difficult to create an accurate model of this 
condition since it would require the replication of both the liver pathology and general 
metabolic environment of NASH. More specifically, a NASH model should ideally cause liver 
cell injury, steatosis, fibrosis, inflammation, in addition to insulin resistance, obesity and 
hyperglycemia (Larter and Yeh, 2008). Therefore, it is important to consider the limitations of 
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the existing NASH models for a more accurate interpretation of the results and the clinical 
translational relevance. 
A popular diet-based model is the methionine choline deficient (MCD) diet, which is the 
choline and methionine deficient analogue of a normal diet. Methionine is an essential amino 
acid that is involved in the biosynthesis of other metabolites including cysteine, S-
adenosylmethionine, taurine and phosphatidylcholine (Mato et al., 2008). Choline has many 
important physiological functions including the synthesis of phospholipids and acetylcholine, 
as well as cholesterol transport (Zeisel, 2004). The metabolisms of choline and methionine 
are inter-linked because betaine, an oxidation product of choline, can be used to methylate 
homocysteine to methionine (Selhub et al., 1991). Alternatively, methionine can also be 
formed through the methylation of homocysteine by methyl-tetrahydrofolate (Zeisel and 
Blusztajn, 1994).  
Mouse studies have shown that methionine free diets do not induce severe health 
complications despite the important physiological function of methionine, potentially 
because of an intracellular methionine conservation response (Tang et al., 2010). 
Furthermore, dietary methionine restriction has also been reported to have positive effects 
such as increasing the lifespan of rats and mice, rendering mice more resistant to drug 
induced oxidative stress, and controlling mouse cancer growth (Cavuoto and Fenech, 2012, 
Miller et al., 2005). In contrast to methionine, in-vivo studies investigating the effect of choline 
deficiency have observed decreased hepatic concentrations of choline, phosphatidylcholine, 
betaine and methionine (Pomfret et al., 1990). Intracellular efforts to replenish the choline 
pools have been previously suggested to lead to the breakdown of membrane lipids such as 
phosphatidylethanolamine (Pomfret et al., 1990). Such lipids have important roles in the 
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formation of lipid rafts, including their interaction with cholesterol, therefore a potential 
breakdown could also affect the cholesterol composition of membranes which would in turn 
have many negative knock on effects (Musso et al., 2013).  
The MCD diet has been traditionally employed to model NASH and its pathology has been 
well documented (Larter and Yeh, 2008, Pelz et al., 2012, Mu et al., 2010, Rinella and Green, 
2004). This diet leads to a condition similar to NASH which is characterized by steatosis, 
mitochondrial dysfunction, inflammation and oxidative stress (Caballero et al., 2010). 
Moreover, elevated levels of ALT and aspartate aminotransferase enzymes have been 
reported in rodent models (Li et al., 2011, Pelz et al., 2012), together with ER stress (Mu et 
al., 2012), increased CYP 2E1 expression (Weltman et al., 1996), altered drug transporter 
localization (Hardwick et al., 2011) and downregulation of SCD-1 (Miyazaki et al., 2001), all of 
which are in line with NASH. However, ER stress might not be essential for the formation of 
MCD diet induced steatohepatitis since it has been observed that reducing ER stress does not 
improve the condition in mice (Henkel et al., 2012).  
The exact mechanism by which the MCD diet causes a NASH like condition has not been 
described yet but impaired hepatic vLDL secretion is thought to play an important role (Rinella 
et al., 2008, Yao and Vance, 1988). This is supported by the role of methionine and choline as 
precursors to phosphatidylcholine, the main phospholipid coating of vLDL particles (Vance 
and Vance, 1985), through the Kennedy pathway (Gibellini and Smith, 2010). Another effect 
of the MCD diet is a decrease in the hepatic folate concentrations of rat livers by a factor of 
two, which would affect other metabolic pathways such as those of the nucleic acids , as well 
as further impact the formation of phosphatidylcholine (Zeisel and Blusztajn, 1994, Horne, 
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1989). Figure 1.3 presents the proposed mechanism by which the MCD diet induces a NASH 
like disease. 
 
Figure 1.3: The proposed mechanism through which the coupled deficiency of choline and methionine 
can lead to NASH is shown. 
As previously mentioned, it is important to acknowledge that the MCD diet has several 
limitations and differences from the clinical pathology of NASH. The liver histology induced 
by the diet resembles that of NASH but the metabolic phenotype is not replicated. More 
specifically, the MCD diet does not induce obesity, insulin resistance, and hyperglycemia 
(Larter and Yeh, 2008, Larter, 2007). Finally, animals on the MCD diet also suffer from 
significant weight loss and there is also evidence to suggest that the diet specifically affects 
male rodents to a greater extent (Rinella and Green, 2004, Kirsch et al., 2003). 
Drug induced liver injury 
Drug induced liver injury (DILI) refers to abnormalities in liver function tests related to the 
intake of medicinal compounds (Bleibel et al., 2007). It has been estimated that more than a 
thousand drugs have been associated with DILI on more than one occasion (Kaplowitz, 2004, 
Bernal and Wendon, 2013). Unfortunately the potential of a drug to cause DILI is often 
realised after it has been released onto the market and therefore DILI has been the single 
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most frequent reason for drug withdrawal from the market (Russmann et al., 2009). Part of 
the reason why DILI cannot be detected before market release is that there are various risk 
factors such as age, sex, underlying diseases, environmental factors or genetic predisposition 
that might not be accounted for during the drug clinical phase 3 trials which typically 
represent a relatively small individual cohort (Kaplowitz, 2004).  
The pathogenesis of DILI is believed to involve the interaction of a toxic drug or a drug 
metabolite, which either affects endocellular function or leads to an immune response 
(Kaplowitz, 2004). Furthermore, DILI can be characterised as intrinsic or idiosyncratic and the 
latter can be further subdivided into allergic or non-allergic. Intrinsic DILI is regarded to be 
dose-dependent and the symptoms usually develop within a few days due to direct toxicity 
from the xenobiotic or its metabolites (Pham, 1997). On the other hand, idiosyncratic DILI is 
more common and it is thought to be independent of the dose, route or duration of drug 
administration (Bleibel et al., 2007). Such cases are unpredictable, and potentially related to 
adaptive immune system reactions, as well as risk factors such as genetic predisposition, age, 
gender and alcohol status. Furthermore, the symptoms might also develop after a period of 
time (Uetrecht, 2007, Urban et al., 2012, Bleibel et al., 2007). Some intrinsic DILI causing drugs 
generally create signature diseases such as acute hepatitis (paracetamol, ritonavir, isoniazid), 
chronic hepatitis (diclofenac), fibrosis (methotrexate) and NASH (tamoxifen) but many drugs 
are also associated with more than one signature (Kaplowitz, 2004). 
Paracetamol 
Paracetamol, 4-Hydroxyacetanilide or N-acetyl-p-aminophenol (APAP) is an antipyretic and 
analgesic drug that was introduced in the USA and UK in the mid-twentieth century (Sneader, 
2005). It is very widely used and more than 170 million tablets of paracetamol or paracetamol 
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containing tablets were prescribed in the UK in June 2011 alone (NHS non-steroidal anti-
inflammatory drugs and analgesics national charts October 2011), while 24.6 billion doses 
were sold in the United States in 2008 (Krenzelok, 2009).  
The therapeutic effect of APAP resembles that of non-steroidal anti-inflammatory drugs 
(NSAIDs) and has been characterized extensively throughout the years (Botting, 2000, Hinz et 
al., 2008). Its therapeutic properties were believed to be linked to the disruption of 
prostaglandin synthesis through the inhibition of cyclooxygenases (COX) 1 and 2 in the brain 
(Flower and Vane, 1972, Mattamal, 1979, Ruud et al., 2013, Botting, 2000). Flower and Vane 
originally showed that the production of prostaglandin is ten times more sensitive in the brain 
when compared to the spleen (Flower and Vane, 1972) but this result has been disputed since 
(Warner et al., 2004, Hinz et al., 2008). Even though COX 1 and 2 were thought to be the 
original targets of APAP, as well as perhaps COX 3 which might be a splice variant of the COX 
1 gene, recent investigations suggest that the main effect of APAP is through COX 2 inhibition 
(Hinz et al., 2008, Botting, 2000).  
APAP is generally considered to be safe at therapeutic doses but it can cause hepatocellular 
damage at excessive doses, as documented approximately 10 years after its release (Davidson 
and Eastham, 1966, Mitchell et al., 1973). As a consequence of its toxic capabilities and 
widespread use, it has been the leading cause of acute liver failure in the developed world 
with respect to both intentional and non-intentional overdose (Lee, 2012b). This has led to 
an extensive study of its hepatotoxic properties and it is commonly referred to as a “model 
hepatotoxin”. Furthermore, the US Food and Drug Administration (FDA) recommended that 
physicians should avoid prescribing medication with a high APAP content due to the risk of 
liver injury (Mitka, 2014). Even though the liver is the main site of APAP toxicity, it can 
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additionally cause acute renal failure (ARF) (Blakely and McDonald, 1995), or other conditions 
such as cataractogenicity (Lubek et al., 1988) and lung malaises (Jeffery et al., 1988).   
APAP is a weak organic acid (pKa ~ 9.5), which is essentially non-ionised at physiological pH 
and is therefore rapidly absorbed by the duodenum after ingestion (McGill and Jaeschke, 
2013). The main site of APAP metabolism is the periportal region of the liver, where 
sulphation and glucuronidation are the major phase 2 conjugation reactions, since the 
conjugates are more soluble than the parent molecule. These reactions are the respective 
additions of sulphate or glucuronide moieties to the para-hydroxyl group on the aromatic ring 
and the resulting products are excreted through the urine or bile in most laboratory species 
and man, with the help of transporters (Bessems and Vermeulen, 2001, Tone et al., 1990, 
McGill and Jaeschke, 2013). The glucuronidation reaction is catalysed by UDP-glucuronosyl 
transferases (UGT) while the sulphation reaction is catalysed by sulfotransferase (SULT) 
enzymes. A human renal excretion study has shown that the majority of the excreted APAP is 
in the form of the glucuronide conjugate (Prescott, 1980) but there is significant intra- or 
inter-species, and gender variation in the production of each metabolite (Savides et al., 1984, 
Chen et al., 2003, Lee et al., 2009). Additionally, higher doses of APAP saturate sulphation 
capacity leading to a higher relatively proportion of the glucuronide conjugate (Tone et al., 
1990, Howie et al., 1977). It is also important to mention that the respective proportion of 
each metabolite is highly dependent on other factors, such as liver health. It has been 
reported that obese mice with steatosis had relative higher levels of the APAP-glucuronide 
conjugate, while microsomal fractions from humans suffering from steatosis had higher SULT 
enzyme activity and would therefore produce more of the sulphate conjugate (Hardwick et 
al., 2013). 
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 The critical biotransformation of APAP is catalysed by the CYP enzymes, which are expressed 
predominantly in the smooth endoplasmic reticulum of hepatocytes in the centrilobular 
region and in the kidneys to a smaller extent (Mohandas et al., 1981, Wrighton and Stevens, 
1992, Omiecinski et al., 1999). Different members of the CYP450 superfamily are thought to 
be involved but CYP 1A2, CYP 3A4 and CYP 2E1 are amongst the most important enzymes in 
humans, while CYP 1A2 and CYP 2E1 are most active in mice (Thummel et al., 1993, Hu et al., 
1993). This superfamily is responsible for oxidation of APAP to N-acetyl-p-benzoquinone 
(NAPQI), a metabolite considered to be responsible for toxicity, as first shown by Dahlin and 
Nelson (Miner and Kissinger, 1979, Dahlin and Nelson, 1982). Other products of CYP450 
catalysed reactions include the 3-hydroxyparacetamol and 3-methoxyparacetamol catechols 
(Forte et al., 1984, Bessems and Vermeulen, 2001), the latter of which has been reported to 
have a similar toxic potential as APAP (Forte et al., 1984).  An overview of APAP metabolism 
is presented in Figure 1.4. 
The exact mechanism by which NAPQI is formed is currently contested by different proposed 
theories and not much progress has been made in the past decades in terms of discovering 
the exact mechanism (Bessems and Vermeulen, 2001). Sidney D. Nelson originally presented 
a summary of the proposed mechanisms, which suggested that the first step involved an 
oxidation either at the amide nitrogen or hydroxyl oxygen of the paracetamol aromatic ring 
that would result to the formation of N-acetyl-p-semiquinone imine (NAPSQI) (Nelson, 1995). 
NAPSQI is a free radical that can have different resonance structures depending on the 
oxidation mechanism. It was further hypothesized that the oxidation reaction at the amide 
nitrogen is more likely because of the orientation of the molecule within the active site of the 
enzyme, since a re-orientation would be required if the oxidation occurred at the oxygen 
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atom of the phenol (Nelson, 1995). However, Koymans et al. used energy calculations and 
spin distributions to conclude that the formation of the phenoxy radical is more energetically 
favourable and it is therefore the most likely mechanism of NAPQI and NAPSQI formation 
(Koymans et al., 1989). In spite of the previously conducted research concerningK the 
mechanism of NAPQI formation, there is a possibility NAPQI is not formed through the 
NAPSQI intermediate, since the formation of NAPSQI has not yet been proven experimentally 
potentially due to its chemical instability (Bessems and Vermeulen, 2001). 
There are several different proposed mechanisms by which NAPQI can cause toxicity but the 
main pathways are considered to be through protein thiol oxidation and protein arylation.  
The electrophilic properties of NAPQI allow it to form covalent bonds with proteins, leading 
to protein arylation (Gibson et al., 1996), while it can also oxidise the exposed thiol groups of 
proteins leading to inter-strand disulphide bridges, cross-linking between proteins or covalent 
binding between proteins and glutathione (GSH) (Bessems and Vermeulen, 2001). The 
covalent binding of NAPQI to hepatic proteins was conclusively linked to APAP-induced 
hepatotoxicity by Hinson et al. (Hinson et al., 1996), who revealed that protein adduct 
formation reached a maximum after one hour and necrotic cells were present by six hours. 
Protein arylation is disruptive because a change in protein structure can impede the normal 
function of a protein and lead to loss of cellular homeostasis once proteins with important 
functions have been affected (Gibson et al., 1996, Cohen and Khairallah, 1997).  
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Figure 1.5: An overview of the hepatic metabolic pathways of APAP metabolism are depicted above. 
The majority of the compound will undergo the glucuronidation and sulphation reactions. A small 
portion will undergo an oxidation reaction leading to the formation of NAPQI. NAPQI can be 
neutralized by binding to glutathione and the resulting product is eliminated in the urine via the 
mercapturic acid pathway. APAP can also undergo a hydroxylation reaction, leading to the catechol. 
Further investigations have studied the binding of NAPQI to proteins in specific cellular 
compartments such as the microsomes, cytosol and mitochondria. In the cytosol, NAPQI was 
shown to bind to N-10-formyltetrahydrofolate dehydrogenase (Pumford and Halmes, 1997), 
GST (Wendel and Cikryt, 1981) and glyceraldehyde-3-phosphate dehydrogenase (Dietze et al., 
1997). NAPQI binds to GST in the microsomes as well, while calreticulin is also another 
microsomal target protein that was identified in murine liver incubations (Holtzman, 1995). 
Many mitochondrial proteins have also been identified as targets of NAPQI, including 
glutamate and aldehyde dehydrogenases (Landin et al., 1996, Halmes et al., 1996) and the 
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ATP-synthase α subunit (Hinson et al., 2010). It is important to note that currently there isn’t 
any direct evidence that selective inhibition of protein binding will nullify the hepatotoxic 
effects of APAP (McGill and Jaeschke, 2013). 
NAPQI can also affect lipid metabolism by inhibiting β-oxidation and initiating lipid 
peroxidation. It blocks the transportation of acyl-carnitine molecules (fatty acid and carnitine 
conjugates) into the mitochondria, which results in an inhibition of mitochondrial β-oxidation 
(Chen, 2009, McGill et al., 2014a). The initiation of lipid peroxidation is not thought to be 
directly induced by NAPQI but NAPQI could be involved in the production of superoxide 
anions through futile redox cycling of CYP450 enzymes (Younes et al., 1986, Mourelle et al., 
1990). NAPQI has additionally been reported to have nuclear effects, in mammalian in-vitro 
studies where high doses of APAP interfered with nucleotide excision repair in keratinocytes 
(Skorpen et al., 1998), as well as inhibiting DNA synthesis by interfering with the function of 
ribonucleotide reductase (Hongslo et al., 1994). However, it can be argued that the 
characterised nuclear effects are simply another consequence of NAPQI protein adduct 
formation and therefore could be classified as an indirect downstream effect. A summary of 
the mechanisms by which NAPQI can cause endocellular toxicity is presented in Figure 1.5. 
Mitochondrial dysfunction 
The aforementioned effects of NAPQI, in addition to other unknown mechanisms, lead to a 
general disruption of cellular processes and especially mitochondrial function. APAP-induced 
toxicity alters the morphology of mitochondria and leads to mitochondrial oxidative stress, 
lower respiration rates and depletion of the ATP pool (Katyare and Satav, 1989, Placke et al., 
1987). It has been observed that mitochondrial damage can be detected in mice in-vivo at an 
earlier time-point than other signs of toxicity and therefore it has been hypothesized that 
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mitochondrial dysfunction is an important milestone for APAP-induced toxicity (Meyers et al., 
1988, Ramsay et al., 1989, Stamper et al., 2010, McGill et al., 2012a). Moreover, a recently 
published study suggested that mitochondrial damage was directly correlated to the mortality 
of acute liver failure in APAP overdose patients (McGill et al., 2014b).  
 
Figure 1.5: The effects of NAPQI are depicted. NAPQI has the ability to modify proteins through thiol 
oxidation or protein arylation and cause glutathione depletion. Examples of known protein targets of 
NAPQI and their respective endocellular compartments of NAPQI are also depicted. APAP – N-acetyl-
p-aminophenol; NAPQI – N-acetyl-p-benzoquinoneimine. CYP – cytochrome P450 enzyme. 
Oxidative stress is considered to be crucial for the induction of mitochondrial dysfunction and 
mitochondrial death. In addition to protein thiol oxidation by NAPQI, peroxynitrite formation 
can also lead to the deterioration of mitochondrial function (Jaeschke et al., 2012, Knight et 
al., 2002). Peroxynitrite is thought to be formed through the reaction of nitric oxide with 
highly reactive superoxide anions (Radi et al., 2001), while it is also possible that the up-
regulation of nitric oxide synthases, such as inducible nitric oxide synthase (iNOS), is also a 
contributing factor (Gardner et al., 1998). Previous investigations have shown that 
peroxynitrite is formed inside the mitochondria of hepatocytes after APAP administration 
(Cover et al., 2005) and  that it can cause extensive damage by binding to mitochondrial 
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proteins, leading to the formation of nitrotyrosine adducts (Agarwal et al., 2011), as well as 
damaging mitochondrial DNA (Cover et al., 2005). Furthermore, additional oxidative stress is 
thought to be caused by the translocation of activated JNK into the mitochondria, through 
the activation of mixed lineage kinase 3 (MLK3) and apoptosis-signal regulating kinase 1 
(ASK1) (McGill and Jaeschke, 2013, Saito et al., 2010a). 
An important detrimental effect of oxidative stress is the formation of the mitochondrial 
permeability transition (MPT), which is a significant and abrupt increase in the mitochondrial 
membrane permeability that allows molecules of smaller than 1500 Da to enter the 
mitochondrion. This leads to loss of membrane potential, uncoupling of oxidative 
phosphorylation and increase of mitochondrial volume (Masubuchi et al., 2005). MPT also 
causes the collapse of the mitochondrial membrane and the subsequent release of 
mitochondrial pro-apoptotic intra-membrane proteins, such as apoptosis inducing factor, 
cytochrome C, and endonuclease G, which are responsible for the characteristic nuclear DNA 
fragmentation seen after APAP hepatotoxicity (Jaeschke, 2008, Bajt et al., 2006).  
Apoptosis versus necrosis 
There used to be a discrepancy in the literature whether apoptosis, necrosis or a combination 
of the two is the predominant mechanism of hepatocyte death following APAP induced injury.  
It was initially reported that both necrosis and apoptosis (3:2 ratio) were observed after APAP 
toxicity (Ray et al., 1996), while other investigations also reported that mild APAP toxicity 
leads to apoptosis (Hu and Colletti, 2010). Apoptosis is thought to be promoted by the release 
of mitochondrial pro-apoptotic factors, such as cytochrome C and caspase enzymes. 
However, the current general consensus is that the predominant mechanism of cell death is 
necrosis (Gujral et al., 2002, Schulze-Osthoff and Bantel, 2011, Hinson et al., 2010). Apoptosis 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
43 
PhD thesis  Michael Kyriakides 
is an energy dependent process, while APAP-induced toxicity is characterized by a depletion 
of ATP, which suggests that apoptosis would have a smaller role during APAP-induced 
hepatotoxicity (Antoine et al., 2010, Schulze-Osthoff and Bantel, 2011). The reliance of 
apoptosis on the energy status of the cell during APAP-induced toxicity has been previously 
demonstrated in fasted mice after APAP administration, where the majority of the 
hepatocytes were undergoing necrosis and not apoptosis (Antoine et al., 2010). 
Glutathione and N-acetylcysteine 
Endogenous GSH, a tri-peptide consisting of glycine, glutamate and cysteine, is the cell’s 
defence mechanism against oxidative stress agents and its depletion is a classic marker of 
oxidative stress. GSH can bind to NAPQI to form an APAP-SG conjugate or reduce NAPQI back 
to its original form, which will lead to the oxidation of GSH to oxidized glutathione (GSSG) 
(Rashed et al., 1990). APAP-SG undergoes several reactions in the intestine and kidney before 
its excretion (Newton et al., 1986). Initially the glutamate group is removed, followed by the 
removal of the glycine molecule, leading to the production of APAP-cysteinyl (APAP-Cys). This 
molecule can be further metabolized by microsomal N-acetyltransferase to from the 
mercapturate; APAP-N-acetyl-cysteinyl (APAP-NAC) (Tate, 1980). An overdose of APAP will 
lead to the irreversible depletion of hepatic GSH stores, leading to incomplete neutralization 
of NAPQI molecules (Mitchell et al., 1973).  
Cysteine availability is the rate-limiting step in GSH formation and therefore N-acetyl cysteine 
(NAC) is given to APAP overdose patients clinically in order to promote GSH synthesis and 
NAPQI neutralization, even though the exact mechanism for its therapeutic action has yet to 
be elucidated (Saito et al., 2010b).  NAC has been reported to attenuate the expression of 
pro-inflammatory cytokines (Bemeur et al., 2010) and reduce renal inflammation (Ucar et al., 
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2013); therefore its therapeutic effects extend beyond GSH regeneration. However, a 
previous study in mice has demonstrated that NAC supplementation leads to an elevation of 
hypotaurine, instead of GSH, levels and has therefore questioned the usage of NAC for 
replenishing endocellular GSH stocks (Zwingmann and Bilodeau, 2006). Moreover, 
administration of NAC is also associated with adverse effects such as vomiting and as a result 
anti-emetics have to be co-administered, but these effects might be minimized by changing 
its dose regimen (Bateman et al., 2013). Finally, it is also important to note that other 
treatments that can be used to replace cysteine, such as methionine and S-
adenosylmethionine, have also been shown to have a similar effect to NAC in rodents (Pratt 
and Ioannides, 1985, Michael et al., 2012). 
N-acetyl-m-aminophenol 
N-acetyl-m-aminophenol (AMAP) is a structural isomer of APAP, with a 3’ hydroxyl group. It 
was originally reported to have similar therapeutic properties in mice and cause significantly 
less toxicity to mice and hamsters in-vivo as well as hepatocytes in-vitro (Nelson, 1980, 
Roberts, 1978, Salminen et al., 1997). Unlike APAP, AMAP is metabolized to a methoxylated 
molecule or two different catechols before the CYP catalyzed formation of quinone reactive 
molecules. The methoxylated molecule is also a metabolite of APAP but it is postulated that 
not enough is formed during AMAP metabolism for severe hepatotoxicity to occur (Rashed 
and Nelson, 1989b, Rashed et al., 1990, Streeter et al., 1984, Hamilton and Kissinger, 1986). 
It has not yet been elucidated which CYP enzymes catalyse the oxidation of AMAP but it is 
believed that there are at least two different enzymes in mice (Forte et al., 1984), including 
CYP 2E1 (Halmes et al., 1998). A summary of AMAP metabolism is presented in Figure 1.6. 
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Reactive metabolites resulting from AMAP metabolism have been demonstrated to be as 
potent as NAPQI in terms of their ability to covalently bind to proteins (Holme et al., 1991). It 
is believed that they bind to proteins close to the point of formation away from the 
mitochondria (Pumford and Halmes, 1997) as supported by evidence that AMAP derived 
reactive metabolites form adducts with cytosolic and microsomal proteins to a much greater 
extent than mitochondrial proteins in-vivo (Tirmenstein and Nelson, 1989, Myers et al., 1995). 
Additionally, AMAP has been shown to decrease cytosolic GSH levels but it had no effect on 
mitochondrial GSH levels, further suggesting that its reactive metabolites do not enter the 
mitochondria and do not cause mitochondrial dysfunction (Tirmenstein and Nelson, 1991, 
Myers et al., 1995, Roberts et al., 1990).  
Several investigations have recently focused on the contrasting toxicities and effect of these 
two compounds. In-vivo gene expression studies have revealed that AMAP had a smaller 
effect on gene expression when compared to APAP, and APAP uniquely affected genes 
associated with the cell cycle, protein kinase cascades, cell death, inflammation and 
biopolymer metabolism (Beyer et al., 2007, Priyadarsiny et al., 2008). These results are in line 
with the hypothesis concerning the contrasting underlying mechanisms of toxicity of the two 
compounds. However, there have also been studies which question the hypothesis 
concerning the contrasting toxicity of AMAP. An in-vitro study revealed that AMAP was more 
toxic in rat and human liver slices than APAP and have therefore questioned whether AMAP 
should be considered as a non-toxic isomer (Hadi et al., 2013). Furthermore, a recent 
computer simulation (DILIsym) suggested that the contrasting toxicities of these two is due 
to the different amounts of reactive metabolite produced by each compound and not due to 
mitochondrial binding (Howell et al., 2014). The decreased burden of AMAP reactive 
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metabolites, relative to APAP, may arise from the reported inhibition of CYP 2E1 enzymes by 
the reactive metabolites of AMAP (Halmes et al., 1998).  
 
Figure 1.6: An overview of the hepatic metabolic pathways of AMAP metabolism are depicted above. 
The majority of the compound will undergo the glucuronidation and sulphation reactions and a 
portion will also undergo hydroxylation and subsequent oxidation reactions leading to the formation 
of reactive quinones that can cause protein arylation. AMAP – n-acetyl-m-aminophenol; CYP – 
cytochrome P450 enzyme. 
Methotrexate  
The folate cycle has a very important role in endocellular metabolism and in particular the 
one carbon, amino acid and nucleotide metabolic pathways. It involves the reduction of the 
pyrazine ring constituent of the folate pterin ring to its active tetrahydro form, the addition 
of glutamate moieties by gamma linkage and the oxidation or reduction of one carbon 
metabolites (Bailey, 2009). There are three tetrahydrofolate (reduced) molecules which have 
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an important role as one carbon donors in the formation of DNA precursors through the 
donation of their methyl groups; 10-formyltetrahydrofolate, 5,10-methylenetetrahydrofolate 
and 5-methyltetrahydrofolate (Kremer, 2004). Since mammals lack the capability of 
synthesizing the constituents of the folate cycle de novo they rely on dietary sources (Bailey, 
2009). 
Amethopterin, 4-amino-N-10-methylpteroylglutamic acid or methotrexate (MTX) is a folate 
analogue that inhibits folate metabolism. It was originally used as a replacement to 
aminopterin for the treatment of acute lymphoblastic leukemia by disrupting the function of 
dihydrofolate reductase (DHFR) (Meyer et al., 1950, Farber et al., 1956) through competitive 
inhibition. DHFR catalyzes the reduction of dihydrofolate to tetrahydrofolate, which is an 
integral component of the folate cycle. Due to the potency of MTX in leukemia treatment 
through the inhibition of DHFR, it was tested with other forms of cancer and other diseases 
(Khan et al., 2012) and was discovered to also inhibit other enzymes such as 
phosphoribosylaminoimidazolecarboxamide formyltransferase (AICAR transformylase) and 
amidophosphoribosyltransferase (Fairbanks et al., 1999, Schroder, 2003). Currently, it is 
widely used for the treatment of malaises such as neoplastic malignancies, rheumatoid 
arthritis, psoriasis or as a general immunosuppressant and anti-inflammatory drug (Genestier 
et al., 2000, Khan et al., 2012).  It was the most popular prescribed anti-rheumatic drug in the 
UK in the period of 2006-2011, according to NHS statistics (NHS NSAIDS and Analgesics 
National Charts October 2011). 
MTX is a weak acid with two carboxylic acid groups located on its glutamate moiety. It has a 
pKa value of approximately 5.0, a low membrane permeability and a low aqueous solubility 
(0.01 mg/ml) (Kasim et al., 2004) and as a result it primarily relies on carrier proteins to enter 
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the cell (Genestier et al., 2000, Khan et al., 2012). There are at least two different folate 
transporter receptors; a low affinity reduced folate carrier or a glycoprotein known as the 
folate-binding protein (FBP), which can transport MTX into the cell. Even though FBP is a more 
efficient transporter of MTX, it has a much higher affinity for reduced folates (Genestier et al., 
2000). At high concentrations MTX can also diffuse passively through the cell membrane 
(Jansen et al., 1990, Goldman and Matherly, 1985). The ability of MTX to undergo passive 
diffusion is important in the case of mutant cells which do not have active transporters 
(Genestier et al., 2000). Removal of MTX from cells is believed to be primarily an active 
process and it relies on transporter proteins classified as the multidrug resistance-associated 
proteins, such as p-glycoprotein or the ATP-binding cassette proteins (more specifically Abcc2 
and Abcc3) (Kremer, 2004, Wang et al., 2011). Crucially, the expression of these proteins can 
vary in cells and is therefore one of the most important mechanisms of tumour resistance to 
MTX (Wang et al., 2011, Genestier et al., 2000). 
Tumour cell experiments have shown that once inside the cell, MTX can undergo 
polyglutamation reactions in the cytosol. These involve the sequential addition of glutamate 
molecules to the terminal glutamate moiety through a gamma linkage, catalysed by the 
enzyme folypolylglutamyl synthetase (Figure 1.7) (Barrueco et al., 1992). This leads to 
accumulation of MTX molecules since the conjugated product cannot be as easily transported 
out of the cell (Fry et al., 1983). There is a direct relationship between the number of 
conjugated glutamate residues and the resulting conjugate’s cell membrane permeability 
(Genestier et al., 2000). It has been demonstrated that the polyglutamate conjugate of MTX 
that consists of five glutamate moieties can remain within cells for at least twenty four hours 
after the removal of the circulating drug (Genestier et al., 2000). Hydrolase enzymes can 
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cleave the glutamate residues so that MTX can be more easily transported out of the cell 
(Kremer, 2004). The polyglutamate conjugates of MTX also have inhibitory capabilities and 
were discovered to inhibit AICAR transformylase (Allegra et al., 1985b), as well as thymidylate 
synthase (Allegra et al., 1985a). The endocellular accumulation of the polyglutamate 
conjugates, coupled to their ability to inhibit enzymes, are both very important factors in the 
disruption of endocellular folate metabolism (Genestier et al., 2000). 
In humans, the majority of MTX seems to undergo a hydroxylation reaction at the 7-position 
of the pterine ring in the liver to form the 7’ hydroxyl derivative (7-OH-MTX) (Figure 1.7) 
(Jacobs et al., 1976). This reaction is either catalysed by aldehyde oxidase or xanthine oxidase 
and there is a significant inter-species variability in the role played by these phase 1 enzymes 
(Moriyasu et al., 2006, Jordan et al., 1999). The hydroxylation reaction is considered to be a 
detoxication step and the resulting product is not as potent an inhibitor as the 
polyglutamation conjugates. However, 7-OH-MTX can also be converted to a polyglutamate 
conjugate at a higher rate than the parent molecule and could therefore inhibit enzymes in 
its polyglutamate form (Genestier et al., 2000, Fabre et al., 1983). Finally, MTX can also be 
excreted via the bile to the intestinal tract where it is converted to diamino-2,4-N-10-
methylpteroic acid (DAMPA) by bacterial carboxypeptidases, before DAMPA is reabsorbed 
again (Widemann et al., 2000). Studies have shown that DAMPA is a less potent inhibitor of 
DHFR than the parent molecule, so this reaction might be a detoxication pathway (Valerino 
et al., 1972). Excretion of MTX and its metabolites occurs primarily through the urine through 
active tubular secretion or glomerular filtration (Reich et al., 1977). This process can be 
affected by other factors including the use of non-steroidal anti-inflammatory drugs (NSAIDs), 
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which can interfere with MTX excretion and lead to a rise in serum levels (Schroder, 2003). 
An overview of MTX metabolism is presented in Figure 1.7. 
 
Figure 1.7: Summary of known MTX metabolism. MTX can undergo hydroxylation reactions to form 
the 7-hydroxy derivative (7-OH-MTX) or polyglutamation reactions to form the polyglutamate 
conjugate (MTX-(Glu)n). MTX can also be excreted to the intestine where its glutamate moiety is 
cleaved by bacterial enzymes to form DAMPA. R1 = H, R2 = OH. 
As a result of its potency in disrupting folate metabolism MTX has a variety of adverse effects 
including nausea, vomiting and diarrhoea (Khan et al., 2012), while it can also cause hepatic 
injury and hematological disturbances (Feagan et al., 1995), as well as intestinal epithelium 
damage that can eventually lead to weight loss (Lobo and Balthasar, 2003). Chronic use of 
MTX can lead to more severe effects on the liver such as fibrosis or cirrhosis, while it is also 
not administered to pregnant women due to its teratogenic properties (Rosenberg et al., 
2007, Khan et al., 2012, Moisa et al., 2006). Because of the severity of the aforementioned 
potential toxicity, MTX is often administered with folate supplements. There have also been 
efforts to improve its delivery and to control its release by creating pro-drugs or using delivery 
systems such as lipid nanoparticles or liposomes (Khan et al., 2012).  
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It is also important to appreciate that the development of many side effects depends on the 
rate of MTX clearance and the underlying health of the patient. Reduced renal clearance of 
MTX could be the cause of MTX-induced renal dysfunction and would significantly enhance 
the risk of toxicity (Ries and Klastersky, 1986, Flombaum and Meyers, 1999). An example of a 
disease that can enhance MTX-induced toxicity is inflammatory bowel disease (IBD). Patients 
who are receiving low dose MTX and are also suffering from IBD can have diarrhoea, fever 
and a higher risk of infection (Schroder, 2003). Other conditions that are risk factors for MTX 
toxicity include diabetes mellitus, fasting or NASH. Finally, potentially dietary supplements 
can also have an effect, such as the root of Pueraria lobata herb which can enhance MTX 
toxicity by reducing MTX elimination (Chiang et al., 2005). Due to the variety of conditions 
that can influence the pharmacology and toxicology of MTX, formal guidelines for MTX 
administration were drafted (Roenigk et al., 1982, Langman et al., 2001).  
Acute liver failure  
Acute liver failure (ALF) is a rare severe condition that occurs in patients without a pre-existing 
liver disease (Bernal and Wendon, 2013). It is associated with a sudden significant hepatocyte 
cell death and general liver dysfunction, while it is commonly described as the onset of 
coagulopathy, as well as encephalopathy in advanced stages (Lee, 2012a, Friedman and 
Emmet, 1998). The presence of ALF can lead to further complications including cerebral 
oedemas, neurological conditions, renal failure, infection and hypoglycaemia, while it may 
also progress to multiple organ failure or death in approximately half of ALF cases (Lai, 2004, 
Bernal and Wendon, 2013, Friedman and Emmet, 1998).  
ALF was originally divided to two subgroups: a) fulmimant hepatic failure where 
encephalopathy (brain dysfunction) develops within eight weeks of illness onset and b) 
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subfulminant hepatic failure where encephalopathy develops between eight weeks and six 
months (Friedman and Emmet, 1998). Modern classifications vary depending on the system 
that is used but they generally attempt to reflect differences in clinical features more 
accurately by quantifying the interval between the onset of the initial symptoms and the 
development of encephalopathy (Bernal and Wendon, 2013, O'Grady et al., 1993). There can 
be hyperacute cases, with encephalopathy developing in less than a week, and subacute 
cases, where encephalopathy requires a longer period to develop. Subacute cases can be 
easily confused with chronic liver diseases and generally have a worse outcome than 
hyperacute cases (Bernal and Wendon, 2013). 
The majority of the cases of ALF are due to viral infections including hepatitis A, B and E, and 
consequently ALF is more common in the developing world. Other important causes include 
drug induced liver injury, which is responsible for approximately 50 % of the cases of ALF in 
the USA, Wilson’s disease, autoimmune hepatitis and mushroom ingestion (Bernal and 
Wendon, 2013, Friedman and Emmet, 1998). However it should also be noted that Wilson’s 
disease, hepatitis B and autoimmune hepatitis are also commonly recognized as chronic liver 
conditions rather than being categorised as ALF (Stravitz and Kramer, 2009).  
The specific cause of ALF is also thought to determine the mechanism of hepatic cell death. 
The extent of apoptosis and necrosis in ALF is currently a controversial topic but it is generally 
thought that cells undergo necrosis when there is a severe disruption to endocellular function 
or when the ATP stores have been depleted. Recent data suggest that the presence of 
necrosis is associated with poor outcome, therefore the distinction of these two processes is 
potentially very important (Bantel and Schulze-Osthoff, 2012). 
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The outcome and pathogenesis of ALF is also thought to depend on the activation of systemic 
immune responses (Antoniades et al., 2008). The presence of the systemic inflammatory 
response syndrome (SIRS), a severe malfunction of the immune system, has been associated 
with a poor prognosis and can have infectious and non-infectious causes (Rolando et al., 
2000). SIRS is described as the clinical manifestation of an abnormal systemic inflammatory 
reaction which is distant from the initiating insult and its severity correlates positively with 
the extent of organ dysfunction and mortality/morbidity. It is characterized by elevated levels 
of pro- and anti- inflammatory cytokines (Antoniades et al., 2008). The mechanism by which 
SIRS develops is thought to be due to the “spill over” of a localized inflammatory response. 
The resulting elevated systemic levels of pro-inflammatory cytokines trigger the release of 
anti-inflammatory cytokines in an attempt to control the immune response. This leads to a 
generally unbalanced immune system that can cause multiple organ failure and death 
(Antoniades et al., 2008). SIRS is an important risk in ALF patients who have several 
immunological defects, while a third of the patients fail to raise an immune response after an 
infection (Rolando et al., 2000). For example, the occurrence of SIRS after a fungal infection 
has been estimated to raise the mortality from 70 % to 100 % (Rolando et al., 2000). 
Cirrhosis and acute on chronic liver failure  
Liver fibrosis is characterized by the replacement of injured tissue by collagen fibres. Liver 
cirrhosis is an advanced condition of liver fibrosis triggered by the distortion of hepatic 
circulation, which can lead to the clinical consequence of portal hypertension (Schuppan and 
Afdhal, 2008). Liver cirrhosis can be further categorized to compensated and decompensated 
cirrhosis depending on the clinical outcome.  Decompensated cirrhosis is characterized by 
more severe portal hypertension, ascites, GI bleeding and encephalopathy, while bacterial 
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translocation is also considered to have a key role in the progression of compensated cirrhosis 
to decompensated cirrhosis (Jalan et al., 2012, Garcia-Tsao et al., 2010, Moreau et al., 2013). 
If left untreated, liver cirrhosis can regress to a hepatocellular carcinoma and is estimated to 
affect 0.15 % of people in the USA (Schuppan and Afdhal, 2008).  
Acute on chronic liver failure (ACLF) is another type of liver failure syndrome that was initially 
described as a condition where an acute insult takes places on a liver suffering from a chronic 
condition (Ohnishi et al., 1995). Currently it is increasingly recognized as a condition 
encompassing a critical deterioration of liver function in patients most commonly suffering 
from cirrhosis, but an evidence based definition is still lacking (Jalan et al., 2012, Pinzani et al., 
2011). ACLF is characterized by a rapid progression and a high short-term mortality rate of 50 
– 90 % (Jalan and Williams, 2002). Improved understanding of this condition will improve 
treatment outcome and answer questions such as whether ACLF patients should be admitted 
to intensive care or not (Das et al., 2010, Moreau et al., 2013). 
Several acute insults have already been identified to be responsible for the acute 
deterioration of chronic liver disease patients to ACLF but these can vary depending on the 
geographical region (Sarin et al., 2009). Alcoholic hepatitis, drug toxicity, bacterial infections 
and viral infections have all been commonly identified as precipitating events. However, the 
acute insult might also not be easily identifiable and it is estimated to be unknown in 
approximately 40 % of patients (Jalan et al., 2012, Ikeda et al., 1990, Moreau et al., 2013). 
Knowledge of the acute episode is important because it might be enable personalized 
treatment which could possibly reverse liver deterioration and avoid the need for 
transplantation (Sarin et al., 2009). Finally, SIRS, commonly triggered through bacterial 
translocation, is also thought to be an important determinant of disease severity in ACLF 
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patients. Furthermore, it can pre-dispose ACLF patients to further infections which would in 
turn further aggravate a pro-inflammatory response and create a vicious cycle (Jalan et al., 
2012). Similarly to ALF, there is a direct positive correlation between the severity of SIRS and 
ACLF mortality (Jalan et al., 2012). An overview of ACLF and ALF development is presented in 
Figure 1.8. 
 
Figure 1.8: Overview of ALF and ACLF development. ALF normally develops in individuals who don’t 
suffer from a background liver disease while ACLF develops in people suffering from a background 
disease, typically decompensated cirrhosis. Both conditions require an acute insult to develop. SIRS – 
systemic inflammatory response syndrome; DILI – drug induced liver injury; ALF – acute liver failure; 
ACLF – acute on chronic liver failure. 
Thesis hypothesis 
The aforementioned liver conditions are hypothesized to be characterized and driven by 
endocellular metabolic perturbations. The aim of this thesis is to determine whether the 
approach of metabonomics, which is introduced in Chapter 2, can be a useful tool in the 
elucidation of the underlying metabolic perturbations that accompany liver diseases through 
the identification of mechanistic or diagnostic markers. This methodology was applied to two 
DILI animal model studies (Chapters 3 and 5) and one liver disease animal model (Chapter 4), 
before concluding with the metabonomic analysis of a clinical liver disease study (Chapter 6).  
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Chapter 2: Metabonomics analytical background 
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Metabonomics 
There is a pressing need for the development of novel technologies that would enable the 
mechanistic bases of liver disease such as DILI to be elucidated and ultimately lead to 
prediction of susceptibility to DILI and of prognosis following an adverse event (Watkins et al., 
2008). The development of technologies such as metabonomics and its subsequent 
application to the prediction of the response of individuals following drug administration, 
pharmacometabonomics, have shown promise in enhancing our understanding of the 
underlying mechanisms of DILI and potentially identifying markers of idiosyncratic 
hepatotoxicity (Lindon et al., 2006). 
Metabonomics is a top-down systems approach that involves the generation of information-
rich metabolic profiles of biological samples and studies the dynamic response of these 
metabolic profiles following a perturbation due to a toxic insult, genetic changes or external 
stimuli (Nicholson et al., 1999, Lindon et al., 2006). A non-targeted approach can be employed 
to profile the metabolic complement of tissues and biofluids and investigate the effect of the 
stimulus of interest such as a toxin, (Nicholson and Lindon, 2008, Coen et al., 2008). In 
addition, targeted approaches are often applied which enable focus on specific classes of 
metabolites or metabolic pathways that are hypothesised to be affected (Chen et al., 2009, 
Want et al., 2010). 
Metabonomics is a rapidly growing, versatile and dynamic approach which is currently used 
in many fields, including toxicological (Coen, 2010, Robertson, 2005, Robertson et al., 2011), 
environmental (Viant et al., 2003), nutritional (Claus and Swann, 2013) and clinical studies  
(Andrew, 1984, Ladep et al., 2014, Lindon and Nicholson, 2014). Recently, metabonomics has 
also been employed to improve our understanding of the important role of the gut 
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microbiome and its metabolic interactions with the host and how it is affected by several 
disease states (Nicholson et al., 2012). 
Analytical platforms employed by metabonomics 
Metabonomic investigations typically rely on two different analytical platforms to acquire the 
metabolic profiles; nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry 
(MS) coupled to different types of chromatography (Nicholson et al., 2002). These analytical 
platforms can analyse a wide range of compounds (<1000 Daltons), known as metabolites 
(Nicholson et al., 1999, Beckonert et al., 2007). Estimates suggest that there are 
approximately 2000 main metabolites in the human metabolome (Beecher, 2003), while 2651 
compounds have been identified in total in human urine (Bouatra et al., 2013). Each analytical 
technique has advantages and disadvantages, and a complimentary use of both techniques 
ensures maximal coverage of the metabolome and recovery of information. 
Due to the versatility of NMR and MS, they can be used to analyse many different sample 
matrices including urine, serum/plasma and tissue extracts, which are most commonly 
examined (Bollard et al., 2005, Beckonert et al., 2007, Dona et al., 2014). Both techniques can 
also be used to study solid tissue samples, such as the magic angle spinning (MAS) application 
of NMR (Beckonert et al., 2010) and the matrix assisted laser desorption ionization (MALDI) 
method of MS (Fagerer et al., 2013). 
Nuclear Magnetic Resonance spectroscopy 
NMR spectroscopy is a non-destructive analytical technique that can be used to profile the 
metabolic composition of complex fluid or solid biological samples (Beckonert et al., 2007, 
Beckonert et al., 2010, Dona et al., 2014). Modern NMR instrumentation consists of a 
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superconducting electromagnet cooled to temperatures close to absolute zero (-273.15 oC) 
in order to achieve a strong magnetic field. The NMR spectrometer also utilizes a probe which 
is responsible for generating and transmitting the radiofrequency pulse to the sample, a pulse 
programmer and radiofrequency transmitter and finally, a signal receiver. Figure 2.1 presents 
the general layout of the superconducting magnet of an NMR spectrometer. 
 
Figure 2.1: The components of an NMR spectrometer superconducting magnet are depicted above. 
Inside the casing of the magnet there is an outer storage tank of liquid nitrogen which is acting as an 
insulator to the inner liquid helium store. The liquid helium cools the superconducting coils sufficiently 
in order to reach a superconducting state. The bore is the space in the centre of the magnet where 
the sample is inserted and the probe is located. The probe holds the sample and has the circuitry 
required to excite the sample, as well as detect the resulting signal (through the receiver coil). 
The theory of NMR relies on the basic physical properties of atomic nuclei, mass quantity and 
spin, which lead to an intrinsic angular momentum, a vector, defined as spin (p) and whose 
absolute value is derived by the following formula: 
𝑝 =  ћ[𝐼(I + 1)]1/2 
I - spin quantum number; ћ - reduced Planck’s constant 
The spin quantum number of each atomic nucleus depends on its number of protons and 
neutrons, and can range from 0 (including 12C and 16O), to 1/2 (including 1H, 13C and 19F), 1 
(including 2H and 14N), 3/2 (15N) and so on.  
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Another important physical property of nuclei is known as magnetic moment (µ), which is 
another vector arising from the spin and positive charge of the nucleus. This property is 
related to the angular momentum through the gyromagnetic ratio (γ), which is a 
proportionality constant unique to each different nucleus. It is important to note that the spin 
quantum formula reveals that if a nucleus has a spin quantum number value equal to zero, it 
will not have an intrinsic angular momentum or a magnetic moment and therefore it will not 
be detectable by NMR. The proton nucleus (1H), which is the most commonly studied nucleus 
in the context of metabonomics and most relevant to this thesis, has a spin quantum number 
of ½. Nuclei with a spin equal to ½ can have two different directions, ±½ћ, and therefore the 
vectors of the proton nuclei can have either of the two possible orientations (Hore, 2011).  
When protons are placed in an external magnetic field, such as that created by a 
superconducting magnet, their nuclei move from a random to an ordered orientation and 
precess about the axis of the magnetic field. This precession and its frequency are defined as 
the Larmor precession and frequency respectively, as first described by Landau and Lifshitz 
(Landau and Lifshitz, 1935). The external magnetic field causes a separation of the nuclei to 
separate energy levels, depending on their spin orientation and spin quantum number. In the 
case of 1H-NMR, protons can have two different orientations, leading to nuclei with spin -½ћ 
to be located at the higher energy level and vice versa. The population of nuclei at each energy 
level is predicted by the Boltzmann distribution. At thermal equilibrium, more nuclei will be 
located at the lower energy state and therefore some high energy state nuclei will give off 
energy to the lattice in order to transition to the lower energy state. This phenomenon is 
known as spin-lattice relaxation and it occurs exponentially with time, with a time constant 
known as the spin-lattice relaxation time (T1). Nuclei can also undergo spin-spin relaxation as 
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a result of inter-nuclei interactions and this is characterized by the spin-spin relaxation time 
(T2). The energy difference between the two energy levels for the nuclei in a magnetic field is 
determined by the strength of the external magnetic field and it can be calculated with the 
following formulae: 
∆𝐸 =  𝛾ћ𝐵𝑜            ∆𝐸 =  𝜈ℎ 
Bo - strength of the external magnetic field; ν - frequency of electromagnetic radiation; h - Planck’s 
constant 
The second formula reveals that electromagnetic radiation, equal to the resonance (Larmor) 
frequency can be used to increase the probability of nuclei transitioning, flipping, between 
energy levels and therefore allowing us to perform NMR spectroscopy (Gutowsky, 1954). It is 
important to note that in order for maximum net absorption to take place thermal equilibrium 
between the two energy levels must be first established, which is dependent on T1. Only at 
this point will the population difference will be maximized, which will therefore permit the 
maximum net absorption (Hore, 2011).  
An important property of NMR spectroscopy is that not all nuclei have identical resonance 
frequencies due to an effect known as chemical shift which is dictated by the electronic 
environment of each nucleus. The external magnetic field applied to a nucleus will also cause 
surrounding electrons to circulate within their atomic orbitals which will subsequently 
generate a smaller opposing magnetic field (due to their mass and charge), known as nuclear 
shielding. Therefore, the effective magnetic field experienced by each nucleus will be the 
difference between the two opposing magnetic fields and as a result will be weaker than the 
external magnetic field. For example, proton nuclei bonded to atoms with high 
electronegativity, such as oxygen, will have a lower electron density, due to the pulling effect 
of the highly electronegative oxygen nucleus. This will cause a smaller degree of shielding 
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against the external magnetic field of the superconducting electromagnet, leading to a 
greater effective magnetic field and to a higher resonance frequency since the difference 
between the aforementioned energy levels will be greater (as predicted by the formula). In 
contrast, proton nuclei in a methyl functional group will have a higher electronic density 
which will lead to greater shielding, a weaker effective magnetic field and a subsequently 
lower resonance frequency. Finally, the chemical shift is defined as the difference of the 
resonance frequency of a nucleus relative to the resonance frequency of a standard nucleus, 
divided by the operating frequency of the magnet and it is expressed in parts per million 
(ppm). This is an important effect because it permits the separation of nuclei from different 
chemical structures within an NMR spectrum (Hore, 2011).  
Another important property of NMR spectroscopy which can provide additional molecular 
structural information arises from spin-spin coupling, also known as J-coupling. Neighbouring 
nuclei can also have different spin orientations and therefore will occupy different energy 
levels when the external magnetic field is applied.  J-coupling describes the through-bond 
interaction between nuclei that are separated by three bonds that leads to an effect on the 
energy level of the each nucleus, depending on the energy level of the neighbouring nucleus. 
This interaction is expressed in Hz and leads to spectral peak multiplicity and therefore 
providing useful information concerning the neighbouring nuclei, which can then be 
converted to structural information (Hore, 2011).  
Modern NMR experiments rely on radiofrequency pulses to excite the nuclei from the lower 
energy state to the higher energy state. Radiofrequency pulses are employed because they 
permit the excitation of nuclei with different Larmor frequencies, instead of exciting each 
nucleus individually. The cumulative effect of a radiofrequency pulse can be demonstrated by 
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using the vector model shown in Figure 2.2. An applied radiofrequency pulse will lead to the 
rotation of the magnetization of a collection of nuclear spins away from the axis of the 
external magnetic field (z axis; as shown in Figure 2.2A). The duration of the pulse dictates 
the extent of the rotation, which is usually 900 or 1800 in experiments relevant to this thesis. 
When a 90o degree radiofrequency pulse is applied, the magnetic vectors are rotated to the 
axis of the pulse (y axis) and precess in the xy plane (Figure 2.2B).  A receiver coil located on 
the y axis detects the magnetic vectors through a change in voltage which is later amplified 
by the receiver. This detectable signal is known as the free induction decay (FID) and it 
represents the sum of all the nuclei within the sample. Once the pulse is switched off, the 
nuclei will precess back to their original position leading to the characteristic decaying FID 
signal (Figure 2.2C). Fourier transformation of the resulting FID leads to a spectrum with the 
chemical shift of the nuclei on the x axis and the intensity the resonances on the y axis, as 
shown in Figure 2.3 (Hore, 2011).  
 
Figure 2.2: The effect of a 90o radiofrequency pulse on aligned magnetic vectors is shown. The 
magnetic vectors are precessing around the axis of the external magnetic field (z axis; A). A 90o degree 
radiofrequency pulse leads to the flipping of the magnetic vectors from the z plane to the xy plane (B). 
Once the radiofrequency pulse is switched off, the magnetic vectors will precess back to the original 
position (C). The resulting decaying signal is known as the FID. 
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Pulse sequences used in NMR experiments 
A diverse array of NMR pulse sequences can be used depending on the sample and analysis. 
Please note that only the pulse sequences relevant to this thesis will be further discussed. 
One dimensional standard solvent suppression pulse sequence (NOESYpr1d pulse 
sequence) 
One dimensional pulse sequences with water pre-saturation are typically used in 
metabonomics to acquire spectra of samples that are typically of low protein or lipid content, 
such as urine or tissue aqueous-soluble extracts (Beckonert et al., 2007, Dona et al., 2014). 
An example is a pulse sequence which is an adaptation of a two dimensional Nuclear 
Overhauser Effect (NOE) experiment which consists of the following sequence: RD – 90o – t – 
90o – tm – 90o – ACQ; where RD is the relaxation delay, 90o is a 90o degree radiofrequency 
pulse, t is the first increment in a NOESYpr1d sequence, tm is the mixing time and ACQ is the 
FID acquisition period (Jeener et al., 1979, McKay, 2011). During relaxation delay (RD) and tm 
the water resonance is selectively irradiated with a low power continuous wave in order to 
pre-saturate and attenuate its resonance by a factor of 105 or more before FID acquisition 
(Nicholson et al., 1995, McKay, 2011). This is advantageous because higher spectrometer 
receiver gains can then be used in order to achieve an improved signal to noise ratio 
(Nicholson et al., 1984). A representative urine spectrum acquired with a standard solvent 
suppression pulse sequence is shown in Figure 2.3. 
CPMG pulse sequence 
The Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse sequence (Carr and Purcell, 1954, 
Meiboom and Gill, 1958) is used for samples that are expected to have significant 
macromolecular (protein and lipid) content such as blood plasma or sera samples which are 
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also typically analysed in metabonomics analyses (Beckonert et al., 2007). This pulse 
sequence has the form: RD – 90o – (t – 180o – t)n – 90o – ACQ, where t is defined as the spin 
echo delay (time delay between the pulses), 180o is a 180o degree radiofrequency pulse and 
n is the number of loops used (Beckonert et al., 2007). The spin echo experiment uses a 180o 
degree radiofrequency pulse to restore the phase of the different magnetic vectors in a 
sample that are precessing at different Larmor frequencies after a 90o degree radiofrequency 
pulse.  The CPMG pulse sequence employs the spin echo experiment multiple times but the 
amplitude of the received signal decays over time due to T2 relaxation (Hahn, 1950, Carr and 
Purcell, 1954, Meiboom and Gill, 1958). Since bigger molecules, macromolecules, have faster 
T2 relaxation their signal will be lost first, leading to the attenuation of their resonance.  
 
Figure 2.3: A representative 1D 1H-NMR urine spectrum acquired at a frequency of 600 MHz is 
depicted above. The chemical shift scale is located at the x-axis (δ1H), while the relative intensity is 
shown on the y-axis. Magnified versions of the aliphatic and aromatic regions of the spectrum are also 
depicted above. 
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Two dimensional NMR experiments 
Multi-dimensional NMR experiments can provide further structural information, by plotting 
the data in multiple frequency axes. Two and three dimensional  experiments, which can 
either be homo- or hetero-nuclear, are typically used in biology (Marion, 2013). The two 
dimensional homo-nuclear NMR experiments commonly used in metabonomics analyses are 
correlation spectroscopy (COSY) and total correlation spectroscopy (TOCSY) and are very 
useful because they reveal structural information concerning adjacent protons in a molecule 
(Aue et al., 1975, Hore, 2011). The COSY experiment reveals the spin-spin coupling between 
protons (three bonds apart), while the TOCSY experiment permits the observation of 
correlation with more distant protons (Hore, 2011). The spectra of both types of experiments 
are presented with a diagonal line containing the chemical shifts of the nuclei, and cross-
peaks on either side of the diagonal that represent the coupling information between the 
nuclei. 
Mass spectrometry 
MS is a very sensitive analytical technique which is typically coupled to upstream 
chromatographic platforms in metabonomic analyses. Unlike NMR, MS is a destructive 
technique since it requires the ionisation of the samples, a process which can be described by 
the following equation for positive polarity ionisation: 
𝑀 + 𝑒−  →  𝑀+  + 2𝑒− 
M - molecule to be ionised; e- - electron used to ionise the molecule; M+ - ionised molecule  
Modern MS instruments require a vacuum and consist of three different main modules: the 
ion source which ionises molecules and converts them to a gaseous phase, the mass analyser 
which separates the resulting ions based on their mass to charge ratio (m/z) and finally the 
detector, where the ions are detected and their relative abundance is calculated. There are 
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different types of ionisation and analyser modules but only the ones most relevant to 
metabonomics and this thesis will be further discussed.  
Ionisation sources used for organic analyses include electron impact ionisation (EI), chemical 
ionisation, fast ion or atom bombardment (FAB) ionisation, MALDI and electrospray ionisation 
(ESI) (De Hoffman et al., 1996, Fenn et al., 1989, Hillenkamp et al., 1990, Nier, 1947).  ESI is 
commonly used in liquid chromatography mass spectrometry (LC-MS) analyses since it is 
considered to be a “soft” ionization method and leads to mass spectra with reduced ion 
fragment content. (Dettmer et al., 2007, Fenn et al., 1989, De Hoffman et al., 1996). ESI 
imposes a strong electric field on the sample passing through a capillary tube and the voltage 
difference between the capillary exit and counter electrode results in the formation of highly 
charged droplets (Figure 2.4A). As the solvent in the droplets evaporates with the help of a 
drying gas, the electrical charges become more dense leading to a cascade of droplet ruptures 
and ion desorption is achieved when the electrical density becomes large enough (De 
Hoffman et al., 1996). An advantage of ESI is that it can lead to ions with multiple charges, 
which aid the separation of the ions in the mass analyser, as well as permit the analysis of 
bigger molecules. Gas chromatography mass spectrometry analyses utilize hard ionisation 
methods, such as EI. This ionisation method uses a heated filament to give off electrons which 
are then accelerated before impact with the gaseous molecules which are injected into the 
source. This leads to the removal of electrons from molecules and the formation of positive 
ions only (De Hoffman et al., 1996). It is also important to note that modern MS instruments 
employ a Z spray system at the ion source in order to avoid direct injection of neutral 
molecules or contaminants in the mass analyser. 
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The mass analysers separate the resulting ions according to their mass to charge ratio before 
they reach the detector. Common mass analysers include the quadrupole (Q), the  time of 
flight (TOF), the fourier transform ion cyclotron resonance and the ion trap analyser, all of 
which have different upper mass limits, transmission and resolution (De Hoffman et al., 1996). 
The quadrupole and TOF mass analysers are typically used in metabonomic analyses (Figure 
2.4). Quadrupoles are real mass to charge analysers that consist of four parallel poles, where 
each pair of parallel rods is connected to each other and share the same radiofrequency 
potential (Figure 2.4B). A direct current is then superimposed on the quadrupoles (Ferguson 
et al., 1965, De Hoffman et al., 1996) which results in an electric field where only ions of the 
selected m/z can pass through to the detector without hitting the quadrupoles, and therefore 
the quadrupole mass analyser is ideal for targeted analyses (De Hoffman et al., 1996).  The 
TOF mass analyser exploits the principle that ions with greater mass to charge ratio will travel 
more slowly in space than ions with a smaller mass-to-charge ratio (Wiley and McLaren, 
1955). They are typically accelerated before reaching the detector by a “pusher” and the 
longer the distance covered before reaching the detector, the better the separation (Figure 
2.4C) (De Hoffman et al., 1996). Different combinations of mass analysers can be used in order 
to achieve improved ion separation, such as the Q-TOF (Figure 2.4) or the triple quadrupole 
(TQ) configuration. TQ setups can be used to perform MS/MS fragmentation analyses, where 
further fragmentation takes place in the middle quadrupole, known as the collision cell. Ions 
can then be identified based on the pattern of the fragment ions.  
Finally, the ions are detected on the detector which can either record a direct measurement 
of the charges or amplify the signal through several multiplication techniques, such as 
electron photon multipliers. The resulting difference in potential caused by the ions is 
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converted to a digital signal by an analogue to digital converter and the computer assigns the 
detected ions to their respective mass to charge ratios and relative intensities (De Hoffman 
et al., 1996).  
 
Figure 2.4: The components of an ESI-Q-TOF MS instrument are illustrated above. The ESI source (A) 
is where the samples are ionised and freed from droplets with the aid of the drying gas (N2 gas). The 
first mass analyser (B) is a quadrupole where ions with specific m/z can be selected for analysis. Finally 
C depicts the time-of-flight mass analyser, with a reflectron which separates ions according to their 
mass and charge. The ion detector is located in compartment C as well. GC – gas chromatography; LC 
– liquid chromatography; CE – capillary electrophoresis 
Chromatography 
Chromatography systems are used upstream of MS instruments to separate or fractionate 
the sample in order to avoid the complications resulting from a direct sample injection, which 
include ion suppression and higher background noise. Metabonomics experiments most 
commonly rely on liquid chromatography (LC), gas chromatography (GC) and capillary 
electrophoresis (CE) platforms (Dettmer et al., 2007, Dunn et al., 2011).  
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Liquid chromatography 
Liquid chromatography is an aqueous-phase separation technique which relies on columns 
with different chemical compositions that can be used depending on the chemical nature of 
the metabolites of interest in the biological sample. Reverse-phase (RP) chromatography 
typically consists of C-18 bonded silica in narrow bore columns and is used to separate 
medium polar and non-polar analytes (Dettmer et al., 2007). In RP chromatography, polar 
metabolites are generally eluted first because they are not well retained by the column, 
whereas the retention time of non-polar molecules depends on the extent of their non-
polarity and the strength of column interaction. For the retention of very polar metabolites, 
hydrophilic interaction liquid chromatography (HILIC) is preferred in metabonomic analyses 
(Tolstikov and Fiehn, 2002, Spagou et al., 2011, Dettmer et al., 2010). HILIC uses silica or 
derivatized silica to retain the polar molecules and requires a significant portion of water in 
the mobile phase in order for the molecules to be retained on the column (Dettmer et al., 
2010). The relative metabolite elution time of molecules in HILIC is opposite to that of RP 
chromatography, where non-polar metabolites are eluted first and vice versa. 
Finally, one of the later methods of liquid chromatography is termed as ultra-performance 
liquid chromatography (UPLC; Waters Corp., MA, USA) because it uses smaller particles sizes 
and operates at higher pressures (10,000 – 15 000 psi) in order to increase chromatographic 
resolution and achieve narrower chromatographic peaks (Wilson et al., 2005). A UPLC-RP 
chromatographic spectrum of a serum sample is shown in Figure 2.5. 
Gas chromatography 
Gas chromatography relies on the thermal stability and volatility of molecules and therefore 
typically uses an EI ion source. In order to increase the proportion of molecules that will fulfil 
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this requirement derivatization of the sample is performed prior to analysis . The two 
derivatizing reagents relative to this thesis are: N-Methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA) which adds a silyl group to active hydrogen functional groups 
such as –SH or –OH and methoxyamine which reacts with carbonyl groups to form the oxime 
derivative and forces sugars to adopt an open ring formation (Dettmer et al., 2007).  
 
Figure 2.5: The reversed phase chromatographic total ion current of a serum sample is shown above. 
The peak retention time is indicated on the x axis, while the y axis reveals the relative intensity of each 
peak. A and B represent the mass spectra associated with two peaks. The m/z of the peaks in the mass 
spectra are shown on the x axis, while the y axis reveals the relative intensity of each peak. 
Chemometrics 
The analysis and interpretation of NMR and MS metabonomic data rely on chemometric 
tools, which primarily include multivariate statistical tools that are employed to deconvolute 
and maximize the recovery of the information from the complex metabolic profiles, which 
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will facilitate their analysis (Fonville et al., 2010). Multivariate statistical methods can produce 
simplified weighted combinations of the tens of thousands of original variables generated by 
NMR and MS analyses, which would reveal metabolic patterns that would not be easily 
determined otherwise (Fonville et al., 2010). These tools can be unsupervised (no input of a-
priori sample class is required) or supervised (sample class is defined) and each type of 
analysis can be used to extract different information. 
Unsupervised methods 
Principal component analysis (PCA) is an unsupervised statistical tool that is typically 
employed at the beginning of the statistical analysis. PCA reduces the number of dimensions 
in order to improve visualisation and reveal patterns in the data, with minimal loss of 
information. PCA uses an orthogonal linear transformation which transforms the original data 
in Euclidean space to a compressed space (characterized by principal components), consisting 
of fewer dimensions, and thus reducing dimensionality and complexity. The first principal 
component characterizes the greatest variance in the matrix, while the second principal 
component is orthogonal to the first and describes the second largest proportion of the 
variance (Wold et al., 1987). Figure 2.6 (A-C) depicts the underlying principle of the dimension 
reduction performed by PCA. The first two principal components describe the largest 
proportion of the variance of the dataset (Figure 2.6A) and define the plane (Figure 2.6B) onto 
which the samples will be projected, which has reduced dimensionality (Figure 2.6C). All 
observations will be projected onto the new plane as scores points and the results can be 
presented in the format of a “scores” (Figure 2.6D) and a “loadings” plot (Figure 2.6E) (Wold 
et al., 1987). The scores plot illustrates the relationship of samples in multivariate space, while 
the loadings plot illustrates the weight of each variable in the separation of the whole sample 
set as observed in the scores plot.  
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Figure 2.6: A demonstration of the dimension reduction in dataset as achieved by PCA is depicted. The 
first two principal components (p1 and p2) describe the majority of the variance in the dataset (A). 
They define a new plane (B) onto which the variables are projected on (C). The results are usually 
presented in scores plot, which reveals the group separation in multivariate space (D), and loadings 
plot, which reveals the weight of each variable (E). Univariate scaling was applied to this dataset. 
Supervised methods 
Supervised statistical tools such as partial least square (PLS) analysis and orthogonal partial 
least squares discriminant analysis (O-PLS-DA) are employed when more subtle differences 
between groups are investigated or when we are trying to distinguish between the real 
differences between groups from variance that is orthogonal to the class membership or  
“background noise” (Fonville et al., 2010). Background noise is defined as variation not in 
direct relation to the biological separation of the groups of interest, such as instrument 
instability. These techniques require a description of the sample classes (Y matrix) in order to 
derive the components that best describe the classes of the Y matrix (Fonville et al., 2010).  
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O-PLS-DA is a useful iteration of the PLS-DA statistical tool because it employs one or more 
orthogonal components in order to account for the variance that is orthogonal to the 
biological variation (Fonville et al., 2010, Trygg and Wold, 2002). O-PLS-DA is typically applied 
to both NMR and MS metabonomic datasets. In NMR analyses, the resulting loadings plot can 
be “back-projected” onto a pseudo-NMR spectrum, which is achieved by back-scaling the unit 
variance scaled model to a correlation matrix (Fonville et al., 2010, Cloarec et al., 2005b). The 
pseudo-NMR spectrum, or loadings coefficient plot, is also coloured with a scale which reveals 
the correlation of each variable and how significantly different it is between the two classes 
(Figure 2.7). 
 
Figure 2.7: A urine O-PLS-DA model comparing a control and treated group is depicted above. The 
scores plot reveals the separation of the two groups (red, control and black, treated) in multivariate 
space, while the loadings coefficient plot illustrates the spectral comparison between the two classes. 
The direction in which each resonance points reveals the relative difference between the two groups. 
Resonances pointing downwards are higher in the control group and vice versa. Tcv (predictive 
component) reveals the inter-group separation, while TYosc reveals the intra-group separation. The 
correlation scale has a range from low correlation (0; blue) to high correlation (1; red) based on the 
squared Pearson correlation coefficient (R2). 
PLS and O-PLS-DA can produce models with greater predictive ability but require validation 
since they are prone to over-fitting. A seven fold cross-validation is commonly applied to 
during the calculation of supervised models, which excludes a seventh of the sample set and 
rebuilds the model in order to predict the class of the excluded set using the model. 
Furthermore, model validity can also be evaluated through the use of permutation tests, 
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which randomize sample class labels and calculate the subsequent predictive ability of each 
model, before comparing it to the predictive ability of the actual model using biologically 
meaningful classes. A 95 % significance threshold (p < 0.05) to test for statistical significance 
is commonly used.  
Complementary statistical tools 
Metabonomic analyses employ an array of multivariate or univariate statistical tools which 
can facilitate the analysis of the complex spectra but biological interpretation and data 
recovery remains a significant challenge. Spectra typically contain thousands of metabolites 
which might be hard to assign because of overlapping or low signal intensities. Therefore, 
various other useful tools have been developed to improve the recovery of information from 
the spectra of both NMR and MS analyses.  
Statistical total correlation spectroscopy (STOCSY) and cluster analysis statistical spectroscopy 
(CLASSY) are two useful tools that complement NMR data analysis and peak assignment 
(Cloarec et al., 2005a, Robinette et al., 2009). STOCSY relies on the correlation patterns that 
arise from a series of spectra in order to identify which peaks are correlated to each other 
and potentially belong to the same compound or metabolic pathway (depending on the 
correlation value). The correlation between peaks to the selected peak of interest is indicated 
by a colour scale which ranges from low correlation (0) to high correlation (typically 1) 
(Cloarec et al., 2005a). CLASSY profiles quantitative changes in the metabolic profiles by using 
a correlation algorithm to simultaneously identify resonances belonging to the same chemical 
structure, as well as clustering metabolites that behave similarly and could therefore belong 
to the same metabolic pathway (Robinette et al., 2009). A chemometric tool specific to MS 
data analysis is “collection of annotation related methods for mass spectrometry data” 
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(CAMERA) , which facilitates the identification of features (including fragments and adducts) 
that belong to single compounds (Kuhl et al., 2012). 
Application of the metabonomics approach 
The metabonomics approach offers a distinct and complimentary view to other –omics 
approaches and has provided valuable, previously uncharacterized, information in the field of 
toxicology and liver disease (Robertson, 2005, Beyoglu and Idle, 2013, Lindon et al., 2003, 
Robertson et al., 2011).  
Metabonomic studies of APAP metabolism and hepatotoxicity 
Early metabonomic studies employed NMR to characterize APAP related metabolites in 
human urine (Bales et al., 1984), as well as rat urine and bile (Spurway et al., 1990). LC coupled 
NMR (LC-NMR) has also been used to characterize APAP metabolites in human urine, rat urine 
and rat bile (Spraul et al., 1994) and LC-NMR-MS had also been employed to study APAP 
metabolites in human urine (Shockcor et al., 1996). Other applications of LC-NMR include 
metabolism studies aiming to identify the glucuronide molecule of an APAP metabolite in 
human urine (Godejohann et al., 2004), as well as to further study the deacetylation and 
reacetylation of APAP metabolites in rat and human urine (Nicholls et al., 1997), which was 
initially reported by NMR in rat urine (Nicholls et al., 1995). Other recent drug assignment 
studies, include the demonstration of how STOCSY can be used to identify APAP metabolites 
in human urine 1H-NMR spectra (Holmes et al., 2007), as well as to characterize the 
prevalence of APAP metabolites in human urine in epidemiological studies (Loo et al., 2012).  
Pharmacometabonomic studies have also focused on predicting the metabolism and toxicity 
of APAP.  Initially, urine metabolic profiles were used to predict the extent of liver necrosis 
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after administration of APAP in an animal model (Clayton et al., 2006). A human 
pharmacometabonomic study involving the administration of non-hepatotoxic doses of APAP 
indicated that it was possible to predict its metabolism, in terms of percentage of sulphation 
and glucuronidation, by looking at the baseline metabolic profiles prior to dosage (Clayton et 
al., 2009). Another human study focusing on APAP metabolism revealed that the urinary 
metabolic profiles of individuals receiving the maximum therapeutic dose (4 grams) per day 
for seven days could predict a sub-clinical rise in ALT activity, indicating the importance of 
early intervention (Winnike et al., 2010). Finally, a recent clinical study showed that resected 
livers had a similar capability of producing similar amounts of NAPQI after APAP 
administration (Galinski et al., 2014). 
Metabonomic analyses have also focused on the mechanisms of toxicity of APAP in a variety 
of species and sample matrices. One of the very first studies revealed that APAP overdose 
could be linked to the disruption of deamination and transamination processes, due to the 
higher level of amino acids in patients’ blood and urine (Bales et al., 1988). Other, more recent 
studies have focused on the APAP-induced disturbance of endocellular metabolism in rodent 
models. APAP intoxication was shown to lead to energy depletion, as indicated by the lower 
hepatic levels of glycogen and glucose in mice (Coen et al., 2003). Moreover, another recent 
study performed on rats has shown that increasingly higher doses of APAP have significant 
effects on the urinary metabolic profiles of rats, such as depletion of hippurate, citrate and 
succinate (Fukuhara et al., 2011). APAP has also been shown to affect lipid metabolism by 
inhibiting fatty acid β-oxidation in serum metabonomic studies (Chen et al., 2009, McGill et 
al., 2014a), while a lipid targeted NMR analysis has shown that APAP intoxication leads to a 
drop in phospholipids and an increase in triglyceride content in murine liver samples (Coen et 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
78 
PhD thesis  Michael Kyriakides 
al., 2004). Finally, metabolic profiling studies have also investigated the potential of 
ophthalmic acid as a marker of APAP-induced oxidative stress and glutathione depletion (Soga 
et al., 2006), as initially reported by Ghauri et al. who characterized oxyprolinuria in rats by 
NMR (Ghauri et al., 1993). 
Metabonomic studies involving MTX 
Kumar et al. employed a metabonomic approach to identify common markers for liver toxicity 
between APAP, MTX and carbon tetrachloride by UPLC-MS. Daily administration of MTX (50 
mg/kg) was reported to affect urinary levels of bile acids, steroids and amino acids, some of 
which were proposed as biomarkers of liver toxicity (Kumar et al., 2012). Another biomarker 
study investigated serum biomarkers for predicting therapeutic efficacy to MTX treatment in 
rheumatoid arthritis patients who were receiving MTX (10 mg/kg) weekly for 24 weeks. The 
levels of metabolites including amino acids, nucleic acids and cholesterol were discovered to 
be discriminatory between responders and non-responders of MTX treatment but the 
investigators also noted that age, sex, diet and individual health were important confounding 
factors (Wang, 2012). Finally, another recent investigation characterized the metabolic and 
toxic effect of MTX on isolated human CD4+ T cells. Even though the levels of 148 metabolites 
were identified to be significantly altered, it was concluded that the toxic effect of MTX on 
CD4+ T cells was minimal at clinically relevant doses (Chimenti et al., 2013). 
Metabonomic studies of NASH and the MCD diet 
There have been a number of metabonomic studies which investigated the human serum 
metabolic profile differences between patients with NASH, NAFLD and healthy volunteers. 
UPLC-MS has been previously employed to characterize and compare the serum metabolic 
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profiles of healthy volunteers versus NAFLD and NASH patients. The results showed that 
increased lipogenesis characterized both NAFLD and NASH conditions. Furthermore, impaired 
polyunsaturated fatty acid (PUFA) metabolism and non-enzymatic oxidation in the 
peroxisomes were associated with the progression to NASH from NAFLD (Puri et al., 2009). 
Another study also implicated that the progression of NAFLD to NASH was associated with 
significant metabolic alterations including the levels of certain glycerophospholipids and 
unconjugated arachidonic acid (Barr et al., 2010). A third clinical study reported that NASH 
and NAFLD could not be distinguished based on their plasma metabolic profiles but however 
discovered that NAFLD was characterized by marked alterations in bile salts levels, while 
NASH had several metabolic alterations, including higher levels of branched chain amino acids 
and carnitine conjugates (Kalhan et al., 2011b).  
There have also been several metabonomic studies investigating the metabolic profiles 
associated with NASH in in-vivo MCD diet rodent models. An NMR based metabonomic study 
comparing the serum metabolic profiles of healthy C57BL/6 mice and C57BL/6 mice fed with 
an MCD diet showed that elevations in the levels of glutamate/glutamine, taurine, glucose 
and lactate could be used to distinguish the two diet groups. When they translated their 
results to a clinical study with people suffering from NAFLD at various stages versus healthy 
controls, they observed that the elevations of serum taurine, glutamate/glutamine and 
lactate were once again predictive of the disease (Li et al., 2011). Another study that 
employed UPLC-MS to investigate the effect of the MCD diet in mice, observed that LPC 
molecules were depleted in the serum while taurine conjugates were upregulated, when 
compared to healthy mice. Furthermore, changes in the gene expression of transporter 
proteins and lysophosphatidylcholine catabolism enzymes were also observed (Tanaka et al., 
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2012). Finally, a recent study also employed a metabolic profiling approach to investigate 
potential therapeutic agents for NASH through the MCD diet model in mice and concluded 
that hypotaurine is a potential therapeutic agent for NASH (Yoshihiko et al., 2014). 
Metabonomic studies of decompensated cirrhosis and ACLF 
The metabolic profiles of serum from patients with decompensated cirrhosis and ACLF have 
only been recently characterized by metabonomics. An investigation employed 1H-NMR 
spectroscopy to distinguish between the plasma metabolic profiles of patients suffering from 
compensated and decompensated cirrhosis. Twelve discriminatory metabolites were 
identified, including pyruvate, phenylalanine and succinate (Qi et al., 2012). Alcoholic 
compensated and decompensated cirrhosis have also been compared to ACLF by plasma 1H-
NMR spectroscopy, revealing that the progression to ACLF involves an increase in the levels 
of metabolites such as phenylalanine, lactate, glutamine and pyruvate (Amathieu et al., 2014). 
Finally, a recent investigation also employed UPLC-MS analysis to compare the serum 
metabolic profiles of hepatitis B induced ACLF, chronic hepatitis B and cirrhotic patients. 
Seventeen prognostic metabolites associated with the development of hepatitis B induced 
ACLF were identified, the majority of which was comprised by lysophosphatidylcholine 
molecules, while eleven of these metabolites were also correlated with treatment outcome 
(Nie et al., 2014). 
Metabonomic studies of ALF 
There has only been a limited application of metabonomics to the study of ALF. Two GC-MS 
studies have characterized the hepatic and serum metabolic changes associated with D-
galactosamine treatment as a model of acute liver failure in mice and rats. They identified 
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changes in the levels of serum and hepatic markers, including amino acids, ketone bodies and 
fatty acid molecules that were associated with hepatic failure in mice (Feng et al., 2007, Feng 
et al., 2013). An LC-MS/MS study identified mainly plasma and hepatic ceramide molecules  
which were also associated with the development of hepatic failure in the rat (Yamaguchi et 
al., 2004). Finally, NMR has also been previously utilized to associate metabolite levels in the 
serum and urine with the therapeutic outcome of ALF treatment (Saxena et al., 2006), as well 
as to identify early prognostic serum markers of irreversible damage in viral hepatitis patients, 
which revealed a general disruption in the urea cycle and amino acid metabolism (Bala et al., 
2013). 
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Chapter 3: Systems level metabolic phenotype of N-acetyl-p-
aminophenol and its non-toxic isomer, N-acetyl-m-aminophenol 
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Introduction 
Study details and aims 
This study employed a comparative metabonomic approach to characterize the systemic 
metabolic consequences induced by the administration of APAP and its non-hepatotoxic 
isomer AMAP (Roberts, 1978). APAP toxicity was hypothesized to be mediated through 
mitochondrial dysfunction and subsequent energetic stress. 1H-NMR spectroscopic analysis 
was initially used in a ‘global’ metabolic profiling approach to acquire the metabolic profiles 
of the aqueous-soluble hepatic extracts, serum and urine. UPLC-MS and GC-MS were 
subsequently employed to analyse the aqueous-soluble hepatic extracts in a more targeted 
approach focusing on metabolites indicative of mitochondrial dysfunction. More specifically, 
the UPLC-MS analysis focused on carnitine metabolism which is an important component of 
β-oxidation, while the GC-MS analysis was employed to profile glycolysis and Krebs cycle 
intermediates in an attempt to characterize the APAP-induced energetic stress. Finally, the 
metabolic effect of AMAP was compared to that of APAP, aiming to isolate the 
pharmacological, or aminophenol non-specific, metabolic effects from those associated 
specifically with APAP toxicity.  The rationale behind this was that common metabolic effects 
between the two compounds would not be related to the effects associated with APAP 
toxicity.  
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Materials and methods 
The animal handling and treatment, clinical chemistry and liver histopathology were 
conducted by our collaborators at the University of Washington (Seattle, Washington, USA). 
The 1H-NMR spectroscopic metabolic profiles were acquired by Miss Lea Maitre. 
Animal handling and treatment 
Male C57BL/6 mice (n = 50, average age of 10 weeks) were purchased from Jackson 
Laboratory (Bar Harbor, Maine, USA) and were kept in a pathogen free environment at the 
University of Washington. The animals were housed in temperature controlled rooms with a 
12 hour light/dark cycle during the duration of the study. Prior to the beginning of the 
experiments, the animals were acclimated for one week and had access to ad libitum rodent 
chow diet and acidified sterile water (pH = 2.77). After a fasting period which lasted 12 hours, 
the animals were treated with APAP (300 mg/kg, n = 15), AMAP (300 mg/kg, n = 15) and sterile 
saline as a control (n = 20) via I.P. injections of 15 µL/g body weight. The selected APAP dose 
has been reported to cause marked liver damage in mice in previous investigations 
(Masubuchi et al., 2005, McGill et al., 2012b). An equimolar dose of AMAP was selected for 
comparative purposes and has also been reported to be non-toxic in this strain of mice 
(Fountoulakis et al., 2000, Priyadarsiny et al., 2008). 
Mice from each treatment group were euthanized by carbon dioxide inhalation and cervical 
dislocation at 1, 3 and 6 hours post treatment (1hr, 3hr and 6hr respectively). At each time-
point liver from the left lateral lobe was immediately snap frozen, blood from a cardiac 
puncture was collected in serum separator tubes (Microtainr, BD Bioscences, San Jose, 
California, USA) and urine was collected in conical tubes containing sodium azide (1 mL, 1 % 
w/v water; NaN3). Sera fractions were collected after the incubation of the collected blood at 
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room temperature for 30 minutes and subsequent centrifugation at 4000 g for 6 minutes. All 
samples were stored at -80oC. 
Liver histopathology 
Tissue sections from the medial lobe of each animal were fixed with 10 % formalin overnight 
prior to dehydration, paraffin embedding and staining with haematoxylin and eosin (H & E). 
The liver sections were examined by light microscopy by a blinded board certified pathologist 
who scored the extent of liver necrosis with the following scoring criteria: 0 (no lesion), 1 (< 
10 % lesion – minimal), 2 (10 – 25 % lesion; mild), 3 (25 – 40 % lesion; moderate), 4 (40 – 50% 
lesion; marked) and 5 (> 50 % lesion; severe). 
Measurement of serum ALT activity 
Serum ALT activity was calculated with a commercially available assay (Diagnostic Chemicals 
Limited, Charlottetown, Canada). Sera fractions were diluted with water (1:5) to a final 
volume of 10 µL. The samples were then placed in duplicate in a 96-well microtiter plate 
containing 100 µL of “ALT activity determination solution”. The optical density at 340 nm of 
each mixture was measured for 2 minutes by a 96-well microplate reader (Gemini 
Spectromax, Molecular Devices, Sunnyvale, California, USA). The mean ALT activity from the 
two replicates was calculated with the following formula: (conversion factor) x (dilution 
factor) x (|gradient|). 
Sample preparation and 1H-NMR spectroscopy of hepatic aqueous-soluble 
component 
Liver tissue metabolite extraction for NMR analysis was performed according to the protocol 
described by Beckonert et al. (Beckonert et al., 2007). Briefly, liver tissue samples (average 
weight of 41.4 mg and standard deviation (STD) ± 3.1 mg) were added to ice-cold 
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acetonitrile/water (1.5 mL, 1:1). The samples were homogenised with 5 mm stainless steel 
beads in a homogenizer (Qiagen Tissue Lyser, Retsch GmBH, Haan, Germany) at 25 Hz for 8 
minutes. The samples were then kept on ice for 10 minutes prior to centrifugation at 17,000 
g for 15 minutes at 4oC (Biofuge Pico, Heraeus, Hanau, Germany). The supernatant was 
concentrated and dried overnight in a centrifugal evaporator (SpeedVac, Thermoscientific, 
Waltham, Massachusetts, United States) at 30oC. The resultant dried supernatant was 
reconstituted in phosphate buffer (600 μL of a 0.2 M solution containing 99.9% D2O, 3 mM 
sodium azide (NaN3) and 1 mM 3-(trimethylsilyl)-[2’,2’,3,3’-2H4]-propionic acid sodium salt 
(TSP)), vortexed for 30 seconds and then centrifuged at 17,000 g for 15 minutes at 4 oC 
(Biofuge Pico). The supernatant (550 μL) was placed in 5 mm NMR tubes (NMR Precision tube 
507-HP-7, Norell, Landisville, New Jersey, United States). NMR spectral data were acquired 
on a Bruker Avance-600 spectrometer operating at 600.13 MHz (14.1 T) 1H frequency and at 
a temperature of 300 K using a Bruker TXI probe (Bruker Biospin, Rheinstetten, Germany) and 
an automated sample handling carousel (Bruker). A standard one-dimensional solvent 
suppression pulse sequence (noesypr1d) was used to acquire the FID (RD - 90° pulse- 4 μs 
delay - 90° pulse - mixing time - 90° pulse - ACQ) (Beckonert et al., 2007). The D2O present in 
the buffer provided a field frequency lock, whilst the TSP was used as the chemical shift 
reference compound. For each experiment, 256 transients were collected into 64,000 data 
points using a spectral width of 12,000 Hz, with a relaxation delay of 4 seconds, mixing time 
of 100 ms and an acquisition time of 4.56 seconds. A line-broadening factor of 0.3 Hz was 
applied to all spectra prior to Fourier transformation (FT). 
A summary of the 1H-NMR acquisition parameters is presented in Table 8.1 in the appendix. 
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Sample preparation and 1H-NMR spectroscopy of urine 
Urine samples were prepared for 1H-NMR analysis as previously described (Beckonert et al., 
2007). Briefly, urine and phosphate buffer (2:1, 600 μL total volume, 0.2 M as above) were 
mixed by vortexing for 1 minute and centrifuged at 17,000 g for 15 minutes at 4 oC (Biofuge 
Pico). The resulting supernatants (550 μL) were then transferred to 5 mm NMR tubes (507-
HP-7). NMR spectral data were acquired on a Bruker Avance-600 spectrometer operating at 
600.13 MHz (14.1 T) 1H frequency and at a temperature set at 300 K, using a Bruker TXI probe 
and an automated sampling handling carousel (Bruker). A standard one-dimensional solvent 
suppression pulse sequence was employed to acquire the FID of 256 transients, with a 
relaxation delay of 4 seconds, mixing time of 100 ms, spectral width of 12,000 Hz, 64,000 data 
points and an acquisition time of 4.56 seconds. A line broadening factor of 0.3 Hz was applied 
prior to FT. A summary of the 1H-NMR acquisition parameters is presented in Table 8.1 in the 
appendix. 
Sample preparation and 1H-NMR spectroscopy of serum 
Sera samples were thawed, vortexed for a period of 15 seconds and allowed to stand for 10 
minutes before mixing with saline solution (1:1, 60 μL total volume; 99.9 % D2O, 0.9 % NaCl 
and 1 mM TSP). The mixtures were then transferred to 1.7 mm capillary NMR tubes (Match 
tubes, Bruker). NMR spectral data were acquired on a Bruker Avance-600 spectrometer 
operating at 600.13 MHz (14.1 T) 1H frequency and at a temperature set at 300 K, using a 
Bruker TXI probe and an automated sampling handling carousel (Bruker). A CPMG pulse 
sequence with a fixed spin-spin relaxation delay 2nτ of 64 ms (n = 160, τ = 200 μs), was used 
to acquire the spectra, with 158 transients, a relaxation delay of 2 seconds, mixing time of 
100 ms and an acquisition time of 2.72 seconds. A line-broadening factor of 0.3 Hz was applied 
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to all spectra prior to FT. A summary of the 1H-NMR acquisition parameters is presented in 
Table 8.1 in the appendix. 
Processing of 1H-NMR spectra 
NMR spectra were imported to TopSpin 3.0 NMR software (Bruker) for manual phasing, 
baseline correction and calibration to the TSP for the aqueous-soluble hepatic extract and 
urine spectra, or the lactate peak for the serum spectra. Full resolution NMR data were then 
imported into MATLAB (R2012, Mathworks Inc., Natick, Massachusetts, USA) using an in-
house script, for further processing including the removal of the TSP and water resonance 
regions before performing probabilistic quotient normalization in the aqueous-soluble 
hepatic extract and serum spectra data (Dieterle et al., 2006). Endogenous metabolite 
assignments were performed using chemometrics tools such as STOCSY (Cloarec et al., 
2005a), COSY experiments, spectral databases (Human Metabolome Database (HMDB) and 
Biological Magnetic Resonance Bank (BMRB)), software including Chenomx NMR Suite 
(Chenomx Edmonton, Alberta, Canada) and previously published assignments in the literature 
(Waters et al., 2005, Nicholson et al., 1995). Finally, the following hepatic metabolites were 
identified by spike-in experiments with the pure standard compounds: phosphocholine, 
dimethylamine, GSSG, choline, succinate, 2-aminoadipate and adenosine monophosphate 
(AMP). Table 8.2 in the appendix presents more detailed assignments of identified 
metabolites in all matrices from all studies. 
The spectral assignments of APAP and AMAP were also based on the existing literature (Bales 
et al., 1984, Holmes et al., 2007, Nicholls et al., 2006), STOCSY and two dimensional COSY and 
TOCSY experiments. In-house scripts were used to calculate the integral of resonances 
belonging to drug related and parent compounds in both groups, in order to estimate their 
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relative abundance to the parent molecule. The integrated resonances in the aqueous hepatic 
extract 1H-NMR profiles were: APAP parent (δ1H = 7.26), APAP-glucuronide conjugate (δ1H = 
7.15). APAP-glutathionyl conjugate (δ1H = 6.96), APAP-N-acetylcysteinyl conjugate (δ1H = 
1.85), AMAP-glucuronide conjugate (δ1H = 7.24) and AMAP parent (δ1H = 7.03). The 
resonances used in the urine 1H-NMR metabolic profiles were: APAP parent( δ1H = 6.88), 
APAP-glucuronide conjugate (δ1H = 7.32), APAP-sulphate conjugate (δ1H = 7.31), APAP-
cysteinyl conjugate (δ1H = 7.50), APAP-N-acetylcysteinyl conjugate (δ1H = 1.86), AMAP-
glucuronide conjugate (δ1H = 7.24), AMAP-sulphate conjugate (δ1H = 7.43), AMAP parent (δ1H 
= 7.01) and APAP-methoxy conjugate (δ1H = 3.88). Each integral was proton adjusted (divided 
by the number of protons it consists of) before the ratio to the parent molecule was 
calculated. Table 3.1 in the appendix presents more detailed assignments of AMAP/APAP 
DRCs, while Figure 8.1 in the appendix depicts the TOCSY/COSY spectra used to assign APAP 
metabolites in the urine. 
GC-MS analysis of hepatic aqueous-soluble component 
Liver tissue samples with an average weight of 25.25 mg and STD ± 0.22 mg were added to 
ice-cold HPLC grade water/methanol (1:1, 1.2 mL total volume) and homogenized with 
zirconia beads at 6,500 Hz (Precellys 24-Dual, Precellys, Montigny-le-Bretonneux, France) for 
two 45 seconds periods with an intermediate 5 minute cooling period on dry ice. The 
homogenized mixtures were incubated for 45 minutes on ice before centrifugation at 13,000 
rpm for 15 minutes at 4 oC (Biofuge Pico). The resulting supernatants were mixed with ice cold 
methanol/water (2:1, 0.5 mL) prior to overnight incubation at -4 oC. The following day the 
samples were centrifuged again at 17,000 g for 15 minutes at 4 oC (Biofuge Pico). 
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Quality control (QC) samples were prepared by collecting 5 μL aliquots from each sample prior 
to drying overnight in a centrifugal concentrator (SpeedVac) at room temperature. The dried 
supernatants were then derivatized using the methoximation/silylation protocol described by 
Fiehn et al. (Fiehn, 2008). Briefly, U-13C-D-Glucose (20 µL of a 1 mM solution in anhydrous 
pyridine) and myristic d27 acid (5 μL of a 6 mM solution in anhydrous pyridine) were mixed 
with the dried supernatants for quantitation purposes and retention time locking 
respectively. Methoxyamine hydrocholoride (40 µL of 0.3 M solution in anhydrous pyridine) 
was then added to each sample prior to incubation at 30 oC for 90 minutes with shaking at 30 
minute intervals. The samples were then incubated with N-methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA; 90 µL) solution at 37 oC for 30 minutes. Finally, 2-fluorobiphenyl 
(10 µL of a 1 mM solution in anhydrous pyridine) was then added as an injection standard. 
GC-MS analysis was performed on an Agilent 7890 gas chromatograph coupled to a 5975 mass 
selective detector quadruple mass spectrometer (Agilent Technologies, Santa Clara, 
California, USA) in accordance to the protocol described by Fiehn et al. (Fiehn, 2008). QC 
samples were set at the beginning of the run to condition the chromatographic column and 
at five sample intervals. The acquired GC-MS spectra were initially processed with the 
Automated Mass Spectral Deconvolution and Identification System software (AMDIS, NIST, 
Gaithersburg, Maryland, USA) by using the Fiehnlib library of compounds (Kind et al., 2009). 
An in-house script was used to import the spectra to MATLAB (Mathworks) where the 
chromatographic peaks of all identified metabolites were manually inspected. Prior to 
integration, features not consistently present in the QC samples were immediately removed 
(Behrends et al., 2011). 
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The GC-MS analysis led to the tentative assignment of 250 different species according to the 
Fiehn library (Fiehn, 2008), of which 50 were confidently assigned and 38 were statistically 
analysed. Reasons of further metabolite exclusion prior to analysis include poor 
chromatographic peak shape and peak overlap.  
Initial examination of the raw data by PCA revealed a significant batch effect between the 
samples and QCs of the two experiments (Figure 3.1A). Furthermore, an exponential decay in 
signal intensity was observed in the majority of the metabolites in the QC samples over time 
in both batches (Figure 3.1B). This meant that the signal intensity of a specific metabolite 
would be significantly lower in the QC samples at the end of the experiment when compared 
to the QC samples used at the beginning of the experiment. The observed signal intensity 
decay was attributed to a combination of instrument instability and decay of the 
derivatization product. 
In order to correct for the observed signal decay in the QC samples 3rd order polynomial 
curves were used (Dunn et al., 2011)(Figure 3.1B1). These functions were used to estimate 
the fractional change (decay factor) of the metabolite signal intensity as the experiment 
progressed, in order to project how the intensity of the metabolite would decay with respect 
to the position of the sample in the experiment. The decay factor for each metabolite in each 
sample, depending on sample position, was multiplied by the original recorded signal 
intensity of that metabolite in that sample. This permitted the interpolation of the metabolite 
intensity to the estimated value of the sample if it was at position one. The resulting PCA 
scores plot (Figure 3.1B2) revealed that a batch effect remained, which was expected since 
the QCs of the two batches (on which the polynomials were based on) were not previously 
clustered in multivariate space.  
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Following intra-batch normalization, inter-batch normalization was performed to account for 
the observed batch effect. Due to the significant range of signal intensity for different 
metabolites in each batch, a logarithmic scale was applied to the data to reduce the variance 
prior to normalization. The median intensity for each metabolite was then calculated in each 
batch and the factor difference between the medians of the two batches was calculated 
individually for each metabolite. The factor of each metabolite was then multiplied with the 
respective intensities in all of the samples in the second batch, which generally had a lower 
intensity value for all metabolites. This multiplication step led to an improved clustering of 
the two batches (Figure 3.1C), as verified by PCA (Wang et al., 2013a). 
UPLC-MS analysis of hepatic aqueous-soluble component 
Liver tissue samples (average weight of 42 mg and STD ± 2.8 mg) were added to ice-cold HPLC 
grade water/methanol (1:1, 1.2 mL total volume) and homogenized with zirconia beads at 
6,500 Hz (Precellys 24-Dual) for two 45 seconds periods with an intermediate 5 minute cooling 
period on dry ice. The homogenized mixtures were incubated for 45 minutes on ice before 
centrifugation at 13,000 rpm for 15 minutes at 4 oC (Biofuge Pico). The resulting supernatants 
were mixed with ice cold methanol/water (2:1, 0.5 mL) prior to overnight incubation at -4 oC. 
The following day the samples were centrifuged at 17,000 g for 15 minutes at 4 oC (Biofuge 
Pico). The samples were then dried overnight in a centrifugal concentrator (SpeedVac) at 
room temperature. The following day the dried supernatants were reconstituted and mixed 
in an acetonitrile/water mixture (1:1, 240 μL total volume) and were then centrifuged at 
17,000 g for 15 minutes at 4 oC. The resulting supernatants (170 μL) were then transferred to 
a 96-well plate.  QC samples were prepared by aliquoting 30 μL from all the remaining 
supernatants into a pooled sample in a glass vial. 
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An Acquity UPLC instrument with an Acquity UPLC BEH HILIC chromatography column coupled 
to an ESI-TOF LCT Premier mass spectrometer (Waters Corp., Manchester, UK) was used to 
acquire the UPLC-MS data. A sample injection volume of 7.50 μL and an elution time of 21 
minutes were used (Spagou et al., 2011). The solvent gradient used gradually changed from 
acetonitrile/water (19:1) to acetonitrile/water (1:1) with a flow rate of 0.4 mL/minute. The 
capillary voltage of the MS instrument was set at 3200 V and the sample cone was 35 V. Mass 
accuracy was ensured with a LockSpray interface (Waters Corp.) with leucine enkephalin 
(556.26 [M+H]+ and 554.26 [M-H]- for positive and negative ionization modes respectively) as 
the mass standards. QC samples were set at the beginning of the run to condition the 
chromatographic column and at seven sample intervals. 
An Acquity UPLC instrument with an Acquity UPLC BEH HILIC chromatography column coupled 
to a Xevo G2-S QTOF (Waters Corp.) was used for metabolite identity verification by MS/MS 
analysis. The UPLC-MS acquisition parameters were set as previously stated, while the 
collision cell voltage was set within the range of 10 kV and 40 kV. MS/MS analysis was used 
to verify the assignments of L-carnitine, acetylcarnitine, propionylcarnitine, adenosine, 
adenine, hypoxanthine, GSSG and APAP. 
The UPLC-MS spectra were processed with MarkerLynx (version 4.1; Waters Corp.) for peak 
detection and marker collection for both ionization methods. The mass boundaries were set 
between 50 and 1000 m/z while the intensity threshold was set at 800 for the positive polarity 
and 600 for the negative mode. The data were normalized by probabilistic quotient 
normalization (Dieterle et al., 2006). Features with CV coefficient of variation (QVcv) greater 
than 30 % were removed prior to analysis. TargetLynx (version 4.1; Waters Corp.) was used in 
a targeted method, with the pure chemical standard, to detect and quantify the positive ion 
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adduct, [M+H]+, of L-carnitine (m/z = 162.115). A 0.2 min retention time deviation window 
was used before peak integration.  
 
Figure 3.1: The three steps of the normalization procedure employed for GC-MS normalization are 
depicted above. A detailed description is provided in the following page QC – quality control; PCA – 
principal component analysis 
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Statistical analysis 
PCA models were initially constructed to obtain an overview of the NMR, UPLC-MS and GC-
MS data following pre-processing and normalization (SIMCA 13.0; Umetrics, Umea, Sweden). 
O-PLS-DA was employed to analyse the NMR (serum and hepatic extract component) and the 
UPLC-MS data in MATLAB (Mathworks) and SIMCA (Umetrics) respectively. In order to avoid 
data over-fitting, a seven fold cross validation, R2Y (goodness of fit) and Q2Y (predictive ability) 
were used. All O-PLS-DA models were tested for statistical significance at p < 0.05 with 
permutation testing (n = 1000 for class membership). A heatmap presenting the Pearson 
correlation coefficient values (R) of the identified discriminatory resonances from the serum 
and hepatic extract NMR O-PLS-DA models was constructed with an R cut-off value of |0.5|. 
Prism 5.0 (Graphpad, La Jolla, California, USA) was used for non-parametric univariate 
statistical analysis (Kruskal-Wallis coupled to Dunn’s multiple test correction) of the liver 
histopathology, clinical chemistry, GC-MS derived integrals and UPLC-MS derived carnitine 
integrals, with a statistical significance threshold set at p < 0.05. 
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Results 
Serum clinical chemistry and liver histopathology  
Serum ALT activity (U/L) was measured for the APAP, AMAP and control groups at 1hr, 3hr 
and 6hr post-treatment (Figure 3.2A). APAP administration led to a statistically significant 
increase of ALT activity at 1hr, 3hr and 6hr (p < 0.05), relative to control levels, while AMAP 
administration did not lead to a statistically significant change at all time-points. At 6hr, the 
APAP group had an average ALT activity of 2052 U/L (STD ± 1486 U/L), while the average ALT 
activities of the control and AMAP groups were 14.5 U/L (STD ± 21 U/L) and 11.8 U/L (STD ± 
10 U/L) respectively. The histopathological analysis which scored the severity of hepatic 
necrosis revealed that APAP administration caused minimal and mild necrosis at 3hr and 6hr 
respectively, relative to the control group. In contrast, the administration of AMAP did not 
lead to an AMAP-induced lesion in the 6 hour timeframe (Figure 3.2B).  
 
Figure 3.2: The mean and standard deviation of the log serum ALT activities (A) and histology necrosis 
scores (B) in the three treatment groups (n = 5 for APAP and AMAP and n = 7 for control per time-
point) are shown above. Statistical significance is indicated by the asterisk (*; p < 0.05). The scoring 
criteria are: 0 = no significant lesions, 1 = minimal, 2 = mild, 3 = moderate. 
APAP and AMAP metabolism 
In the hepatic extracts of the APAP treated group, the APAP-glucuronide, glutathionyl  
conjugates, APAP parent and the N-acetylcysteinyl conjugate were detected at 1hr in order 
of abundance. Similarly, the AMAP-glucuronide conjugate was the most concentrated drug 
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related metabolite in the AMAP treated group, while the AMAP parent was also detected at 
lower levels at the 1hr time-point (Figure 3.3; Figure 3.6A). 
 
Figure 3.3: Representative 1H-NMR spectra of the hepatic extract metabolic profiles for each 
treatment group at 1hr. DRC resonances are coloured in red. Please note that the respective 
intensities of the high and low field regions are not equal. APAP-G – APAP glucuronide conjugate; 
APAP-SG – APAP glutathionyl conjugate; APAP –NAC – APAP N-acetylcysteinyl conjugate; AMAP-G – 
AMAP glucuronide conjugate; asterisk – APAP methoxy conjugate; APAP/AMAP NCOCH3 – Overlapped 
APAP/AMAP and conjugate N-acetyl resonances; D-3-HB – D-3-hydroxybutyrate; Phe – phenylalanine; 
asterisks – AMP resonances. 
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In the serum metabolic profiles at 1hr, the APAP parent and APAP-glucuronide conjugate 
were detected in the APAP treated groups, while the AMAP-glucuronide conjugate was the 
only detected DRC in the AMAP treated group (Figure 3.4).  
 
Figure 3.4: Representative 1H-NMR spectra of the serum metabolic profiles for each treatment group 
at 1hr. Please see legend of Figure 3.3. 
In the urinary metabolic profiles of the APAP treated group at 1hr, the APAP-glucuronide 
conjugate, APAP parent, sulphate, cysteinyl and N-acetylcysteinyl conjugates were detected 
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in order of abundance. In the respective AMAP treated group, the AMAP-glucuronide, 
sulphate and APAP-methoxylated conjugates as well as the parent molecule, were detected 
in order of concentration (Figure 3.5; Figure 3.6B). 
  
Figure 3.5: Representative 1H-NMR spectra of the urinary metabolic profiles for each treatment group 
at 1hr. Please see legend of Figure 3.3. APAP-C – APAP cysteinyl conjugate; asterisk – APAP 
methoxylated conjugate; AMAP-S – AMAP sulphate conjugate 
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In summary, the glucuronide conjugate was the most abundant metabolite for AMAP and 
APAP in all sample matrices. There was no evidence of an AMAP-glutathionyl, cysteinyl or N-
acetylcysteinyl conjugates in all sample matrices. The assignments of all assigned DRCs are 
shown in Table 3.1. Please note that due to extensive overlap, it was not possible to assign all 
of the resonances arising from some compounds. 
 
Figure 3.6: The mean and standard deviations of the integral DRC ratios relative to APAP or AMAP (n 
= 5 for each treatment group) in the hepatic extracts (A) and urine (B) metabolic profiles at 1hr are 
depicted. -G – glucuronide conjugate; -SG – glutathionyl conjugate; NAC – N-acetylcysteinyl conjugate 
; -C – cysteinyl conjugate; -S, sulphate conjugate; Methoxy – methoxylated conjugate. 
 
1H-NMR spectroscopic detected endogenous changes in hepatic extracts after 
APAP and AMAP administration 
The 1H-NMR metabonomic analysis of the hepatic extracts revealed that the concentrations 
of glutathione (reflecting both oxidized and reduced forms – resonance δ 2.54) was 
statistically significantly lower after the administration of APAP at 1hr (2 fold change) and 3hr 
(1.4 fold change) post-treatment (Figure 3.7). In contrast, the administration of AMAP did not 
induce a visible change to glutathione levels at all time-points. 
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Table 3.1: The assigned resonances of AMAP and APAP related molecules are depicted above. 
AMAP/APAP-G – AMAP/APAP glucuronide conjugate; AMAP/APAP-S – AMAP/APAP sulphate 
conjugate; APAP-NAC – APAP N-acetylcysteinyl conjugate; APAP-Cys – APAP cysteinyl conjugate; 
APAP-O-CH3 – APAP methoxylated conjugate; s – singlet; d – doublet; ppm – parts per million; Hα – -
NCOCH3  resonance. 
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Figure 3.7: The mean and standard deviation of total glutathione integrals from the hepatic extracts 
metabolic profiles from the three different treatment groups , at all time-points groups (n = 5 for APAP 
and AMAP and n = 7 for control per time-point), are shown above. Statistical significance, tested by 
Kruskal-Wallis analysis coupled to Dunn’s multiple test correction, is indicated by the asterisks (*) and 
(**) representing p < 0.05 and p < 0.01 respectively. 
 
The hepatic metabolic effect of each xenobiotic at each of the three different time-points 
relative to the control group was characterized by pair-wise O-PLS-DA models. The O-PLS-DA 
model describing the metabolic effect of APAP at 1hr relative to control (Figure 3.8A, R2Y = 
0.9955 and Q2Y = 0.5083) revealed a complete discrimination in the predictive component of 
the scores plot (Tcv, Figure 3.8A1). The corresponding loadings coefficient plot showed that 
endogenous metabolite level perturbations included the elevation in the levels of succinate, 
glycine, fumarate and formate, as well as the depletion of glutathione in the APAP group. The 
robust O-PLS-DA model of the hepatic extracts NMR profiles characterizing the effect of APAP 
at 3hr, relative to control, (Figure 3.8B, R2Y = 0.9820 and Q2Y = 0.4497; p < 0.05) achieved 
partial discrimination in the scores plot (Tcv, Figure 3.8B1). The equivalent coefficient plot 
(Figure 3.8B2) revealed that APAP administration led to the elevation of leucine, glutamate, 
succinate, fumarate and 2-aminoadipate, as well as the depletion of AMP and glutathione. 
Finally, the O-PLS-DA model describing the effect of APAP at 6hr (Figure 3.8C, R2Y = 0.9758 
and Q2Y = 0.4716; p < 0.05) achieved partial separation between the two groups in the scores 
plot (Tcv, Figure 3.8C1). The corresponding coefficient plot (Figure 3.8C2) showed that APAP 
caused an elevation in the levels of glutamate, D-3-hydroxybutyrate (D-3-HB), acetate, 2-
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aminoadipate and leucine, as well as depletion in the levels of glucose, glycogen, AMP and 
glutathione.  
 
Figure 3.8: O-PLS-DA of the hepatic extract 1H-NMR spectra of the APAP-treated group versus the 
control group at 1hr (A), 3hr (B) and 6hr (C) post-treatment. The scores plots (A1, B1 and C1) show the 
separation of the APAP (black) and control (red) samples where Tcv is the predictive component and 
TYosc is the orthogonal component. The coefficients plots (A2, B2 and C2) illustrate the discriminatory 
metabolites between the groups. Resonances pointing up indicate an increase in that specific 
resonance in the APAP group and vice versa. The Pearson correlation scale (R2) ranges from low (0; 
blue) to high (red; 1). The models were validated at p < 0.05 using 1000 permutations. (n = 5 for APAP 
1hr and APAP 6hr, while n = 4 for APAP 3hr, n = 3 for Ctrl 1hr, n = 7 for Ctrl 3hr and n = 6 for Ctrl 6hr) 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
105 
PhD thesis  Michael Kyriakides 
The O-PLS-DA models constructed to describe the 1H-NMR hepatic metabolic effect of AMAP 
relative to the control group at 1hr (R2Y = 0.9940, Q2Y = 0.6844) achieved complete separation 
between the groups in the predictive component of the scores plot. The equivalent coefficient 
plot revealed that AMAP administration led to the elevation of D-3-HB and the concomitant 
depletion of dimethylamine, glucose and glutamine, relative to control levels. The O-PLS-DA 
models characterizing the effect of AMAP at 3hr and 6hr were of low predictive ability, as 
deduced by the Q2Y values, and were therefore not further analysed. 
Overall, the O-PLS-DA of the hepatic extracts metabolic profiles revealed that APAP had a 
progressively more disruptive metabolic effect, as suggested by the increasing amount of 
metabolic perturbations overtime. In contrast the metabolic effect of AMAP was restricted to 
1hr. A summary of the identified metabolic effects of APAP and AMAP can be viewed in the 
form of a heatmap in Figure 3.10 which displays the Pearson correlation value with a cut off 
value of |0.5|. 
Serum O-PLS-DA of APAP and AMAP administration 
Pair-wise O-PLS-DA models were computed to describe the serum metabolic effect of APAP 
and AMAP relative to the control group at the 1hr, 3hr and 6hr time-points. The O-PLS-DA 
models of the sera 1H-NMR spectroscopic profiles that discriminated between APAP and the 
control groups at 1hr and 3hr were of low predictive ability, as deduced by the Q2Y values and 
permutation testing, and were therefore not further analysed. The O-PLS-DA model 
describing the effect of APAP relative to control at 6hr (Figure 3.9A; R2Y = 0.8737 and Q2Y = 
0.4352; p < 0.05) achieved a degree of discrimination in the predictive component of the 
scores plot (Figure 3.9A1). The corresponding coefficients plot (Figure 3.9A2) showed that 
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APAP administration led to the elevation of glutamine and acetate and the concomitant 
depletion of alanine and pyruvate. 
The O-PLS-DA models constructed to reveal the discriminatory metabolites between the 
AMAP administration group and the control group at 1hr (Figure 3.9B; R2Y = 0.9703 and Q2Y 
= 0.6037; p <0.05) achieved partial separation between the two groups in the predictive 
component of the scores plot (Figure 3.9B1. The corresponding coefficients plot (Figure 
3.9B2) revealed that AMAP led to an increase in the levels of citrate and D-3-HB and depletion 
in the levels of alanine, betaine and lactate. The O-PLS-DA model describing the metabolic 
effect of AMAP administration at 3hr, relative to control, (Figure 3.9C; R2Y = 0.8957 and Q2Y 
= 0.4635; p <0.05) achieved partial separation between the two groups in the scores plot 
(Figure 3.9C1). The corresponding coefficients plot (Figure 3.9C2) showed that AMAP 
administration caused a decrease in the levels of betaine, alanine and creatine. The O-PLS-DA 
model describing the metabolic effect of AMAP on serum at 6hr was of low predictive ability, 
as deduced by the Q2Y and permutation testing, and was therefore not further analysed. 
The metabolic effect of APAP in the serum was more pronounced at 6hr, while the metabolic 
effect of AMAP was restricted to the early time-points of 1hr and 3hr, reflecting the results of 
the aqueous soluble hepatic extract analysis’ results. A summary of the APAP and AMAP 
induced metabolic effects in the serum can be seen in Figure 3.10. 
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Figure 3.9: O-PLS-DA models of the serum 1H-NMR spectra of the APAP-treated group (n =5) versus 
the control group at 6hr (n = 7; A) and AMAP-treated group (n = 5) versus the control group at 1hr (n 
= 7; B) and 3hr (n = 5 and n = 5 for the AMAP treated and control groups respectively; C). The scores 
plots (A1, B1 and C1) show the separation of the APAP (black) and control (red) samples, as well as 
AMAP (green) and control (red) samples. Please see legend of Figure 3.8. AMAP-G – AMAP glucuronide 
conjugate. AMAP-NCOCH3 – AMAP and conjugates N-acetyl resonance. 
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Figure 3.10: A summary of the discriminatory metabolites assigned in the O-PLS-DA models of the 
hepatic extracts and serum metabolic profiles after APAP/AMAP administration. Positive correlation 
values (red colour) indicate an increase in the levels of a metabolite and vice versa (blue colour). A 
|0.5| Pearson correlation (R) value cut-off point was used. D-3-HB - D-3-hydroxybutyrate; AMP – 
adenosine monophosphate. 
HILIC-UPLC-MS analysis of hepatic extracts and carnitine 
HILIC-UPLC-MS analysis was used to characterize the hepatic metabolic perturbations 
associated with AMAP and APAP administration. Initially, a PCA trajectory plot was 
constructed to map the trajectory of the HILIC-UPLC-MS hepatic metabolic profiles after APAP 
and AMAP administration overtime, relative to the control groups at each time-point (Figure 
3.11; R2X = 0.5110, Q2X = 0.4740).  The PCA trajectory analysis revealed unique hepatic 
metabolic trajectories for both AMAP and APAP across time. At the 1hr time-point, the 
metabolic profiles of the AMAP-treated group were distinct from those of the control and 
APAP treated groups but at 3hr and 6hr post-AMAP administration, the hepatic extract 
metabolic profiles clustered with those of the control groups. The hepatic extract metabolic 
profiles 1hr post-APAP administration were distinct from those of the AMAP and control 
groups at 1hr. At 3hr and 6hr post-APAP administration, the hepatic metabolic profiles of the 
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APAP treated groups did not return to control levels (as determined by the multivariate space 
clustering) revealing a maintained perturbed metabolic homeostasis at 6hr post-treatment 
and a different trajectory from that of AMAP (Figure 3.11). 
 
Figure 3.11: PCA trajectory plot of HILIC-UPLC-MS hepatic extract analysis. The first and second 
principal component (pc1 and pc2 respectively) average values and standard deviations were 
calculated for each group. The APAP-treated (n = 5), AMAP-treated (n = 5) and control groups (n = 7) 
at all time-points are shown in red, blue and green respectively, while the QCs are shown in black.  
Following the PCA trajectory plot, O-PLS-DA was subsequently employed to discriminate the 
metabolic profile of APAP and AMAP relative to the control group at each time-point. The O-
PLS-DA model (positive polarity) describing metabolic effect of APAP administration relative 
to control at 1hr (Figure 3.12; R2Y = 0.9590 , Q2Y = 0.6940, p < 0.05) achieved complete 
separation in multivariate space (Tcv; Figure 3.12A) and the corresponding S-plot (Figure 
3.12B) revealed that the levels of hypoxanthine, GSSG and L-carnitine were depleted after 
APAP administration, while the levels of adenosine, adenine and the APAP-glucuronide 
conjugate (tentatively assigned) were at higher levels (Figure 3.12B).  Following the discovery 
that L-carnitine was one of the most significant discriminatory metabolites of the APAP-
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treated group at 1hr, it was decided to conduct a targeted analysis on carnitine metabolism 
since this class of metabolites was not characterized by 1H-NMR spectroscopy.  
The targeted analysis of the data acquired in positive polarity showed that free carnitine (L-
carnitine; m/z = 162.114) was statistically significantly depleted at 1hr in the APAP cohort, 
relative to the control cohort as calculated by TargetLynx (Waters Corp.) and tested with the 
Kruskal-Wallis test coupled to Dunn’s multiple test correction (Figure 3.12C). The levels of free 
carnitine in the APAP-treated cohort were not statistically significantly different at 3hr and 
6hr from those of the control group, while AMAP was not observed to have an effect at any 
time-point. Figure 3.12D illustrates the mass fragmentation pattern of L-carnitine. Other 
carnitine conjugates were detected during the targeted analysis but were not found to be 
statistically significantly different between all treated groups at all time-points. 
GC-MS analysis of hepatic extracts 
The GC-MS analysis of the hepatic extracts revealed that APAP-administration led to the 
statistically significant elevation of guanosine, xanthine and nicotinamide at 1hr and the 
depletion of hypotaurine and thymine at 3hr (Table 3.2). At 6hr, APAP administration led to 
the elevation of phosphoenolpyruvate, 3-phosphoglycerate and uracil, as well as the 
concomitant depletion of hypotaurine, AMP, inosine monophosphate, adenosine, 
methionine and aspartate. The respective analysis characterizing the metabolic effect of 
AMAP revealed a statistically significant elevation of guanosine at 1hr while there were not 
any observed statistically significant changes at the later time-points. A summary of the 
xenobiotic-induced statistically significant effects in the aqueous soluble hepatic extracts 
after GC-MS analysis is presented in Table 3.2. Overall the GC-MS analysis results revealed a 
similar pattern to that observed in the 1H-NMR spectroscopic analysis.  
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Figure 3.12: The O-PLS-DA hepatic extract model scores and S-plots (positive polarity data) describing 
the metabolic effect of APAP (n =5) relative to the control (n = 7) at 1hr are depicted above (A and B 
respectively). The mean and standard deviation of the L-carnitine integrals (m/z 162.115 [M-H]+) in 
each treatment group (n = 5 for APAP/AMAP and n = 7 for control per each time-point) is shown at C 
and the fragmentation pattern of carnitine by MS/MS is also depicted (D). Kruskal-Wallis tests coupled 
to Dunn’s multiple test correction was used to determine statistical significance which is signified by 
the asterisk (*), representing p < 0.05. GSSG – oxidized glutathione; APAP-G – APAP glucuronide 
conjugate (tentatively assigned); 13C – molecule isotope with an additional 13C atom (+1 in m/z). 
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Treatment 
group 
 
Time-points 
 
1hr 
 
3hr 
 
 
6hr 
Elevated 
 
Depleted 
 
Elevated 
 
Depleted 
 
Elevated 
 
Depleted 
 
 
APAP 
guanosine* 
xanthine* 
nicotinamide* 
  
hypotaurine** 
thymine* 
3-PG* 
PEP** 
uracil* 
hypotaurine** 
AMP* 
IMP* 
adenosine* 
methionine* 
aspartate* 
 
 
AMAP 
 guanosine*        
 
Table 3.2: Summary of the statistically significant discriminatory metabolites from the GC-MS analysis 
of the hepatic extracts after APAP/AMAP administration (n = 5 at each time-point per treatment 
group) relative to control (n = 7 at each time-point). Statistical significance is represented by the 
asterisks (*) and (**) which signify p < 0.05 and p < 0.01 respectively. PEP – phosphoenolpyruvate; 3-
PG – 3-phosphoglycerate; AMP – adenosine monophosphate; IMP – inosine monophosphate. 
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Discussion 
APAP and AMAP metabolism in C57BL/6 mice 
The 1H-NMR spectroscopic profiling of the serum, hepatic extract and urine matrices 
characterized and contrasted the biotransformation products of the two xenobiotic 
compounds. The glucuronide conjugate was consistently the most abundant DRC in all three 
sample matrices for both treatment groups, as also reported in the literature in Swiss-
Webster mice (Rashed et al., 1990). The most significant difference between the observed 
DRCs of the two administered compounds was the absence of glutathionyl conjugate related 
molecules after in the AMAP administration groups. In contrast, the APAP-glutathionyl and 
N-acetylcysteinyl conjugates were detected in the hepatic extract metabolic profiles, while 
the APAP-cysteinyl and APAP-N-acetylcysteinyl were observed in the urine. The presence of 
glutathione conjugates in the hepatic extract and urinary metabolic profiles post-APAP 
administration corroborated the observed APAP-induced depletion of hepatic glutathione at 
1hr and 3hr, relative to control levels. In contrast, the absence of AMAP glutathionyl 
conjugates and of an AMAP-induced depletion of hepatic glutathione suggested that the 
administration of AMAP did not lead to oxidative stress. It is however likely that AMAP 
metabolism did lead to the formation of reactive quinones and subsequent glutathione 
conjugates which were simply below the detection limit of NMR or where excreted through 
the bile, as reported (Rashed and Nelson, 1989a). Moreover, previous studies in the mice have 
suggested that the majority of AMAP quinones in Swiss-Webster mice are formed through 
the 3-OH-APAP intermediate (common metabolite with APAP), whose methoxylated 
derivative was detected in the metabolic profiles of the AMAP treated group at 1hr post-
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treatment (Rashed and Nelson, 1989a, Rashed et al., 1990) and therefore further suggesting 
the formation of undetected AMAP derived reactive quinones. 
APAP administration leads to hepatotoxic endpoint characterized by oxidative 
and energetic stress  
Liver histopathology and clinical chemistry inferred that the APAP-induced oxidative stress 
resulted in hepatocellular cell death at 3hr and 6hr. The metabolic effect of APAP was visible 
from the early 1hr time-point and was deemed to be, as deduced by the highest number, in 
terms of metabolic perturbations, maximal at the 6hr time-point in all sample matrices. The 
progressive nature of the APAP-induced metabolic effect and the histopathological evidence 
of liver necrosis reveal that the hepatocytes did not recover from the initial toxic insult, which 
led to oxidative stress (visible from the 1hr time-point) and subsequently resulted in a 
disruption of homeostasis and eventual cell death. 
The depletion of hepatic glutathione at 1hr and 3hr post-APAP administration resulted in 
other downstream hepatic metabolic effects, such as the consumption of hypotaurine at 3hr 
and 6hr and methionine at 6hr, as observed by the GC-MS analysis. Glutathione depletion will 
cause a higher rate of glutathione synthesis, which will lead to a higher rate of utilization and 
subsequent depletion of cysteine. Lower levels of cysteine would lead to the consumption of 
other sulphur containing compounds, including methionine and hypotaurine in order to 
replenish cysteine stocks. Methionine can be converted to cysteine through homocysteine in 
the transsulfuration pathway (Lu, 1999), while hypotaurine is a downstream metabolite of 
cysteine. In-vitro studies have shown that methionine levels are decreased in response to 
oxidative stress through the formation of cysteine (Panayiotidis et al., 2009), while liver 
hypotaurine depletion has also been reported to occur in response to drug-induced oxidative 
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stress (Jung et al., 2013). Finally, a previous investigation has demonstrated that APAP 
administration can lead to hepatic hypotaurine and methionine depletion in rats (Yamazaki 
et al., 2013). 
APAP-induced oxidative stress, coupled to the covalent binding of NAPQI to mitochondrial 
proteins, can cause mitochondrial dysfunction which results in energetic stress (Jaeschke et 
al., 2012). NAPQI has been reported to bind to mitochondrial proteins such as glutamate 
dehydrogenase (Halmes et al., 1996), aldehyde dehydrogenase (Landin et al., 1996), succinate 
dehydrogenase (part of mitochondrial complex II in the electron transport chain) (Dixon, 
1984, Katyare and Satav, 1989) and the α-subunit of ATP synthetase (Qiu et al., 1998). 
Covalent modification of mitochondrial proteins will impair their function and lead to a loss 
of mitochondrial homeostasis. The perturbation of mitochondrial protein function could 
explain the elevated hepatic levels of succinate and fumarate at 1hr and 3hr, as well as 
glutamate at 3hr and 6hr. However, another possible hypothesis for the observed elevations 
of fumarate and succinate is that the disruption of mitochondrial function led to a decreased 
rate of utilization of Krebs cycle intermediates, leading to the early elevation in the levels of 
succinate and fumarate (Burcham and Harman, 1991) (Figure 3.13). 
APAP-induced mitochondrial impairment has already been reported to decrease 
mitochondrial ATP production (Katyare and Satav, 1989), which could trigger an upregulation 
of glycolysis as a compensatory mechanism. This hypothesis is supported by the observed 
concomitant depletion of glucose and glycogen coupled with the elevation in the levels of D-
3-hydroxybutyrate and acetate at 6hr after APAP administration which could be indicative of 
energetic stress and a shift to glycolysis, as previously suggested by other metabonomic 
studies (Coen et al., 2003, Coen et al., 2004). Furthermore, an upregulation of glycolysis and 
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an increased consumption of glucose would lead to a rise in the levels of glycolytic 
intermediates such as phosphoenolpyruvate and 3-phosphoglycerate, as observed in the GC-
MS analysis of the hepatic extracts at 6hr post APAP-administration (Figure 3.13). 
Another class of metabolites that is closely associated with mitochondrial function is free 
carnitine and the acylcarnitine conjugates. Fatty acid molecules bind to carnitine in order to 
be transported into the mitochondria for fatty acid β-oxidation to take place (Bremer, 1983). 
In addition to its role in fatty acid metabolism, carnitine is also known for its anti-oxidative 
properties during drug-induced oxidative stress (Yapar et al., 2007). The observed depletion 
of hepatic carnitine at 1hr could therefore be indicative of oxidative stress and early 
mitochondrial dysfunction through the impairment of β-oxidation impairment (Figure 3.13). 
Serum carnitine has been reported to be depleted in humans after exposure to APAP 
(Nowaczyk et al., 2000), while the serum levels of carnitine conjugates have also been 
reported to be elevated in mice shortly after APAP administration (Chen et al., 2009) and 
humans (McGill et al., 2014a). It is worth noting that the time scale required by APAP-induced 
toxicity to affect the levels of carnitine (in the serum or liver) compared to the latter observed 
metabolic effects, suggests that the inhibition of β-oxidation could be an early milestone of 
mitochondrial dysfunction as previously hypothesized (Chen et al., 2009). 
In addition to the perturbation of energy metabolites, APAP administration was also observed 
to affect nitrogenous base containing compounds. The NMR and GC-MS analysis revealed that 
AMP was depleted at the 6hr time-point after post APAP administration while the GC-MS 
analysis also revealed other perturbations in the levels of nucleobases (uracil and thymine) 
and nucleosides (adenosine) throughout the duration of the study. The UPLC-MS analysis also 
showed a general APAP-induced perturbation in the levels of adenosine related molecules, 
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such as hypoxanthine and adenine. However, since adenosine, adenine and hypoxanthine are 
all derivatives of AMP it might be possible that the energy associated with molecule ionization 
in the MS source could lead to the fragmentation of the parent compound and therefore the 
apparent perturbations of the levels of these metabolites might not be directly linked to the 
metabolic effect of APAP. This hypothesis is also supported by MS/MS experiments which 
revealed that the AMP ion ([M+H]+; m/z = 348.064; data not shown) was fragmenting to the 
smaller nucleosides and nitrogenous bases. APAP has been previously suspected to have a 
general effect on the levels of nitrogenous base compounds through DNA damage (Bessems 
and Vermeulen, 2001) and the inhibition of adenosine deaminase (Ataie et al., 2004). 
Furthermore, it is has also been hypothesized that an APAP-induced degradation of adenine 
nucleotides is an attempt to produce more energy as a response to the depletion of ATP 
(Tirmenstein and Nelson, 1990). A summary of the observed hepatic metabolic and toxic 
effect of APAP is shown in Figure 3.14. 
Finally, the general delay observed in the metabolic effect of APAP in the serum metabolic 
profiles, relative to the liver, was expected since the liver is the primary site of APAP 
metabolism and would therefore be the first site to develop drug-induced metabolic changes. 
The lower levels of both pyruvate and alanine at 6hr post-APAP treatment could be linked to 
the potential up-regulation of gluconeogenesis in response to the aforementioned hepatic 
glucose depletion (Exton, 1972). However, this observation is in contrast to what has been 
reported in a different strain of mice (Coen et al., 2003) and the underlying reason for this 
discrepancy is not clear.  
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Figure 3.13: Summary of metabolic perturbations associated with APAP-induced mitochondrial 
dysfunction and oxidative stress. Diagrammatic representations of the glycolysis pathway (A), Krebs 
cycle (B) and glutathione synthesis (C) are shown. Red shading depicts APAP-induced elevations, while 
blue shading represents APAP-induced depletions. D-3-HB – D-3-hydroxybutyrate. 
AMAP administration leads to a reversible non-hepatotoxic endpoint 
The clinical chemistry and histopathology results did not reveal any signs of AMAP-induced 
liver damage and were therefore in agreement to the drug metabolism analysis, where the 
reactive metabolites of AMAP were not observed to cause oxidative stress or form 
glutathione adducts. Relatively lower concentrations of AMAP related quinones have also 
been reported by previous investigations which noted that the mercapturic acid conjugates 
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of AMAP in Swiss-Webster mice represented 5% of the  dose (600 mg/kg), while the 
mercapturic and cysteinyl conjugates of APAP comprised of approximately 20 % of the APAP 
dose (250 mg/kg) (Rashed et al., 1990). Assuming that the administration of APAP and AMAP 
result in a comparable hepatic exposure, the literature findings coupled to the results of this 
study, suggest a difference in their propensity for bioactivation or their relative affinity for 
alternative routes of metabolism, such as glucuronidation or sulphation. Furthermore, this 
hypothesis is also supported by a recent computer simulation (DILIsym) which suggested that 
the difference of toxicity between the two compounds exists due to a quantitative difference 
in the amount of reactive metabolite formed by APAP and AMAP. This is understood to be 
due to the inability of the AMAP parent molecule to be directly oxidized to a quinone by CYP 
enzymes, as well as the reported CYP 2E1 inhibition by AMAP-related reactive metabolites 
(Howell et al., 2014, Halmes et al., 1998). 
The interpretation of the metabolic effects of AMAP was difficult because of their transient 
nature. It is interesting however that AMAP had a more pronounced metabolic effect in the 
serum at 1hr and 3hr relative to control, in comparison to the metabolic effect of APAP. This 
could be an indication that the hepatic metabolic effect of AMAP is more immediate, as 
previously suggested (Potter et al., 1974, Roberts et al., 1990), while it is also indicative of 
non-critical protein binding since the effect was transient and did not lead to an observable 
liver damage. Finally, another possible explanation of the early AMAP-induced metabolic 
effect is that AMAP might be metabolized at other sites other than the liver, but this is less 
likely since the liver has the highest concentration of CYP enzymes. 
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Figure 3.14: The interpreted APAP-induced hepatic metabolic changes at each of the time-points are 
shown above. Elevated metabolites are shown in red while depleted metabolites are shown in blue. 
PEP – phosphoenolpyruvate; 3-PG – 3-phosphoglycerate; ALT – alanine amino transferase. 
Study limitations 
The absence of data revealing the degree of covalent binding of the reactive metabolites of 
each compound at the selected dose rendered the direct comparison of their metabolic 
effects more difficult because it was not possible to determine whether the contrasting 
metabolic differences were simply the result of a smaller amount of AMAP quinones being 
formed. It is worth noting however that using relative amounts of APAP and AMAP which 
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result to a similar degree of covalent binding might not be the optimal way of comparing their 
contrasting toxicities because their reactive metabolites interact with different proteins 
(Roberts et al., 1990). Ideally, a dose response study with a low non-toxic dose, a mid and a 
high toxic dose would have facilitated the contextualization of the metabolic effects induced 
by each compound, as well as the separation of the pharmacological and toxicological effects. 
This is especially true for AMAP, where higher doses could have led to a greater potential of 
causing an adverse effect, as reported in rat and human liver slices (Hadi et al., 2012). Finally, 
another important limitation of this study was the absence of animal food intake records. 
Energy metabolite levels were expected to be perturbed since APAP is hypothesized to cause 
toxicity through mitochondrial dysfunction but the extent of contribution of a potential 
reduced dietary intake to the observed metabolic effect is unknown. 
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Chapter 4: Metabolic characterization of a model of non-alcoholic 
steatohepatitis 
 
The hepatic extract and urine analysis presented in this chapter have been previously 
published (Kyriakides et al., 2014). A copy of the publication is provided in the appendix.  
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Introduction 
Study details and aims 
The work in this chapter presents the metabonomic characterization of the MCD diet model 
in rats. Specifically, hepatic aqueous-soluble extract, faecal water and urine 1H-NMR 
spectroscopic metabolic profiles of rats fed with either a normal or MCD diet are described. 
The aim of this investigation was to generally characterize the baseline metabolic profile of 
the MCD diet model of NASH in order to further understand the metabolic perturbations 
associated with the hepatic physiological changes, as induced by the MCD diet relative to the 
control diet. The metabonomic analysis of the three sample matrices would also facilitate the 
characterization of the systemic metabolic changes hypothesized to be associated with the 
physiological effects of this condition. 
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Methods 
This study was conducted in parallel to the work presented in Chapter 5, where the metabolic 
consequences of MTX administration in rats fed with either a control or MCD diet were 
investigated. The methods relevant to both chapters are presented below. The animal 
handling and treatment was conducted by our collaborators at the University of Arizona, 
Tucson, Arizona, USA. 
Animal handling and treatment 
Male Sprague-Dawley rats (n = 44, Harlan Laboratories; Indianapolis, IN) were housed in an 
AAALAC-accredited animal facility for one week prior to the initiation of the experiments, 
where they were acclimated to 12-hour light and dark cycles. The rats were then split 
randomly into the two diet groups (n = 20 and n = 22 for the control and MCD diet group 
respectively) and were provided ad libitum tap water and either fed a choline sufficient and 
amino-acid defined diet or the equivalent methionine-choline deficient diet (Dyets Inc; 
Bethlehem, PA) for a period of 8 weeks. Each diet group was then randomly split to four 
different treatment groups which were administered either 10, 40, 100 mg/kg of MTX (0.3 M 
sodium bicarbonate ;Toronto Chemicals; Toronto, Canada; n = 5 per dose group per diet; n = 
6 for 100 mg/kg in the MCD diet group) or vehicle (n = 5; 0.3 M sodium bicarbonate) via a 
single intra-peritoneal injection. 
Faecal samples were collected at two pre-dose time periods, baseline, (-12 to -6 and -6 to 0 
hours; 0hr; n = 36 and n = 42 for the control and MCD diet respectively) and at a single post-
dose time period (36 – 48 hours; 48hr). Urine samples were collected at a single pre-dose 
time period, baseline, (-6 to 0 hour collection; 0hr; n = 21 and n = 22 for the control and MCD 
diet respectively) and across the following time periods (n = 5 per MTX dose group per diet; n 
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= 6 for 100 mg/kg MTX in the MCD diet): 6 - 12 (12hr), 18 -24 (24hr) and 36 - 48 (48hr) hours 
post-dose. At 96 hours post-dose, animals were euthanized (n = 5 per MTX dose group per 
diet; n = 6 for 100 mg/kg MTX in the MCD diet) via CO2 asphyxiation and liver samples were 
collected. All samples were immediately snap frozen after collection and stored at -80 °C. 
Liver histopathology and imaging 
Histomorphologic examination of the medial lobe from the liver tissue of each animal was 
carried out by fixing it in 10% neutral-buffered formalin for 24 hours and then placing it in 
70% ethanol until paraffin embedding and H & E staining. Liver sections were examined by 
light microscopy by a board certified blinded veterinary pathologist for liver necrosis, 
inflammation, fibrosis, lipid accumulation and biliary hyperplasia. The scoring criteria were as 
follows: 0 (no lesion), 1 (<10% lesion; minimal), 2 (10 - 25 % lesion; mild), 3 (25 - 40 % lesion; 
moderate), 4 (40 - 50 % lesion; marked) and 5 (>50 % lesion; severe). 
Sample preparation and 1H-NMR spectroscopy of urine 
The protocol for sample preparation and 1H-NMR spectroscopy of urine was performed as 
previously described in Chapter 3. NMR spectral data were acquired on a Bruker Avance-600 
spectrometer operating at 600.13 MHz (14.1 T) 1H frequency and at a temperature of 300 K 
using a Bruker TXI probe and an automated sample handling carousel (Bruker). A standard 
one-dimensional solvent suppression pulse sequence was used to acquire the FID as 
described previously. The acquisition parameters can be seen in Table 8.1 in the appendix. 
Sample preparation and 1H-NMR spectroscopy of faecal water 
Faecal samples were prepared for 1H-NMR analysis as previously described in the literature 
(Saric et al., 2008). Briefly, 50 mg of faecal sample from each rat (average of 49.98 mg and 
STD ± 2.64) was mixed with phosphate buffer  (1.1 ml, 0.2M final concentration, 99 % D2O) 
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containing NaN3 (3.3 mM) and TSP (1 mM). The mixture was homogenized thrice for 40 
seconds, each followed by a five minute cooling down period on ice. The resulting 
homogenate was then centrifuged at 17,000g for 20 minutes and then 700 µl of the 
supernatant was centrifuged again at 14,000 g for 5 minutes. Finally 550 µl of the final 
supernatant was then transferred to an NMR tube for spectral acquisition. A standard one-
dimensional solvent suppression pulse sequence and CPMG spin-echo pulse sequence were 
used to acquire the FID. The acquisition parameters can be seen in Table 8.1 in the appendix. 
Sample preparation and 1H-NMR spectroscopy of hepatic aqueous-soluble 
extracts 
The general protocol for liver metabolite extraction and 1H-NMR spectroscopy of the hepatic 
aqueous-soluble extracts was performed as previously described in Chapter 3. The weighed 
liver tissue samples had a mean weight of 52.5 mg and a standard deviation of ± 0.73 mg. 
NMR spectral data were acquired on a Bruker Avance-600 spectrometer operating at 600.13 
MHz (14.1 T) 1H frequency and at a temperature of 300 K, using a Bruker TXI probe and an 
automated sample handling carousel (Bruker). A standard one-dimensional solvent 
suppression pulse sequence and CPMG spin-echo pulse sequence were used to acquire the 
FID. The acquisition parameters can be seen in Table 8.1 in the appendix. 
1H-NMR spectral data processing 
The NMR spectra were processed in TopSpin 3.0 NMR software (Bruker) and MATLAB 
(Mathworks) as described in Chapter 3. Processing prior to alignment and normalization 
included the removal of the TSP, tartrate, water and glucosan resonances from the hepatic 
aqueous-soluble component spectra, the removal of the ethanol, methanol, urea, water, 
glucosan, TSP and tartrate resonances from the urinary spectra and finally the removal of TSP, 
tartrate, ethanol and water resonances from the faecal water spectra. Spectral assignments 
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were performed using STOCSY, spectral databases (in-house, Human Metabolome Database 
and Biological Magnetic Resonance Bank), Chenomx NMR Suite and previously published 
assignments (Nicholson et al., 1995, Waters et al., 2005, Saric et al., 2008). The assignments 
of uracil, hypoxanthine, inosine, uridine, maltose, mannose, choline, phosphocholine and 
glycine in the hepatic aqueous-soluble extracts, sarcosine, propionate, isovalerate and 5-
aminovalerate in the faecal water and dimethylamine, methylamine, phenylacetylglycine, 
putrescine, 3-indoxylsulphate, tartrate, glucosan and taurine in the urine were confirmed by 
addition of the pure standard compounds (‘spike-in’ experiments). Please note that the 
glutathione assignment in the hepatic extracts refers to total hepatic glutathione (sum of 
oxidized and reduced glutathione), while dihydroxyacetone and choline have been tentatively 
assigned in the faecal water metabolic profiles. 
Statistical analysis 
Multivariate statistical tools were employed to analyse the 1H-NMR spectroscopic data of the 
urine, faecal water and hepatic extracts. O-PLS-DA in MATLAB (Mathworks, using in-house 
scripts) was subsequently performed, which discriminated between the two diets.  The pre-
dose time periods (0hr) of the urine and faecal water spectra were compared, while the 
vehicle groups were compared in the hepatic extracts. Area normalization was used in the 
faecal extract analysis and probabilistic normalization was used for the urinary and hepatic 
extract analysis. The models were validated by permutation testing (p < 0.05, n = 1000) and 
the results are presented in the form of a heatmap as discussed in Chapter 3. Prism 5.0 
(Graphpad) was used for non-parametric univariate analysis (Kruskal-Wallis tests coupled to 
the Dunn’s multiple test correction). A significance threshold value of p < 0.05 was set 
throughout.  
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Results 
Liver histopathology 
Liver was histopathology scored for liver necrosis, liver inflammation, lipid accumulation, 
biliary hyperplasia and liver fibrosis. The MCD diet was observed to be characterized by 
marked lipid accumulation, mild liver necrosis and moderate liver inflammation, while there 
were no signs of biliary hyperplasia or liver fibrosis (Figure 4.1). The control diet group did not 
have any observed histopathology. 
 
Figure 4.1: Histopathology scores representing lipid accumulation (A), liver necrosis (B) and liver 
inflammation (C) (mean and standard deviation) of the vehicle groups in both the control and MCD 
diet groups (n = 5 for each) are depicted above. The scoring criteria are: 0 = no significant lesions, 1 = 
minimal, 2 = mild, 3 = moderate, 4 = marked and 5 = severe. Veh – Vehicle. 
 
Animal body weight 
The body weight of the animals was recorded at the beginning and at the end of the study. At 
the beginning of the study, the control diet animals had an average weight of 391 g (STD ± 40 
g) whilst the animals fed with the MCD diet had an average weight of 202 g (± 10 g), while 
minimal weight loss was recorded by the end of the study (Figure 4.2). The weight difference 
of the two different diet groups was statistically significant at both time-points (p < 0.05). 
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Figure 4.2: The mean and standard deviation of the weight of the animals at the beginning of the study 
(Start) and at the end (End) for both diet groups (n =5 for each group) are shown above. Statistical 
significance is indicated by the asterisks (**), representing p < 0.01. 
Hepatic metabolic phenotype of the NASH model 
Pair-wise O-PLS-DA models were constructed to identify the discriminatory metabolites 
between the two diet groups in the hepatic aqueous soluble component. A robust O-PLS-DA 
model (Figure 4.3A; R2Y = 0.9913, Q2Y = 0.9315 and p < 0.05) achieved complete separation 
between the metabolic profiles of the two diet groups as seen in the scores plot (Tcv; Figure 
4.3A1). The corresponding coefficient plot (Figure 4.3A2) inferred that the metabolic 
signature of the MCD diet group included depleted levels of glucose, glycogen, mannose, 
maltose, glutathione, lactate, niacinamide, choline, phosphocholine, trimethylamine, 
tyrosine, 1-methylhistidine, inosine and uridine, together with elevated levels of glycine, 
lipids, fumarate and formiminoglutamic acid (FIGLU), with respect to the control diet group. 
A summary of the discriminatory metabolites is presented in Table 4.1. 
Urinary metabolic phenotype of the NASH model 
The O-PLS-DA model computed to compare the urinary baseline (pre-dose, -6 to 0 hours) 
metabolic profiles of the two diet groups (Figure 4.3B; R2Y = 0.9519, Q2Y = 0.9040 and p < 
0.05) achieved complete discrimination as evidenced by the scores plot (Tcv, Figure 4.3B1). 
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The corresponding coefficient plot (Figure 4.3B2) showed that the MCD diet group animals 
had elevated levels of citrate, urocanate, guanidinoacetate, methylamine, taurine, formate 
and FIGLU, and depleted levels of trimethylamine-N-oxide (TMAO) and dimethylamine 
relative to the control diet animals. A summary of the findings is presented in Table 4.1. 
Faecal water metabolic phenotype of the NASH model 
O-PLS-DA models were also computed to compare the pre-dose faecal water metabolic 
profiles of the two diet groups (-12 – -6 and -6 to 0 hours). The two pre-dose time periods in 
each diet were not statistically significantly different and were therefore grouped together to 
achieve greater statistical power. The robust model (Figure 4.3; R2Y = 0.8429 Q2Y = 0.7533 
and p < 0.05) achieved a significant degree of separation in multivariate space (Tcv, Figure 
4.3C1). The corresponding coefficient plot revealed that the MCD diet group had higher levels 
of glucose and fructose and reduced levels of tyrosine, choline, galactose and methionine. A 
summary of the findings is shown in Table 4.1. 
Pathways Hepatic component Urine Faecal water 
 
Choline 
metabolism 
 methylamine  
 
choline, phosphocholine, 
trimethylamine 
dimethylamine 
trimethylamine-N-oxide 
choline 
 
Energy 
metabolism 
fumarate citrate glucose, fructose 
 
 
 
glucose, glycogen, lactate, maltose, 
mannose 
 galactose 
 
Nucleic acids inosine, uridine   
 
 
Amino acids 
 
FIGLU, glycine 
FIGLU, urocanate, 
guanidinoacetate, taurine 
 
 
glutamate, glutathione, niacinamide, 
tyrosine 
 tyrosine, methionine 
    
Other  formate  
Table 4.1: All of the metabolic perturbations shown are relative to the MCD diet group. Red and blue 
indicate elevation and depletion of the metabolite levels respectively with respect to the control 
group. A cut-off point of |R| > 0.5 was used. FIGLU, formiminoglutamic acid. 
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Figure 4.3: The O-PLS-DA models comparing the vehicle group or baseline (0hr) metabolic profiles of 
the two diets in the hepatic component (A; n = 5 per group), urine (B; n =22 per diet group) and faecal 
water (n = 36 and n = 42 for control and MCD diet respectively; C) are depicted above. The scores plots 
(A1, B1, C1) reveal the separation in multivariate space between the MCD diet (red) and the control 
diet (black), while the corresponding coefficient plots (A2, B2, C2) reveal the discriminatory 
metabolites predicted by each model. Resonances pointing up are higher in the control diet groups 
and vice versa. The colour scale on the right reveals the Pearson correlation coefficient (R2) of each 
data point. TMAO – trimethylamine-N-oxide; FIGLU – formiminoglutamic acid.  
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Discussion 
The MCD diet is an important model for the study of the hepatic consequences of fat 
accumulation, inflammation, fibrogenesis, oxidative stress and altered drug metabolism 
which are all features of NASH (Kucera and Cervinkova, 2014, Fisher et al., 2009). Despite the 
extensive existing research on this model, we have a limited understanding concerning the 
metabolic phenotype of the MCD diet model and why significant inter-species and inter-
gender differences are observed in rodents (Kirsch et al., 2003, Kucera and Cervinkova, 2014). 
Such questions emphasize the importance of improving our understanding of the underlying 
hepatic pathology induced by the MCD diet in order to further contextualize its use as an 
animal model of NASH. 
Histopathology of the MCD diet baseline 
Histopathological analysis revealed that the MCD diet model of NASH was characterized by 
inflammation, necrosis and lipid accumulation (steatosis), all of which are part of the NASH 
clinical presentation (Brunt, 2001). The systems level metabolic profiles revealed that the 
MCD diet induced significant metabolic perturbations, affecting a spectrum of important 
metabolic pathways, especially methionine, choline and energy metabolism, as well as 
causing oxidative stress. The MCD diet is linked to the disruption of one carbon metabolism 
through deficiency of choline and methionine (Figure 4.4), which would lead to a cascade of 
consequences that would affect the biosynthesis of nucleotides, lipids and proteins (Locasale, 
2013).  
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Figure 4.4: A simplified diagrammatic representation of the interaction of the methionine cycle 
(blue), folate cycle (black), choline catabolism (red) and histidine catabolism (orange) pathways, are 
depicted above. THF; tetrahydrofolate; FIGLU – formiminoglutamic acid. 
Hepatic metabolic phenotype of NASH 
Multivariate modelling of the hepatic metabolic profiles revealed the MCD diet induced 
significant metabolic perturbations affecting amino acid, energy, lipid, choline and nucleoside 
metabolisms. The observed depletion of hepatic choline, phosphocholine and trimethylamine 
in the MCD diet relative to the control diet were most likely directly linked to the choline 
deficient nature of the diet. Glutathione levels, a marker of oxidative stress, was also observed 
to be at lower levels in the MCD diet group, which could be another direct effect of the 
methionine deficiency of the diet or linked to the NASH condition itself since it has previously 
been reported to cause oxidative stress (Musso et al., 2013). The depletion of nicotinamide 
in the MCD diet group could also be linked to oxidative stress through the upregulation of 
nicotinamide adenine dinucleotide (NAD) synthesis (Xu and Sauve, 2010). 
Interestingly, the elevation of glycine in the MCD diet group seemed to contradict the other 
observed changes. Glycine is an amino acid that can be synthesized via various metabolic 
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pathways, the majority of which require choline or tetrahydrofolate (THF) (Wang et al., 
2013b); therefore the methionine and choline deficient nature of the diet would have been 
expected to lead to glycine depletion. Furthermore, a previous study has reported that glycine 
levels remain unchanged in NASH patients (Dasarathy et al., 2009). The observed elevation 
could be due to an up-regulation of glycine synthesis to compensate for the aforementioned 
glutathione depletion or because of a disruption of the mitochondrial glycine cleavage system 
which is the main pathway of glycine degradation (Wang et al., 2013b). 
The observed hepatic depletion of glycogen, lactate, maltose, mannose and glucose in the 
MCD diet group were suggestive of impairment in hepatic energy metabolism. Energy 
metabolism dysfunction could be a consequence of a defective mitochondrial respiratory 
chain which has been reported to be a characteristic of NASH (Perez-Carreras et al., 2003) or 
the inhibition of SCD-1, an enzyme involved in the regulation of the rate of metabolism (Rizki 
et al., 2006) and whose inhibition has been previously linked to higher energy expenditure in 
mice. A potential inhibition of SCD-1 is not likely to be linked to the accumulation of lipids 
since it has been reported to lead to an up-regulation of genes involved in β-oxidation which 
results in protection from adiposity (Miyazaki et al., 2004). The accumulation of lipids is 
believed to be linked to a disruption of cholesterol transport as a result of choline deficiency 
(Larter and Yeh, 2008). 
As previously mentioned, an important effect of the methionine and choline deficiency is the 
disruption of the folate cycle (Figure 4.4), which would result in an inhibition of THF formation. 
As Figure 4.4 illustrates, depletion of THF would lead to an inhibition of conversion of FIGLU 
to glutamate, which would result in higher levels of hepatic FIGLU in the MCD diet group. 
Furthermore, a disruption of the folate cycle would have a severe effect on nucleotide 
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biosynthesis and could be linked to the observed higher levels of hepatic nucleosides; inosine 
and uridine (Crider et al., 2012). 
Urinary metabolic phenotype of the MCD diet 
The majority of the discriminatory metabolites identified in the urinary baseline metabolic 
profile of the MCD diet were directly correlated to the observed hepatic metabolic 
perturbations. The higher levels of TMAO and dimethylamine in the urine of the control diet 
group could be attributed to the choline deficiency of the MCD diet. Higher levels of formate, 
urocanate and FIGLU are possibly due to the aforementioned disruption of the folate cycle by 
the MCD diet (Figure 4.4). Finally, higher levels of guanidinoacetate, a urinary metabolite of 
glycine, in the MCD diet group are most likely linked to the aforementioned higher levels of 
hepatic glycine. 
Potential perturbation of microbial populations 
Metabolic profiling of the faecal water could potentially provide information concerning 
gastrointestinal or microbial population disturbances. The microbiota are thought to have an 
important role in the development of NAFLD and NASH (Zhu et al., 2013, Moschen et al., 2013, 
Abu-Shanab and Quigley, 2010), while lactic acid bacteria in the colon have been reported to 
be involved in the development of the NASH like disease induced by the MCD diet (Okubo et 
al., 2013). The lower levels of galactose in the MCD diet group could be linked to a disturbance 
in the microbial population in the colon since galactose can be derived from the catabolism 
of dietary fibres or mucin oligosaccharides via bacterial fermentation in the colon (Slomiany 
et al., 1980). However, further investigations are required to determine the effect of the MCD 
diet on the gut microbiome of rodents and whether gut microbiota play an important role in 
the development of the condition induced by this diet. 
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The lower levels of faecal water methionine and choline in the MCD diet, relative to the 
control diet group, were most likely due to the deficient nature of the diet. The elevated levels 
of fructose and glucose could be a sign of malabsorption, which would also be related to the 
lower levels of glucose identified in the hepatic metabolic profiles. Fructose is a product of 
sucrose hydrolysis that occurs mainly in the proximal small intestine where it is absorbed with 
glucose (Dahlqvist and Thomson, 1963). The lower levels of these energy metabolites could 
therefore be linked with intestinal dysfunction, as previously linked to NAFLD (Volynets et al., 
2012).   
Other models of non-alcoholic steatohepatitis 
Animal models of NASH should not only replicate the pathological pattern of liver injury of 
the human disease but should ideally model the metabolic syndrome component (Larter and 
Yeh, 2008). This metabolic syndrome is characterised by insulin resistance, hypertension, low 
concentration of high density lipoproteins, an altered adipokine profile and obesity (Pagano 
et al., 2002, Larter et al., 2010). An association of metabolic syndrome and the development 
of liver steatosis has already been reported but further work is required to elucidate the 
underlying mechanism (Marceau et al., 1999, Larter, 2007, Larter and Yeh, 2008). 
The MCD diet can rapidly induce a condition that is thought to be an accurate reflection of 
clinical steatohepatitis and is therefore important in the characterisation of NASH pathology. 
This condition is characterized by neutrophil infiltration, elevated triglyceride content, 
oxidative stress, macrovesicular steatosis and fibrosis (Rinella et al., 2008, Larter and Yeh, 
2008). However the mechanism by which the aforementioned pathological pattern develops, 
as induced by the depletion of choline and methionine, is understood to be different from the 
clinical condition. Furthermore, the absence of the metabolic syndrome in rodents fed by the 
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MCD diet is reflected by the significant weight loss experienced by the rodents after three 
weeks and this is considered to be the most significant disadvantage of this model (Rinella 
and Green, 2004, Larter and Yeh, 2008). 
Other animal models of NASH can be generally categorized to genetic and dietary models and 
have been reported to have a varying degree of success in creating an accurate model of 
NASH. Alternative dietary models such as the high fat diet or the atherogenic diet (contains 
cholesterol and cholic acid) have been reported to similarly mimic the pathological pattern 
but not the metabolic syndrome of the clinical condition (Matsuzawa et al., 2007, Larter and 
Yeh, 2008). Genetic models such as leptin (ob/ob) or leptin receptor (db/db) deficient mice 
are thought to be poor models of the liver histology of NASH, even though they model the 
metabolic phenotype associated with the disease (Browning and Horton, 2004). Other animal 
models, such as the high fat fed foz/foz (Alms1 mutant) mice (Arsov et al., 2006), which 
incorporate a genetic and dietary component are thought to be the most accurate models of 
NASH (Larter and Yeh, 2008). However, it is worth noting that the high fat fed foz/foz mouse 
model does not induce a rise in FFA levels and is therefore not reflective of our current 
understanding of the clinical condition (Van Rooyen et al., 2011). 
All models will inevitably be associated with a different extent of limitations in their ability to 
replicate human NASH. These limitations are accentuated by our restricted knowledge 
concerning the underlying mechanism of NASH development and the use of organisms which 
will not behave in the same manner due to genotypic differences. Therefore, the use of each 
specific model should depend on the aim of the investigation, while comparative studies of 
the different models will be a valuable contribution to our knowledge in this field (Kucera and 
Cervinkova, 2014). 
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Study limitations and future work 
The observed weight difference between the two diet cohorts at the beginning and end of 
the study was an important confounding factor which would have a pronounced effect on the 
metabolic profiles and more specifically on the intermediates of energy metabolism. Even 
though, it was not possible to determine which metabolic perturbations were induced 
specifically by the weight loss of the MCD diet, it was nonetheless important to characterize 
the complete metabolic baseline induced by the MCD diet for a better understanding of this 
dietary model. It is important to note that the reported pattern of urinary markers linked to 
caloric restriction was not observed in this study, as further discussed in Chapter 5 (Connor et 
al., 2004, Szkudelski et al., 2004). 
Apart from the limitations associated with the MCD diet as a model of NASH, there were 
several complications associated with the analytical work which could be further optimized 
in follow-up studies. In the liver, the high lipid content of the MCD diet group was not 
sufficiently accounted for with the metabolite extraction protocol and therefore a CPMG 
pulse sequence had to be used during 1H-NMR spectral acquisition to supress resonances 
from the lipidic species. There have been several comparisons of metabolic extraction 
methods but perhaps the use of a bi-layer extraction (methanol and chloroform) would have 
sufficiently isolated the lipids (Masson et al., 2010). In the faeces, the significant variation in 
inter-sample consistency could be better addressed through collection of the entire faecal 
output in a given time period, rather than the extraction of a single pellet. 
A future targeted approach using UPLC-MS could be used to study how choline and 
methionine deficiency can affect folate metabolism through targeted study of intermediate 
metabolites (Wang et al., 2014). Finally, 16S RNA gene sequencing and a metagenomic 
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analysis should also be performed to verify whether microbial populations are perturbed by 
this diet and how relevant these perturbations could be to the actual clinical condition (Janda 
and Abbott, 2007). 
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Chapter 5: Systems level metabolic phenotype of methotrexate 
administration in non-alcoholic steatohepatitis in the rat 
 
The hepatic extract and urine analysis results presented in this chapter have been published 
(Kyriakides et al., 2014). A copy of the publication is provided in the appendix. 
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Introduction 
Study details and aims 
This study was performed in parallel to the investigation detailed in Chapter 4. It characterizes 
the metabolic effect and disposition of MTX in healthy rats and in the context of NASH, as 
induced by the MCD diet. The hepatic aqueous-soluble extract, urine and faecal water 
metabolic profiles were acquired and analysed by 1H-NMR spectroscopy. Similar to the 
metabolic characterization of the MCD diet presented in Chapter 4, this study provided the 
novel opportunity to describe the systemic effect of MTX in a healthy and a diseased state. 
The characterization of the metabolic effect of MTX in the diseased state was hypothesized 
to provide novel mechanistic insight of potential clinical relevance for further understanding 
the link between liver pathology and occurrence of ADRs. 
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Methods 
Only the methods not already discussed in Chapter 4 will be presented in this chapter. The 
time period abbreviations are as follows: -6 to 0 hours (pre-dose; 0hr), 6 – 12 hours (12hr), 18 
– 24 hours (24hr) and 36 – 48 hr (48hr).  
Dosing of MTX 
The doses of MTX used in the current study were designed to reflect low dosage of MTX such 
as that used to treat inflammatory diseases (10 and 40 mg/kg doses) and high doses such as 
that used to treat acute lymphoblastic leukemia (100 mg/kg dose). MTX is dosed in patients 
based on body surface area (1000 mg/m2). When taking into account the average body 
surface area of pediatric patients aged 1-10 years and converting to a mg/kg dose, a 100 
mg/kg dose in rats falls well under that used clinically (Genestier et al., 2000). 
Quantification of urinary excretion of MTX 
The urinary excretion of MTX (100 mg/kg) per kg of rat (the weight was measured at the 
beginning of the study) at 12hr, 24hr and 48hr was quantified in both diet groups. Local 
baseline correction was performed in TopSpin 3.0 (Bruker) before integrating the resonance 
of MTX at δ 8.63, whose identity was verified by a spike-in experiment. The TSP resonance, of 
known concentration from the buffer solution, was used to estimate the quantity of MTX in 
the sample. The total urine volume collected per rat at each time period was then used to 
estimate the total amount of excreted MTX per rat per time period. The results were verified 
independently by LC-MS achieving a correlation (Pearson R value) with the NMR data greater 
than 0.99. Table 5.1 depicts the assignments of the MTX resonances, as well as the resonances 
assigned to DAMPA and 7-OH-MTX. 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
143 
PhD thesis  Michael Kyriakides 
 
Table 5.1: The urinary and hepatic extract assigned resonances of MTX related molecules are depicted 
above. DAMPA - 2, 4-diamino-N(10)-methylpteroic acid; 7-OH-MTX – MTX hydroxyl conjugate; s – 
singlet; d – doublet; ppm – parts per million; Hα – N-acetyl  resonance. 
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Statistical analysis 
O-PLS-DA models were constructed to model the metabolic effect of MTX in both diet groups 
with and without the MTX and related resonances in order to ensure that the endogenous 
metabolic changes were statistically significantly different for both models. PLS regression 
analysis was also used to characterize the correlation of the hepatic metabolic profiles of both 
diet groups with each of the biliary hyperplasia and liver fibrosis scores. Univariate testing 
(Kruskal-Wallis coupled to Dunn’s multiple test correction) was used to test for significant 
differences in the phenylalanine levels in each group per diet (based on the integral of the 
resonance at δ 7.38). Please note that each diet group was normalized separately due to their 
distinctly different metabolic profiles and therefore the phenylalanine levels are not directly 
comparable. Permutation tests (n = 1000) were used to test O-PLS-DA and PLS model validity, 
while a p < 0.05 statistical significance threshold was set throughout. 
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Results 
Histopathology 
Histopathological assessment of the control diet group showed that MTX treatment (40 and 
100 mg/kg) led to hepatic necrosis (Figure 5.1A). One animal also developed liver 
inflammation (40 mg/kg) and another biliary hyperplasia following MTX treatment (100 
mg/kg respectively; Figure 5.1C and 1E respectively). MTX treatment in the MCD diet group 
(40 mg/kg) led to a statistically significant reduction in lipid accumulation and liver 
inflammation (Figure 5.1B and 1C). Minimal liver fibrosis and mild biliary hyperplasia were 
also detected in the MCD diet group following treatment of MTX at a statistically significant 
level (100 mg/kg; Figure 5.1D and 1E). Small intestinal histopathology inferred that MTX (100 
mg/kg) led to moderate villous atrophy, villous fusion and dilated crypts, as well as minimal 
apoptosis, inflammation and vacuolization in both groups at similar levels. 
 
Figure 5.1: The mean and standard deviation of the histopathology scores representing liver necrosis 
(A), lipid accumulation (B), liver inflammation (C), liver fibrosis (D) and biliary hyperplasia (E) following 
MTX administration (vehicle, 10, 40 and 100 mg/kg; n = 5 for each per diet and n = 6 for 100 mg/kg 
MTX dose in the MCD diet). Statistical significance is indicated by (*) or (**) representing p < 0.05 and 
p < 0.01 respectively. The scoring criteria are: 0 = no significant lesions, 1 = minimal, 2 = mild, 3 = 
moderate, 4 = marked and 5 = severe; Veh – Vehicle. 
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Animal weight 
The body weight of animals was recorded at the beginning (prior to MTX administration) and 
at the end of the study (post MTX administration, 96 hours). At the beginning of the study, 
the average weight of the animals was 390 g (STD ± 57 g) in the control diet group and 200 g 
(STD ± 46 g) in the MCD diet group. The average weight loss observed following administration 
of MTX in the control diet groups were 7 %, 16 % and 26 % for the groups administered 10, 
40 and 100 mg/kg MTX respectively. Weight loss was also observed in the MCD diet group 
with an average percentage weight loss of 18 %, 20 % and 20 % for the groups administered 
10, 40 and 100 mg/kg MTX respectively. The percentage weight loss in each diet relative to 
the vehicle can be seen below in Figure 5.2.  
 
Figure 5.2: The mean percentage body weight loss and standard deviation of all dose groups in both 
diet groups during the duration of the study is depicted above (n = 5 for each per diet and n = 6 for 
100 mg/kg MTX dose in the MCD diet). Statistical significance at p < 0.05 and p < 0.01 are indicated by 
(*) and (**) respectively. The vehicle and three doses of MTX are indicated at the horizontal axis (0, 
10, 40 and 100 mg/kg). Veh – Vehicle. 
Hepatic metabolic phenotype after MTX administration in the control diet group 
 
The metabolic consequences following MTX administration in the control diet group were 
characterized by O-PLS-DA pair-wise models, relative to the vehicle group. The statistically 
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robust O-PLS-DA model describing the effect of 10 mg/kg MTX administration (Figure 5.3A; 
R2Y = 0.9888, Q2Y = 0.5029 and p < 0.05) achieved complete separation between the two 
groups in the scores plot (Tcv, Figure 5.3A1). The corresponding coefficient plot (Figure 5.3A2) 
revealed that the MTX treated group had lower levels of lactate, glucose, glycogen, maltose, 
inosine, betaine, phosphocholine, glutathione and dimethylamine, as well as elevated levels 
of D-3-hydroxybutyrate, uracil, glutamate, valine, isoleucine and leucine. The statistically 
robust O-PLS-DA model describing the metabolic effect of 40 mg/kg MTX administration 
(Figure 5.3B; R2Y = 0.9384, Q2Y = 0.7846 and p < 0.05) led to complete separation between 
the two groups in the scores plot (Tcv, Figure 5.3B1). The corresponding coefficient plot 
(Figure 5.3B2) revealed depleted levels of glucose, maltose, mannose, glycogen, lactate, 
betaine, phosphocholine, dimethylamine and glutathione, as well as higher levels of uracil, D-
3-hydroxybutrate, glutamate, valine, isoleucine, leucine, choline and glycerophosphocholine 
(tentatively assigned). Finally, the model computed to characterize the metabolic effect of 
the highest dose of MTX (100 mg/kg; Figure 5.3C; R2Y = 0.9985, Q2Y = 0.8485 and p < 0.05) 
was also statistically robust and achieved complete separation in the scores plot (Tcv, Figure 
5.3C1). The equivalent coefficient plot (Figure 5.3C2) revealed that the administration of 100 
mg/kg MTX led to the depletion of lactate, glucose, maltose, mannose, glycogen, betaine, 
inosine, dimethylamine and glutathione. It also led to the concomitant rise in the levels of 
valine, glutamate, leucine, isoleucine, glycerophosphocholine (tentatively assigned), D-3-
hydroxybutyrate, formate, uracil, hypoxanthine, creatine and choline following MTX 
administration, relative to the vehicle group. A summary of the hepatic metabolic effects 
induced by MTX administration at all doses in the control diet group is presented in Figure 
5.5A. 
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Figure 5.3: Hepatic extract O-PLS-DA models comparing the vehicle groups and 10, 40 and 100 mg/kg 
MTX administration groups in the control diet at 96hr post-treatment (n = 5 per group). The scores 
plots (A1, B1 and C1) depict the separation of the MTX administered groups (red) and vehicle group 
(black) in multivariate space. Tcv is the predictive component, whilst TYosc is the orthogonal 
component. The coefficient plots (A2 and B2) illustrate the discriminatory spectral resonances with 
the height of spectral peaks representing covariance. The colour-scale corresponds to the coefficient 
of discrimination (R2) ranging from low (0; blue) to high (red; 1). Resonances pointing up indicate an 
increase in that specific resonance in the control group and vice versa. Choline-NCH3 – N-methyl 
resonance of choline, phosphocholines and glycerophosphocholines; DMA – dimethylamine; D-3-HB 
– D-3-hydroxybutyrate; glutathione – oxidized glutathione. 
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Hepatic metabolic phenotype after MTX administration in the MCD diet group 
A complementary O-PLS-DA was used to elucidate the metabolic effect of MTX (10, 40 and 
100 mg/kg) relative to the vehicle group in the MCD diet. The statistically robust O-PLS-DA 
model characterizing the effect of 10 mg/kg MTX (Figure 5.4A; R2Y = 0.9949, Q2Y = 0.5491 and 
p < 0.05) achieved complete separation in the scores plot (Tcv, Figure 5.4A1). The 
corresponding coefficient plot (Figure 5.4A2) revealed that the MTX treated group had lower 
levels of inosine, glucose, maltose, glycogen and betaine, as well as higher levels of uracil, D-
3-hydroxybutyrate, glutamate, acetate, valine, leucine, urocanate and FIGLU, relative to the 
vehicle group. The O-PLS-DA model computed to describe the metabolic effect of 40 mg/kg 
MTX (Figure 5.4B; R2Y = 0.9945, Q2Y = 0.7928 and p < 0.05) achieved complete discrimination 
in the scores plot (Tcv, Figure 5.4B1). The corresponding coefficient plot (Figure 5.4B2) 
revealed that there was a depletion of glucose, maltose, mannose, glycogen, acetate, betaine 
and choline, as well as a concomitant elevation of uracil, D-3-hydroxybutyrate, acetate, valine, 
isoleucine, leucine, phenylalanine, betaine, creatine, FIGLU, niacinamide and formate. Finally, 
The O-PLS-DA model computed to characterize the effect of the highest dose of MTX (100 
mg/kg; Figure 5.4C; R2Y = 0.9957, Q2Y = 0.9155 and p < 0.05) achieved complete group 
separation in the scores plot (Tcv, Figure 5.4C1). The equivalent coefficient plot (Figure 5.4C2) 
revealed that MTX administration led to the depletion of inosine, maltose, mannose, lactate, 
glycogen and phosphocholine, as well as the elevation of uracil, D-3-hydroxybutyrate, 
acetate, glutamate, valine, leucine, phenylalanine, choline, creatine, FIGLU, niacinamide, 
formate and urocanate. A summary of the hepatic metabolic effects induced by MTX 
administration at all doses for the MCD diet group is presented in Figure 5.5B. 
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Figure 5.4: The O-PLS-DA models comparing the hepatic metabolic profiles of the vehicle groups 
(black) and each of the 10, 40 and 100 mg/kg MTX administered groups (red) in the MCD diet at 96hr 
post-treatment are shown (n = 5 for vehicle, 10 and 40 mg/kg doses of MTX, n = 6 for 100 mg/kg MTX 
dose group). The scores plots (A1, B1 and C1) depict the separation of the MTX administered groups 
(red) and vehicle group (black) in multivariate space. Please see legend of Figure 5.3. 
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Figure 5.5: The hepatic metabolic effects of MTX administration in the control diet (A) and MCD diet 
(B) at 96hr are shown. The maximum Pearson correlation coefficient values (R) for each discriminant 
metabolite from the O-PLS-DA models separating between the metabolic profiles of MTX treated (10, 
40, 100 mg/kg) and the vehicle groups are displayed. The scale ranges from -1 (perfect negative 
correlation; blue) to 1 (perfect positive correlation; red). A cut-off value of |0.5| was set. Please see 
legends of Figures 5.3 and 5.4. 
Phenylalanine elevation 
A statistical regression analysis between the biliary hyperplasia and liver fibrosis scores with 
the hepatic metabolic profiles inferred that phenylalanine was the only endogenous 
metabolite to be correlated to the development of those conditions (R2Y = 0.5218 and Q2Y = 
0.2423, and R2Y = 0.5406 and Q2Y = 0.2542 respectively; Figure 5.6A). Analysis of the 
phenylalanine resonance integrals at δ 7.38 revealed that the administration of the highest 
dose of MTX (100 mg/kg) in the MCD diet group led to a statistically significant elevation of 
phenylalanine relative to the vehicle group of the same diet (p < 0.05; Figure 5.6B).  
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Figure 5.6: Excerpts from the PLS regression coefficient plots of the phenylalanine resonance from the 
regression analyses are shown (A). The correlation scale ranged from low (0; blue) to high (0.8; red). 
The integrals (mean and standard deviation) of phenylalanine from the displayed resonance in all 
dosage groups in both diets at 96hr are shown (B; n = 5 for each MTX dosage group per diet and n = 6 
for 100 mg/kg MTX dose in the MCD diet). Please note that the integrals cannot be directly compared 
between the two diet groups due to individual separate pre-processing and normalization of each diet 
group. Statistical significance was set at p < 0.05 (*). Veh – Vehicle. 
Faecal water metabolic phenotype after MTX administration in the control diet 
The collection of faecal samples at sequential time-points enabled the characterization of the 
temporal metabolic consequences of MTX at each dose level for each diet group. O-PLS-DA 
pair-wise models were computed to model the metabolic effect of MTX administration at 
each of the time-points. The comparisons between the pre-dose baseline (0hr time-point) 
and the 48hr post-dose time-point were the only models that were statistically robust due to 
sufficient sample numbers. The model discriminating between the 10 mg/kg dose of MTX at 
48hr and the baseline group at 0hr (R2Y = 0.9552, Q2Y = 0.6297, p < 0.05) achieved complete 
discrimination in multivariate space between the two groups (Tcv). The corresponding 
coefficient plot revealed that propionate and acetate were depleted following MTX 
administration, while succinate, dihydroxyacetone (DHA), valine and sarcosine were elevated. 
The O-PLS-DA model describing the metabolic effect of 40 mg/kg at 48hr, relative to the 
baseline (R2Y = 0.9821, Q2Y = 0.7191, p < 0.05), achieved complete separation between the 
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two groups as well (Tcv). The corresponding coefficient plot revealed that MTX administration 
led to the depletion of tyrosine, propionate and acetate, while DHA, valine, 5-aminovalerate, 
sarcosine and putrescine were at higher levels. The model discriminating between the highest 
dose of MTX (100 mg/kg) at 48hr, relative to the baseline, (Figure 5.7A; R2Y = 0.9606, Q2Y = 
0.7261, p < 0.05) achieved complete discrimination of the two groups in the scores plot as 
well (Tcv, Figure 5.7A1). The corresponding coefficients plot (Figure 5.7A2) revealed that MTX 
administration led to higher levels of uracil, galactose, fucose, DHA, valine, 5-aminovalerate 
and putrescine. A summary of the metabolic effects of MTX at all doses is presented in the 
form of a heatmap in Figure 5.8A. 
Faecal water metabolic phenotype following MTX administration in the MCD diet.  
The metabolic effect of MTX administration (10, 40 and 100 mg/kg) in the MCD diet group 
was also modelled by O-PLS-DA.  The comparisons between the pre-dose baseline (0hr time 
period) and the 48hr post-dose time period were the only models that were statistically 
robust at all doses of MTX. The model discriminating the metabolic effect of the 40 mg/kg 
dose at 48hr, relative to the pre-dose baseline, was not statistically robust and was therefore 
not analyzed further. The model constructed to discriminate the metabolic effect of the 10 
mg/kg MTX dose at 48hr relative to the pre-dose baseline (0hr) achieved complete separation 
in the scores plot (R2Y = 0.9674, Q2Y = 0.6389, p < 0.05). The equivalent coefficient plot 
revealed that acetate and tyrosine were depleted after MTX administration, while uracil, 
succinate, galactose, DHA, fucose, methionine, sarcosine and putrescine were elevated. 
Finally, the robust O-PLS-DA model characterizing the metabolic effect of the highest dose of 
MTX at 48hr, relative to 0hr, (Figure 5.7B, R2Y = 0.9627, Q2Y = 0.6492, p < 0.05) achieved 
complete separation of the two groups in the scores plot (Tcv, Figure 5.7B1). The 
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corresponding coefficient plot (Figure 5.7B2) revealed that the levels of uracil, galactose, DHA, 
methionine, 5-aminovalerate, sarcosine and putrescine were elevated after MTX 
administration. A summary of the metabolic effects of MTX administration (10 and 100 
mg/kg) at 48hr is presented in a heatmap in Figure 5.8B. 
 
Figure 5.7: Faecal water O-PLS-DA models comparing the pre-dose time period (0hr; black) and 48hr 
(red) after 100 mg/kg MTX administration in the normal diet (A1 and A2; n = 12 and n = 3 respectively) 
and MCD diet (B1 and B2; n = 12 and n = 5 respectively). DRC – Drug related compound; DHA – 
dihydroxyacetone (tentatively assigned). Please see legend of Figure 5.3. 
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Figure 5.8: Heatmap describing the faecal water metabolic effects of MTX administration in the 
control diet (A) and MCD diet (B) at 48hr relative to 0hr (pre-dose; 10, 40 and 100 mg/kg in the control 
diet; 10 and 100 mg/kg in MCD diet). DHA – dihydroxyacetone. Please see legend of Figure 5.5. 
 
Urinary metabolic phenotype following MTX administration in the control diet 
The collection of sequential time-point urine samples enabled the characterization of the 
temporal MTX-induced metabolic effect. O-PLS-DA pair-wise models were used to describe 
the metabolic effect of MTX at the 12hr, 24hr and 48hr time-periods relative to the pre-dose 
baseline (0hr). The results of the models that discriminated the high dose (100 mg/kg) group 
with controls will only be presented since they were consistently statistically robust and had 
the greatest predictive ability.  
The O-PLS-DA models describing the metabolic effect of MTX (100 mg/kg) at 12hr, 24hr and 
48hr relative to the pre-dose baseline inferred that MTX had a time-dependent progressive 
metabolic effect. This is reflected in the statistical parameters of the models for each time-
point shown in Table 8.3 in the appendix. The robust O-PLS-DA model discriminating between 
the metabolic profiles of the control diet 0hr and 48hr time-points after MTX administration 
(Figure 5.9A; R2Y = 0.9865, Q2Y = 0.7581, p < 0.05) achieved complete discrimination between 
the groups in the scores plot (Tcv; Figure 5.9A1). The corresponding coefficient plot (Figure 
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5.9A2) showed that the levels of alanine, methylamine, dimethylamine, hippurate, TMAO and 
3-indoxylsulphate were depleted, while the levels of levels of succinate, creatine, 
phenylacetylglycine and formate were elevated.  
Urinary metabolic phenotype following MTX administration in the MCD diet 
The corresponding O-PLS-DA analysis of the urinary metabolic effect of MTX (100 mg/kg) 
administration in the MCD diet group also revealed a progressive metabolic effect up to 48hr. 
The statistically robust O-PLS-DA model characterizing the metabolic effect of the MTX at 48hr 
relative to the pre-dose baseline (0hr) (Figure 5.9B; R2Y = 0.9474, Q2Y = 0.8328, p < 0.05), 
achieved complete discrimination between the two groups in the scores plot (Tcv, Figure 
5.9B1). The corresponding coefficient plot (Figure 5.9B2) revealed that MTX administration 
led to a rise in the levels of FIGLU and formate, and a depletion of methylamine, alanine and 
hippurate. The progressive metabolic effect of MTX (100 mg/kg) from 12hr to 48hr revealed 
a depletion of methylamine and hippurate, and an elevation of formate and FIGLU. The 
depletion of alanine at 48hr was specific to that time-point, while depletions of other 
metabolites unique to other time periods were also observed, such as the decreases in the 
levels of 3-indoxylsulphate and phenylacetylglycine which were specific to 24hr. A summary 
of the models of each time-point can be seen in Table 8.3 in the appendix. 
The elevation of FIGLU and formate at 48hr were also observed after the administration of 
the lower doses of MTX (10 and 40 mg/kg) in the MCD diet group. Interestingly, the O-PLS-DA 
models of these lower doses also revealed some metabolic effects at 48hr that were not 
observed after the administration of 100 mg/kg, including the depletion of methylamine and 
3-indoxylsulphate, as well as the elevation of dimethylamine and TMAO.  
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The comparison of the metabolic effects of the administration of MTX (100 mg/kg) between 
the two diet groups revealed several diet specific MTX-induced effects. At 48hr, the higher 
levels of creatine, citrate, succinate and phenylacetylglycine were specific to the control diet 
group, while the observed MTX-induced elevated levels of FIGLU were specific to the MCD 
diet group. Figure 5.10 illustrates a summary of the metabolic effect of MTX (100 mg/kg) at 
the three time-points in both diet groups.  
 
Figure 5.9: Urinary O-PLS-DA models comparing the pre-dose time period (0hr; black) and at 48hr (red) 
after 100 mg/kg MTX administration in the normal diet (A1 and A2; n = 5 and n = 4 respectively) and 
MCD diet (B1 and B2; n = 6 for both). See Legend for Figure 5.3. 
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Figure 5.10: A heatmap of the urinary metabolic effects of MTX administration in the control diet (A) 
and MCD diet (B) from the O-PLS-DA models that discriminated between the metabolic profiles of the 
post-dose time-periods (12hr, 24hr and 48hr) of MTX administration (100 mg/kg) and the pre-dose 
time-periods (0hr), in both diets. Phenylacetyl-G phenylacetylglycine; TMAO – trimethylamine-N-
oxide. 
 
Urinary quantitation of MTX 
The quantity (µg) of MTX in the urine of animals from each diet group was also compared at 
a number of post-dose time-points following administration of the highest dose of MTX (100 
mg/kg). The levels of excreted MTX were observed to be higher in the control diet group at 
all time-periods (Figure 5.11). 
 
Figure 5.11: Mean and standard deviation of the quantity of urinary MTX (µg) per kg of rat following 
the administration of 100 mg/kg MTX at 6-12 hours, 18-24 hours and 36-48 hours. 
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Discussion 
The metabolism, toxicity, pharmacokinetics and clinical profile of MTX have been extensively 
studied since the first report by Farber et al concerning the treatment of children with acute 
leukaemia (Kremer, 2004, Farber et al., 1956). Despite our existing knowledge, there is a lack 
of sound understanding concerning the hepatotoxic and multiorgan toxic effects of the drug 
or its potential to cause ADRs in people with underlying diseases such as NASH.  Therefore, 
an improved understanding of the complexities of MTX metabolism will inevitably lead to 
safer and more effect therapeutic treatments (Kremer, 2004).  
Metabolic and toxic effect of MTX administration in healthy rats 
The observed liver necrosis and small intestine toxicity induced by MTX administration (40 
and 100 mg/kg and 100 mg/kg respectively) comprise some of the classic ADR symptoms of 
MTX (Feagan et al., 1995, Lobo and Balthasar, 2003). The 1H-NMR O-PLS-DA models of MTX 
administration in the three sample matrices characterized the metabolic perturbations 
associated with these pathophysiological conditions. A general dose-dependent progressive 
metabolic effect was observed in all three sample matrices while a temporal effect was also 
observed in the faecal water and urine O-PLS-DA models, where the effect of MTX was 
becoming more significant over time. The MTX-induced metabolic effect was observed to 
affect various pathways including those of amino acids, nucleobases, nucleosides, energy 
metabolites and choline metabolisms. 
The metabolic effects pertaining to nucleic acid related molecules are most likely due to the 
inhibitory properties of MTX on enzymes involved in nucleic acid and folate cycle metabolism. 
The observed elevation in the levels of hepatic and faecal water uracil after the administration 
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of the (100 mg/kg) dose is potentially a result of MTX-induced thymidylate synthetase 
inhibition. The depletion of hepatic inosine (10 and 100 mg/kg MTX) could also be due to the 
reported MTX-induced inhibition of AICAR transformylase (Genestier et al., 2000). Moreover, 
the elevation of hypoxanthine observed after the administration of the highest dose of MTX 
could be linked to the inhibition of xanthine oxidase, an enzyme that forms xanthine from 
hypoxanthine (Lewis et al., 1984).  
The inhibition of DHFR by MTX would lead to a disruption of the folate cycle which would 
have consequences in a spectrum of metabolic pathways including the aforementioned 
nucleic acid metabolism (Genestier et al., 2000). Since we could not detect any of the folate 
cycle intermediates in the 1H-NMR metabolic profiles, the effect of the disruption could be 
observed via the levels of metabolites that directly interact with folate cycle intermediates. 
For example, the higher levels of hepatic formate could be due to the lower rate of formyl-
THF formation, as a consequence of a drop in THF production. The higher levels of sarcosine 
after administration of MTX (10 and 40 mg/kg) could also be a consequence of THF depletion 
since THF is required by sarcosine dehydrogenase for the conversion of glycine to sarcosine 
(Lu and Mato, 2012). However, it is not clear why this wasn’t observed after the 
administration of the highest dose but it could be due to the variation in faecal content 
between the individual samples. Furthermore, raised putrescine levels in the faecal water 
metabolic profiles could be linked to a reduction of S-adenosylmethionine regeneration. 
Putrescine is converted to spermidine and spermine through a methyl group addition 
provided by S-adenosylmethionine (Tabor et al., 1958). MTX could affect S-
adenosylmethionine regeneration through the disruption of the folate cycle or through the 
inhibition of S-adenoyltransferase expression, which would reduce the rate of conversion of 
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methionine to S-adenosylmethionine (Nesher et al., 1991, Wang and Chiang, 2012). Finally, 
the absence of an elevation of urinary and hepatic FIGLU at any dose of MTX suggests that 
the disruption of the folate cycle was not absolute (Cooperman and Lopez, 2002).  
The observed depletion of energy metabolites including lactate, glucose, glycogen and 
maltose is associated with the observed weight loss. Weight loss could have occurred due to 
a reduced dietary intake, intestinal toxicity of MTX (gut absorption dysfunction and mucositis) 
and a possible MTX-induced inhibition of oxidative  phosphorylation, which would lead to a 
higher utilization of energy metabolites through other metabolic pathways (Yamamoto et al., 
1988, Yamamoto et al., 1992, Naruhashi et al., 2000). The elevation of D-3-hydroxybutyrate 
could also reflect an increased rate of lipid breakdown as a consequence of a general shift in 
energy metabolism.  This conclusion is also supported by the elevated levels of DHA in the 
faecal water which could also be a sign of lipid breakdown and gluconeogenesis. DHA is a 
product of glycerol breakdown while its phosphorylated form is an important intermediate of 
glycolysis and gluconeogenesis (Ouellette et al., 2013, Liu et al., 1995). 
Another metabolic consequence linked to dietary intake could be the depletion of 
metabolites linked to choline metabolism including hepatic phosphocholine and 
dimethylamine (Figure 5.5) as well as urinary TMAO, methylamine, dimethylamine and 
trimethylamine (Figure 5.10). However, the observed elevations of hepatic choline and 
glycerophosphocholine (tentative assignment) are contradictory to the overall pattern and 
suggest that the levels of these metabolites are not directly indicative of dietary intake. 
Furthermore, the fluctuation of choline levels is expected to be controlled by multiple factors 
since choline has many important functions within the body (Zeisel and Blusztajn, 1994).  
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Finally, other metabolic perturbations that could be linked to the weight loss or reduced 
dietary intake include the depletions of hepatic glutathione, urinary 3-indoxylsulphate (a 
tryptophan catabolism intermediate) and hippurate (Szkudelski et al., 2004, Connor et al., 
2004). However, the overall pattern of urinary metabolic changes after MTX administration 
did not reflect the pattern observed in the Wistar Han rat fasting studies by Connor et al, 
while the levels of metabolites such as citrate and succinate were actually elevated in this 
study, in contrast to that investigation (Connor et al., 2004).  Therefore it cannot be assumed 
that a potential reduced dietary intake is the driving force for the observed aforementioned 
metabolic changes. A summary of the metabolic effects and histopathology in the control diet 
after MTX administration is presented below in Figure 5.12. 
 
Figure 5.12: A summary of the histopathology and metabolic effects common to both diets after the 
administration of the highest dose of MTX (100 mg/kg). 
The MCD diet affects the disposition and toxicity of MTX 
The hypothesis of this investigation was that the MCD diet background, which has been 
reported to affect drug metabolizing enzymes and hepatic transporters (Fisher et al., 2009, 
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Hardwick et al., 2011), would alter the metabolic effect of MTX. Hepatic histopathology 
revealed that administration of MTX (40 mg/kg) in the MCD diet group led to a 
histomorphologic reduction of liver inflammation and lipid accumulation at a statistically 
significant level. This reduction could be due to the anti-inflammatory properties of MTX, 
while it has also been reported to affect cholesterol transport and accumulation (Genestier 
et al., 2000, Coomes et al., 2011). Administration of the highest dose of MTX (100 mg/kg) led 
to the development of biliary hyperplasia and liver fibrosis revealing an enhanced MTX 
toxicity in a NASH background. The lipid accumulation and liver inflammation scores were 
similar to those of the baseline (vehicle) group after the administration of the highest dose, 
suggesting that the toxic effects of MTX were outweighing its therapeutic properties at the 
highest dose. 
Differences in the MTX-induced metabolic effect between the two diets were also identified 
suggesting that the NASH background altered the metabolic consequences of MTX 
administration. More specifically, the increased levels of FIGLU, urocanate, phenylalanine, 
acetate, fumarate and niacinamide were only seen in the hepatic extract analysis. 
Furthermore, the MTX-induced increase of urinary succinate, citrate, creatine and 
phenylacetylglycine in the control diet group were not observed in the MCD diet group, while 
the MTX-induced elevation of faecal water methionine was also specific to the MCD diet 
group. 
Phenylalanine was identified as the only endogenous metabolite to be associated with the 
development of liver fibrosis and biliary hyperplasia by a regression analysis (Figure 5.6). The 
levels of phenylalanine can be used as a measure of liver function since they are reflective of 
phenylalanine hydroxylase activity, which converts phenylalanine to tyrosine (Burke et al., 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
164 
PhD thesis  Michael Kyriakides 
1997). MTX has also been associated with higher serum phenylalanine levels and it is thought 
to be through the MTX-induced inhibition of dihydropteridine reductase, an enzyme that 
produced an essential cofactor for the conversion of phenylalanine to tyrosine (Hilton et al., 
1989). Both of these hypotheses would suggest that hepatic tyrosine should be at lower levels 
in response to the higher levels of phenylalanine but that was not observed throughout the 
analysis. Therefore there must be another mechanism by which MTX affects phenylalanine 
levels, which is likely to be closely associated with the development of liver fibrosis and biliary 
hyperplasia.  
The elevations of hepatic metabolites associated with the folate cycle following MTX 
administration, such as FIGLU and urocanate are signs of a significant disruption of the cycle 
through the depletion of THF. Furthermore, the MTX-induced higher levels of methionine in 
the MCD diet group could be linked to the inhibition of methionine S-adenosyltransferase and 
are indicative of methionine cycle dysfunction (Wang and Chiang, 2012). The absence of these 
effects in the control diet suggest that the MCD diet and MTX can synergistically disrupt the 
folate and methionine cycles more severely than MTX on its own. Since NASH has also been 
reported to affect the methionine cycle through the depletion of glutathione, these are 
potentially clinically relevant demonstrations of how NASH and MTX can affect folate and 
methionine metabolism and lead to more severe ADRs (Kalhan et al., 2011a). 
The relatively higher levels of MTX excretion in the in the 48hr time period in the control diet, 
relative to the MCD diet group, was potentially related to the higher excretion of MTX in the 
MCD diet in the first six hours post-dose (recently published data by our collaborators). The 
observed higher early urinary excretion in the MCD diet group could be due to a reduced 
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absorption of MTX from the gastrointestinal tract or through a diminished expression of 
uptake transporter genes in unhealthy livers ,as reported (Lake et al., 2011). 
 
Figure 5.13: Summary of the unique effects of MTX in the MCD diet group.  
 
Effect of MTX on gut microbial co-metabolites 
The urinary and faecal water extract metabolic changes after MTX administration are also 
suggestive that there might be a disturbance of gut microbial populations in both diet groups. 
MTX has been reported to affect gut microbial composition (Naruhashi et al., 2000), while 
small intestinal toxicity was also observed in this study after MTX administration in both diet 
cohorts (100 mg/kg). MTX has been reported to induce intestinal mucositis through the 
reduction of gut mucin content (Boukhettala et al., 2009).  The reduction of mucin levels could 
be related to the ability of bacteria to degrade mucin to smaller components leading to the 
higher levels of galactose and fucose that were observed in the faecal water extract of both 
diets after MTX administration (Hoskins et al., 1992, Chow and Lee, 2008). However, further 
investigation is required to verify the link between mucositis and an increased excretion of 
fucose and galactose. 
The higher levels of valine and 5-aminovalerate in the faecal water extracts of the MTX 
administered rats could be reflective of intestinal malabsorption or bacterial overgrowth. 
Branched chain amino acids such as valine can be released from dietary protein via gut 
microbial mediated hydrolysis (Romick-Rosendale et al., 2009), while 5-aminovalerate is a 
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product of lysine degradation (Fothergill and Guest, 1977). In contrast to the suspected 
bacterial overgrowth in the small intestine, the MTX-induced reduction in the levels of 
propionate and acetate, two products of colonic fermentation, are indicative of a reduction 
or a change in the population of gut microbiota in the colon. However, another possible 
scenario unrelated to a population change of gut microbiota is the possible increased uptake 
of these gluconeogenesis substrates by the liver in order to produce more energy due to the 
aforementioned shift in energy metabolism (Tremaroli and Backhed, 2012). Finally, signs of 
changes in the gut microbial balance were also observed in the urinary metabolic profiles 
through the depletion of methylamine, TMAO and 3-indoxylsulphate (Nicholson et al., 2012). 
Study limitations and future work 
The limitations associated with the use of the MCD diet as a model of NASH have been 
previously discussed in Chapter 1 and 4, while the limitations associated with the analytical 
procedures that were used in this study have been already discussed in Chapter 4. 
Furthermore, the faecal water analysis was especially confounded by the low sample numbers 
per group post-MTX administration (100 mg/kg) in the control diet. 
The administration of MTX to animals fed the MCD diet could perhaps induce an exaggerated 
disruptive effect on the folate cycle. Even though the clinical condition of NASH can also affect 
the folate cycle, it would be interesting to determine how concomitant folate 
supplementation would affect the subsequent metabolic and toxic effect of MTX in the 
context of the MCD diet. Another important limitation associated with the study design is the 
lack of food intake recording which complicated the interpretation of the metabolic profiling 
analysis. Induction of toxicity through the administration of MTX would expectedly lead to a 
reduction in food intake by the animals but it was not possible to quantify the exact effect 
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since food intake was not recorded. Regression analyses between the hepatic extract 
metabolic profiles and the percentage weight loss revealed that mostly energy metabolites 
were correlated to the weight loss, but that was not necessarily due to a reduction in food 
intake since MTX can also affect gut absorption. It is worth noting that the aforementioned 
unique hepatic effects of MTX in the MCD diet group were not found to be correlated to 
weight loss. Finally, it was difficult to infer the exact effect of MTX on gut microbial 
populations through the induced metabolic changes. The observed changes could be more 
directly related to the MTX induced gastrointestinal toxicity which would have secondary 
effects on the gut microbial population.  
A future more targeted approach could be employed to investigate the potential mechanisms 
by which MTX administration can lead to greater toxicity in the MCD diet. More specifically, 
the underlying mechanism of the elevation of phenylalanine could be determined through 
the quantification of the expression of genes or proteins relative to phenylalanine catabolism 
as a first step, in order to obtain an improved mechanistic understanding. In relation to the 
suspected gut microbial perturbations, metagenomic sequencing could also be performed to 
decisively conclude whether the administration of MTX affected gut microbial populations 
(Janda and Abbott, 2007).   
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Chapter 6: Cross liver metabolic characterization of decompensated 
cirrhosis, acute on chronic liver failure and acute liver failure 
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Introduction 
Study details and aims 
This study employed metabolic profiling to discriminate serum 1H-NMR metabolic profiles 
from decompensated cirrhotic, ACLF and ALF patients. The metabolic discrimination of the 
serum reflecting different liver conditions, relative to healthy controls, enabled the 
determination of metabolic perturbations associated with each disease, with the aim to 
improve our understanding of the respective underlying mechanisms associated with disease 
development. In addition, this study incorporated a novel “cross liver” metabolic 
characterization of  serum using 1H-NMR spectroscopy to acquire the metabolic profiles of 
the hepatic portal vein, hepatic vein and a peripheral artery in the context of differential 
aetiologies requiring liver transplantation. The comparison of the metabolic profiles from the 
three blood vessels facilitated the transverse characterization of the metabolic state of the 
liver during disease.  
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Methods 
The study design, patient selection and sample collection were performed by our 
collaborators at Kings College Hospital. The “cross liver” sample set was acquired during liver 
transplantation. 
Patient selection and sample collection 
A local national research ethics service (NRES) approval was obtained for this study and 
patients or their nominee provided written informed consent within 24 hours of admission to 
Kings College Hospital. Patients suffering from decompensated cirrhosis (n = 33), ACLF (n = 
26) and ALF (n = 17) were enrolled in the study, while patients suffering from viral diseases 
such as hepatitis B/C were not included. Nine volunteers were also recruited as healthy 
controls. For the hepatic disease comparison sample set, blood samples from an artery or 
vein in the upper limb were collected from each patient during the first day of admission as 
well as from the nine healthy volunteers. For the “cross liver” sample set, blood samples from 
the hepatic portal vein, hepatic vein and peripheral artery (usually radial or brachial artery) 
were collected during liver transplantation (n = 14). A mixture of propofol, noradrenaline, 
alfentanyl or fentanyl was administered to the patients during the surgical procedure. Sera 
fractions were collected after the incubation of the collected blood samples at room 
temperature and centrifugation at 4,000 g for 10 minutes at 4oC. All samples were then stored 
at -80oC.  
Clinical and demographic data including, age, sex, BMI, serum biochemistry and physiology 
are provided, while the 30 day, 90 day and one year survival rates, as well as the hepatic 
encephalopathy (HE) grade, Child Pugh, sequential organ failure assessment (SOFA) and 
model for end-stage liver disease (MELD) scores were also calculated and provided per 
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disease group. The MELD score is used to assess whether a patient requires a liver transplant, 
while the SOFA score is used to track a patient’s status in the intensive care unit. A summary 
of the patient population of the general disease comparison and “cross liver” sample sets can 
be seen in Tables 6.1 and 6.2 respectively. 
Sample preparation and 1H-NMR spectroscopy of serum 
Sera samples were thawed, vortexed for a period of 15 seconds and allowed to stand for 10 
minutes. The samples were then mixed with phosphate buffer (1:1, 600 μL total volume; 20 
% D2O, 0.142 M NaHPO4, 2 mM NaN3, 4 mM TSP) and were centrifuged for 15 minutes at 
16,000 g at 4oC. The resulting supernatants were then transferred to 5 mm NMR tubes 
(SampleJet Tube Z105684; Bruker) for NMR spectral acquisition. A standard one-dimensional 
solvent suppression pulse sequence and CPMG spin-echo pulse sequence were used to 
acquire the FID. The acquisition parameters for each pulse sequence can be seen in Table 8.1 
in the appendix. 
1H-NMR spectral data processing 
The NMR spectra were processed in TopSpin 3.0 NMR software (Bruker) and MATLAB 
(Mathworks) as previously described in Chapter 3. Processing prior to alignment included the 
removal of the TSP and water resonances, while the data were not normalized prior to 
statistical analysis. Spectral assignments were performed using STOCSY, spectral databases 
(in-house, Human Metabolome Database and Biological Magnetic Resonance Bank), 
Chenomx NMR Suite and previously published assignments (Nicholson et al., 1995).  
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Statistical analysis 
Non-parametric ANOVA (Kruskal-Wallis) coupled to Dunn’s multiple test correction was used 
to compare the baseline characteristics and clinical data of the different disease groups 
(Tables 6.1 and 6.2). 
Hepatic disease comparison sample set: O-PLS-DA in MATLAB (Mathworks, using in-house 
scripts) was used to discriminate in pair-wise models between the serum metabolic profiles 
of the healthy volunteers and the three disease groups. PLS analysis in MATLAB (Mathworks, 
using in-house scripts) was used to identify the correlation between the metabolic profiles of 
the decompensated cirrhotic and ACLF metabolic profiles with the 30 day, 90 day and 1 year 
survival rates. 
“Cross liver” sample set: Prism 5.0 (Graphpad) was used to conduct non-parametric univariate 
analysis between the integrals of metabolites from the three blood vessels (Friedman test 
coupled to Dunn’s multiple correction test) and between the chronic liver disease samples 
(decompensated cirrhotics and ACLF) and the ALF samples, for each blood vessel (Mann-
Whitney with Bonferonni multiple test correction). A non-parametric repeated measures 
ANOVA (Friedman test) was used because intra-individual variance between the blood vessel 
metabolic profiles of each patient was lower than the inter-individual variance of the 
metabolic profiles of the blood vessels between different individuals.  
All multivariate models were validated by permutation testing (p < 0.05, n = 1000) and the 
summary of results are presented in the form of a heatmap presenting the maximum Pearson 
correlation values for each resonance obtained from models with a cut-off of R > |0.5|. 
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Results 
Clinical characteristics of decompensated cirrhosis, ACLF and ALF 
The baseline characteristics and clinical data of the decompensated cirrhosis, ACLF and ALF 
patients who were enrolled in the study are presented in Table 6.1. The clinical data include 
age of the patient, grade of hepatic encephalopathy (HE) and total bilirubin levels which are 
part of the King’s College criteria (O'Grady et al., 1993), as well as other clinical parameters 
which are commonly measured in ALF cases, such as lactate, total bilirubin, urea and 
haemoglobin levels (Polson et al., 2005).  
Decompensated cirrhosis patients had a statistically significantly higher age than their ACLF 
and ALF counterparts, as well as higher levels of haemoglobin relative to ACLF patients. In 
contrast, bilirubin levels were statistically significantly lower in decompensated cirrhosis 
patients relative to ACLF patients, while the levels of creatinine were also lower relative to 
both ACLF and ALF patients. Clinically derived disease scores such as HE grade, Child Pugh, 
MELD and SOFA scores were statistically significantly higher in ALF and ACLF patients, relative 
to decompensated cirrhotics. White blood cell count and lactate levels were also statistically 
significantly elevated in ALF patients relative to decompensated cirrhosis patients. 
Furthermore, liver enzymes such as aspartate aminotransferase (AST) and ALT were 
statistically significantly higher in the ALF group, relative to the other two disease groups, 
while ACLF patients also had higher levels of AST relative to decompensated cirrhosis patients. 
Finally, ACLF was associated with the lowest survival rate (30 day, 90 day and 1 year), which 
was statistically significantly lower at all periods relative to decompensated cirrhosis, as well 
as at 90 day and 1 year relative to ALF patients. Figure 6.1 presents the mean and standard 
deviation of the aforementioned statistically significantly clinical parameters for each group. 
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Parameter 
Disease 
Healthy 
volunteers 
Decompensated 
cirrhosis 
Acute on chronic 
liver failure 
Acute liver 
failure 
Number 33 26 17 9 
Age 
57.0 
(46.0 – 62.0) 
47.5 
(35.5 – 53.5) 
34.0 
(34.0 – 46.0) 
34.0 
(32.0 – 39.0) 
Gender (% female) 39.4 26.9 70.6 44 
BMI 
26.5 
(21.2 – 28.9) 
22.9 
(20.9 – 23.1) 
21.3 
(20.8 – 23.0) 
- 
HE grade 
1 
(0 – 1) 
3 
(2 – 4) 
3 
(1 – 4) 
- 
Child Pugh score 
9.0 
(8.0 – 11.0) 
12.0 
(11.0 – 13.8) 
12.0 
(11.0 – 13.0) 
- 
MELD score 
12.7 
(10.8 – 23.9) 
35.7 
(29.8 – 39.3) 
42.0 
(35.8 – 50.0) 
- 
SOFA score 
5.0 
(3.3 – 8.3) 
15.0 
(12.0 – 17.0) 
10.0 
(9.0 – 16.0) 
- 
30 day survival (%) 87.9 53.8 82.4 - 
90 day survival (%) 84.8 46.2 82.4 - 
1 year survival (%) 71.5 32.0 78.6 - 
ALT (IU/L) 
33.0 
(25.0 – 57.0) 
60.5 
(26.8 – 289.8) 
3734.0 
(1407.0 – 6843.0) 
- 
AST (IU/L) 
55.0 
(40.0 – 100.0) 
169.0 
(66.8 – 525.3) 
5216.0 
(1840.0 – 9480.0) 
- 
GGT (IU/L) 
85.0 
(38.0 – 186.0) 
59.0 
(36.0 – 172.3) 
88.0 
(36.0 – 174.0) 
- 
Bilirubin (µM) 
54.0 
(29.0 – 172.0) 
186.5 
(95.8 – 331.8) 
96.0 
(57.0 – 177.0) 
- 
Serum creatinine 
(µM) 
82.0 
(61.0 – 116.0) 
155.5 
(124.8 – 197.5) 
148.0 
(79.0 – 248.0) 
- 
Lactate (mM) 
1.7 
(1.4 – 2.3) 
2.3 
(1.4 – 5.1) 
3.1 
(2.6 – 6.2) 
- 
Urea (mM) 
7.1 
(5.0 – 10.9) 
9.5 
(6.4 – 13.1) 
11.2 
(3.6 – 12.2) 
- 
Haemoglobin 
(g/dL) 
109 
(91.0 – 124.0) 
89.5 
(83.3 – 98.3) 
98.0 
(88 – 121.0) 
- 
WBC (10^9/L) 
6.5 
(4.5 – 9) 
10.2 
(7.0 – 15.7) 
13.3 
(8.7 – 17.8) 
- 
Table 6.1: Baseline and clinical parameters of the patients are shown above. The median values and 
25%/75% interquartile range values (in brackets) are shown for each parameter where applicable. 
WBC - white blood cell; ALT – alanine aminotransferase; AST – aspartate aminotransferase; SOFA – 
sequential organ failure assessment; MELD – model for end-stage liver disease; HE – hepatic 
encephalopathy; GGT – gamma-glutamyl transferase. 
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Figure 6.1: The mean and standard deviation are shown for the statistically significantly different 
parameters between the three disease groups. Kruskal-Wallis coupled to Dunn’s multiple test 
correction was used to test for statistical significance at p < 0.05, p < 0.01 and p < 0.001 which are 
represented by *, ** and *** respectively. Please see legend of Table 6.1 for more details concerning 
the subjects.  
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Serum metabolic phenotype of decompensated cirrhosis, ACLF and ALF 
O-PLS-DA models were constructed to identify the discriminatory metabolites in the serum 
metabolic profiles of decompensated cirrhosis (n = 33), ACLF (n = 26) and ALF (n = 17) relative 
to those of healthy controls (n = 9).  The O-PLS-DA model discriminating between the serum 
metabolic profiles of decompensated cirrhosis from healthy controls (Figure 6.2A; R2Y = 
0.8719 and Q2Y = 0.6679; p < 0.05) achieved complete separation between the two groups in 
multivariate space (Tcv; Figure 6.2A1). The equivalent coefficient plot (Figure 6.2A2) revealed 
that the levels of phenylalanine and tyrosine were elevated in the decompensated cirrhotic 
metabolic profiles, while the levels of lipid fatty acyl chains (resonance at δ 0.89), choline 
containing phospholipids (resonance at δ 3.23) and valine were depleted, relative to controls.  
The O-PLS-DA model discriminating between the ACLF and control serum metabolic profiles 
(Figure 6.2B; R2Y = 0.8776 and Q2Y = 0.7517; p < 0.05) also achieved complete separation in 
the scores plot (Tcv; Figure 6.2B1). The corresponding coefficient plot (Figure 6.2B2) showed 
that the levels of phenylalanine, pyruvate and isobutyrate were elevated in the ACLF patients, 
while the levels of lipid fatty acyl chains (resonance at δ 0.89) and choline containing 
phospholipids (resonance at δ 3.23) were depleted. Finally, the O-PLS-DA model 
discriminating between the ALF and control serum metabolic profiles (Figure 6.2C; R2Y = 
0.9032 and Q2Y = 0.7970 and; p < 0.05) also achieved complete separation in the scores plot 
(Tcv; Figure 6.2C1). The equivalent coefficient plot (Figure 6.2C2) inferred that lysine, 
glutamine, phenylalanine, tyrosine, methionine, citrate, fumarate, acetate, glycerol, 
pyruvate, formate and isobutyrate were elevated in the ALF patients, while the levels of lipid 
fatty acyl chains (resonance at δ 0.89) and choline containing phospholipids (resonance at δ 
3.23) were depleted, relative to control.  
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Figure 6.2: Serum O-PLS-DA models comparing the decompensated cirrhotic (n = 33; A), ACLF (n = 26; 
B) and ALF (n = 17; C) metabolic profiles, relative to those of healthy controls (n = 9) are shown above. 
The scores plots (A1, B1 and C1) depict the separation of each disease group (red) relative to the 
control group (black) in multivariate space. The coefficient plots (A2, B2 and C2) show the correlated 
resonances with the height of spectral peaks indicating the covariance. The colour-scale represents 
the coefficient of Pearson correlation (R2), ranging from low (0; blue) to high (red; 0.9). Resonances 
pointing up reveal a positive correlation with the metabolic profiles of healthy controls and vice versa. 
A permutation test was used to test for model validity at p < 0.05. HC – healthy controls; DC – 
decompensated cirrhosis; ALF – acute liver failure; ACLF – acute on chronic liver failure. 
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Some metabolic perturbations were consistent across all three diseases, including the 
elevation of phenylalanine, tyrosine, citrate and pyruvate, as well as the general depletion of 
lipids. However, ALF was associated with the most extensive metabolic disturbance, in terms 
of the number of perturbed metabolites. A summary of the discriminatory metabolites from 
the O-PLS-DA models is presented in the form of a heatmap in Figure 6.3. 
 
Figure 6.3: The metabolic changes associated with decompensated cirrhosis, ACLF and ALF, relative to 
healthy controls, are shown above. The maximum Pearson correlation coefficient values (R) for each 
discriminant metabolite from the O-PLS-DA models are displayed. The scale ranges from -1 (perfect 
negative correlation; blue) to 1 (perfect positive correlation; red). A cut-off value of |0.5| was set. 
Metabolic characterization of APAP-induced ALF 
O-PLS-DA was employed to compare the metabolic perturbations associated with APAP-
induced ALF and ALF of other aetiologies grouped together, relative to the control group. 
Other ALF aetiologies included acute Budd-Chiari syndrome, non-APAP induced drug 
overdose and pregnancy. The O-PLS-DA model discriminating between the non-APAP induced 
ALF group (n = 9) and healthy controls (n = 9) achieved complete discrimination in the 
multivariate space (R2Y = 0.9234 and Q2Y = 0.7774 and; p < 0.05). The corresponding 
coefficient plot revealed that the non-APAP induced ALF group had higher levels of lysine, 
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glutamine, tyrosine, phenylalanine, methionine, histidine, fumarate, acetate, glycerol, 
pyruvate, formate, lactate and isobutyrate, as well as lower levels of lipid fatty acyl chains 
(resonance at δ 0.89) and choline containing phospholipids (resonance at δ 3.23), relative to 
the control group. The O-PLS-DA model differentiating between the serum metabolic spectra 
of APAP-induced ALF (n = 8) and healthy control (n = 9) also achieved complete discrimination 
of the two groups in multivariate space (R2Y = 0.9490 and Q2Y = 0.8303 and; p < 0.05).  The 
corresponding coefficient plot revealed that APAP-induced ALF was associated with elevated 
levels of lysine, glutamine, phenylalanine, tyrosine, methionine, histidine, citrate, fumarate, 
acetate, glycerol, pyruvate, formate and isobutyrate, as well as the concomitant depletion of 
lipid fatty acyl chains (resonance at δ 0.89) and choline containing phospholipids (resonance 
at δ 3.23). The majority of the metabolic changes associated with non-APAP induced ALF and 
APAP-induced ALF were common to both disease groups, albeit at different extents (as 
determined by the relative correlation values in each model) and the general effect of ALF 
versus control was observed to be an average of the two sub-groups. The most significant 
difference in the models of the ALF aetiological sub-groups was the absence of elevated 
citrate in the non-APAP induced serum metabolic profiles and the absence elevated lactate 
in the APAP-induced serum metabolic profiles. Furthermore, the levels of tyrosine, 
methionine, histidine, isobutyrate and formate were significantly more discriminatory in the 
APAP-induced ALF model. A summary of the discriminatory metabolites from the O-PLS-DA 
models is presented in Figure 6.4. 
Decompensated cirrhosis and ACLF survival PLS analysis 
PLS discriminant analysis was employed to characterize the correlation between 30 day, 90 
day and 1 year survival rates of the decompensated cirrhosis and ACLF patients with the 
respective 1H-NMR serum metabolic profiles. The PLS model of the 30 day survival rate (Figure 
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6.5A; R2Y =0.2075, Q2Y = 0.1312, p < 0.05) revealed minimal clustering of survivors versus non-
survivors in the predictive component of the scores plot (Figure 6.5A1). The corresponding 
coefficient plot (Figure 6.5A2) showed that alanine, lysine, glycine, histidine, leucine, 
glutamine, phenylalanine, lactate, pyruvate, isobutyrate and creatine levels were negatively 
correlated with the 30 day survival rate. The PLS model describing the correlation of the 90 
day survival rate with the 1H-NMR serum metabolic profiles (Figure 6.5B; R2Y = 0.2069, Q2Y = 
0.1263, p < 0.05) also revealed minor grouping of survivors versus non-survivors in the scores 
plot (Figure 6.5B1). The equivalent coefficient plot (Figure 6.5B) showed that the 90 day 
survival rate was negatively correlated to alanine, lysine, histidine, leucine, glutamine, 
phenylalanine, lactate, pyruvate, isobutyrate and creatine levels. Finally, the PLS model 
characterizing the association between the 1 year survival rate and the serum metabolic 
profiles (Figure 6.5C; R2Y =0.1563, Q2Y = 0.0726, p < 0.05) showed a higher degree of clustering 
between the metabolic profiles of survivors versus non-survivors in multivariate space (Figure 
6.5C1). The corresponding coefficient plot inferred that lysine, glycine, leucine, glutamine, 
phenylalanine, lactate, pyruvate, isobutyrate and creatine levels were negatively correlated 
with the survival rate. 
 
Figure 6.4: The metabolic changes identified by the O-PLS-DA models to be associated with APAP and 
non-APAP induced ALF, relative to healthy controls, are displayed above. Please see legend of Figure 
6.3. 
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Figure 6.5: The PLS models of the 30, 90 and 1 year survival rates with the 1H-NMR serum metabolic 
profiles of decompensated cirrhosis black; n = 32) and ACLF (green; n = 26) patients are shown. The 
scores plots (A1, B1 and C1) depict the first predictive component (Tcv) and the survivors vs. non-
survivors of ACLF (green) and decompensated cirrhosis (black) patients in multivariate space. 
Resonances pointing upwards reveal a positive correlation with survival and vice versa. Please note 
that there is extensive overlap of the dots in the scores plot. Please see the legend of Figure 6.2. 
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The 30 and 90 day PLS analysis had a common pattern of metabolites which were negatively 
associated with patient survival. A similar pattern was also predicted in the 1 year survival 
models excluding glutamine, glycine, phenylalanine, histidine and alanine which were not 
predicted to be negatively correlated with patient survival rate at this time-point. The 
equivalent PLS analysis which included the ALF patients also showed a similar pattern of 
negatively correlated metabolites. A summary of the results is presented in the form of a 
heatmap in Figure 6.6. Please note that the 1 year survival of some patients is still pending, 
therefore those patients were excluded prior to the PLS analysis. 
 
Figure 6.6: The metabolites associated with the 30 day, 90 day and 1 year survival rates of the 
decompensated cirrhosis and ACLF patients are shown. Please see legend of Figure 6.3. 
Clinical characteristics of the “cross liver” sample set 
The baseline characteristics and clinical data of the “cross liver” patients obtained on the day 
of admission are presented in Table 6.2. A statistical comparison (Kruskal-Wallis test coupled 
to Dunn’s multiple test correction) of the clinical data between the different disease groups 
found that the MELD and SOFA scores, as well as aspartate aminotransferase activity were 
statistically significantly higher in ALF patients, relative to decompensated cirrhosis patients 
(p < 0.05). The lack of any other differences between the baseline characteristics and clinical 
data of the different disease groups is potentially due to the very low sample numbers per 
group. 
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Parameter 
Disease 
Stable 
cirrhosis 
Decompensated 
cirrhosis 
Seronegative 
acute liver 
failure 
Acute on 
chronic liver 
failure 
Acute liver 
failure 
Number 1 4 1 3 5 
Age 57.0 
51.0 
(51.0 – 54.5) 
49.0 
49 
(33.5 – 55.0) 
27.0 
(23.0 – 28.0) 
Gender (% 
female) 
0.0 50.0 100.0 33.3 100.0 
BMI - 
25.1 
(23.6 – 26.7) 
20.1 
23.1 
(21.8 – 25.0) 
21 
(20.7 – 21.6) 
HE grade 0.0 
0.0 
(0 – 0.3) 
0 
1.0 
(0.5 – 2.5) 
4.0 
(3.0 - 4.0) 
Child Pugh 
score 
9.0 
9.0 
(7.5 – 10.3) 
12.0 
11.0 
(11.0 – 12.0) 
13.0 
(12.0 – 13.0) 
MELD score 20.8 
17.8 
(14.5 – 22.4) 
30.2 
34.3 
(30.4 – 35.0) 
40.0 
(40.0 – 40.0) 
SOFA score 5.0 
6.0 
(4.8 – 7.5) 
7.0 
12.0 
(10.0 – 15.5) 
16.0 
(14.0 – 16.0) 
Survival  
(%, 1 year) 
100.0 100.0 100.0 100.0 50.0* 
ALT (IU/L) - 
23.0 
(11.5 – 26.5) 
1138.0 
91.0 
(45.5 – 253.0) 
2071.00 
(316.3 - 4273.3) 
AST (IU/L) 118.0 
47.5 
(39.8 – 60.5) 
307.0 
206.0 
(204.0 – 380.5) 
3087.00 
(279.0 - 5216.0) 
GGT (IU/L) 116.0 
56 
(41.8 – 92.8) 
215.0 
 
37.0 
(32.0 – 113.0) 
32.0 
(31.0 – 36.0) 
Bilirubin (µM) 234.0 
111.0 
(32.8 – 206.8) 
335.0 
197.0 
(186.5 – 346.0) 
96.0 
(88.0 – 374.0) 
Serum 
creatinine 
(µM) 
89.0 
72.0 
(66.0 – 9.8) 
115.0 
134.0 
(109.5 – 150.0) 
61.0 
(56.0 – 112.0) 
Lactate (mM) 1.8 
1.6 
(1.3 – 2.0) 
1.9 
1.6 
(1.4 – 1.7) 
4.0 
(2.7 – 4.9) 
Urea (mM) 9.0 
5.1 
(4.6 – 14.1) 
4.8 
9.6 
(8.2 – 11.5) 
5.0 
(2.5 – 10.6) 
Haemoglobin 
(g/dL) 
133.0 
101.1 
(97.5 – 106.3) 
131 
93.0 
(86.0 - 95.0) 
111.0 
(88.0 – 121.0) 
WBC (10^9/L) 10.5 
5.7 
(3.8 – 6.0) 
10.6 
8.2 
(6.4 – 15.8) 
9.0 
(8.7 – 13.3) 
Table 6.2: Summary of baseline characteristics and clinical data of the patients subjected to a liver 
transplant. The median values and 25%/75% interquartile range values (in brackets) are shown for 
each parameter where applicable. Please note that the asterisk indicates that the one year survival 
rate of the ALF sub-group has not been finalized yet. Please see the legend of Table 6.1. 
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 “Cross liver” metabolic profiling 
The “cross liver” disease groups were grouped together to achieve sufficient sample numbers 
per blood vessel (total n = 14) before comparing the metabolite levels in the metabolic profiles 
of the hepatic portal vein, hepatic vein and peripheral artery by non-parametric repeated 
measures ANOVA (Friedman test coupled to Dunn’s multiple test correction). The analysis 
revealed that all changes of metabolite levels were relative to the hepatic vein. The levels of 
histidine, isoleucine, valine, alanine, and lactate were observed to be depleted in the artery 
relative to the hepatic vein at a statistically significant level (p < 0.05), while the levels of an 
unidentified DRC (aromatic resonances at δ 8.13) were elevated. The levels of glycine, 
glutamine, lysine, lactate and an N-acetyl resonance (resonance at δ 2.15) were observed to 
be statistically significantly depleted relative in the hepatic portal vein to the hepatic vein. 
The integrals of the statistically significant differences are presented in Figure 6.7 and 
summarized in Table 6.3. 
Metabolites 
Blood vessel (relative to hepatic vein)  
Artery Hepatic portal vein  
Histidine **   
Isoleucine **   
Valine ***   
Alanine **   
Glycine  *  
Glutamine  *  
Lysine  *  
Lactate *** ***  
N-acetyl group  * Depleted 
DRC  *  Elevated 
Table 6.3: Summary of the metabolic differences is presented above. The Friedman test coupled to 
Dunn’s multiple test correction was used to test for statistical significance. Statistical significance is 
shown by the asterisks *, ** and *** which indicate p < 0.05, p < 0.01 and p < 0.001 respectively. 
Elevated metabolites are shown in red and vice versa for blue. DRC – drug related compound. 
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Figure 6.7: The statistically significant metabolic differences between the peripheral artery, hepatic 
portal vein and hepatic vein are shown above. The Friedman test coupled to Dunn’s multiple test 
correction was used to test for statistical significance. Statistical significance is shown by the asterisks 
*, ** and *** which indicate p < 0.05, p < 0.01 and p < 0.001 respectively.  
“Cross liver” metabolite comparison of decompensated cirrhosis and ACLF 
relative to ALF in serum metabolic profiles 
The levels of metabolites in the decompensated cirrhosis and ACLF patients (n = 7), relative 
to the ALF patients (n = 5) were contrasted in the peripheral artery, hepatic portal vein and 
hepatic vein. Non-parametric univariate analysis (Mann-Whitney test) revealed that the levels 
of histidine, lysine, fumarate, phenylalanine and glycine were elevated in the peripheral 
artery of the ALF patients. The levels of histidine, lysine and phenylalanine were also higher 
in the hepatic portal vein of the ALF patients, while the levels of lysine and histidine were 
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higher in the hepatic vein of the ALF patients. The elevated levels of histidine in all three blood 
vessels of the ALF patients were the only statistically robust metabolic differences after 
Bonferonni multiple testing correction was applied. The integrals of the statistically significant 
endogenous metabolites are presented in Figure 6.8 and Table 6.4 presents a summary of the 
statistically significant results. 
Metabolites 
Blood vessel  
Artery 
Hepatic portal 
vein 
Hepatic vein 
 
Histidine ** ** **  
Lysine * * *  
Fumarate *    
Phenylalanine * *  Depleted 
Glycine *   Elevated 
Table 6.4: The summary of the statistically significant metabolic differences between the 
ACLF/decompensated cirrhosis patients, relative to the ALF patients, is shown above. Statistical 
significance was tested with the Mann-Whitney test coupled to the Bonferonni multiple correction 
test and is shown by the asterisks * and **, which indicate p < 0.05 and p < 0.01 respectively. Histidine 
was the only metabolic difference that was statistically robust after the Bonferonni test. 
It is important to note that the observed metabolic differences between the diseased states 
are a potential confounder of the metabolite level comparison between the three blood 
vessels (Table 6.3). The observed differences in the levels of lysine, histidine and glycine were 
also observed in the blood vessel comparison, indicating that the blood vessel differences 
might be driven by a specific disease state. However, the presence of unique metabolic 
differences between the disease states, such as fumarate and phenylalanine, which were not 
detected between the blood vessels suggest otherwise. Finally, it was not possible to compare 
the metabolite levels between the individual diseases in each blood vessel separately due to 
low sample numbers per disease group. 
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Figure 6.8: The statistically significantly different integrals of metabolites in the peripheral artery, 
hepatic portal vein and hepatic vein of ALF and decompensated cirrhosis/ACLF (grouped together) 
patients are shown above. Statistical significance was tested with the Mann-Whitney test coupled to 
the Bonferonni multiple correction test. Statistical significance is shown by the asterisks * and ** 
which indicate p < 0.05 and p < 0.01 respectively. Please note that only the perturbations in histidine 
levels were statistically robust after the application of the Bonferonni multiple correction test. 
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Discussion 
Pattern of metabolic perturbations associated with decompensated cirrhosis, 
ACLF and ALF 
The metabonomic comparison of the baseline 1H-NMR serum metabolic profiles of 
decompensated cirrhosis, ACLF and ALF patients relative to healthy controls compared and 
contrasted the metabolic perturbation pattern associated with each disease. The metabolic 
profiles of the decompensated cirrhosis patients were observed to have lower levels of the 
branched chain amino acids valine and isoleucine, relative to healthy controls. The underlying 
mechanism responsible for lower levels of branched chain amino acids is thought to be linked 
to insulin, which promotes their breakdown in order to conserve endocellular glucose stores 
(Leweling et al., 1996, Holecek et al., 1996). Furthermore, malnutrition, which is an important 
clinical complication in chronic liver disease patients, is also considered to be another 
contributing factor to the depletion of branched chain amino acids (Mezey, 1982, Silk, 1986) 
and therefore the administration of branched chain amino acids to chronic liver disease 
patients is considered beneficial (Khanna and Gopalan, 2007, Plauth and Schutz, 2011). 
Furthermore, the decompensated cirrhosis group also had elevated levels of the aromatic 
amino acids tyrosine and phenylalanine relative to control levels. Severe liver diseases such 
as decompensated cirrhosis and ALF are typically associated with high serum aromatic amino 
acid levels (tyrosine and phenylalanine) because of a disruption of the hepatic capability to 
breakdown these amino acids (Soeters and Fischer, 1976). A high serum ratio of aromatic 
amino acids (phenylalanine and tyrosine) to branched chain amino acids (also known as the 
Fischer ratio) is linked to a worse prognosis and development of encephalopathy (Soeters and 
Fischer, 1976, Campollo et al., 1992). Finally, these metabolic perturbations have also been 
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previously characterized by other metabonomic analyses in cirrhosis and ACLF (Qi et al., 2012, 
Gao et al., 2009, Amathieu et al., 2014). 
A similar metabolic pattern of perturbations was observed in the ACLF patients with the 
additional elevations of isobutyrate and pyruvate. Isobutyrate is a branched chain fatty acid 
which is an intermediate of amino acid metabolism and can be produced by bacterial 
metabolism in the gut (Cummings et al., 1987). Higher levels of pyruvate, a glycolysis end 
product, have been previously been reported to be associated to decompensated cirrhosis 
(Gao et al., 2009) and could be a cumulative result of gluconeogenesis inhibition (Record et 
al., 1975), up-regulation of anaerobic respiration and down-regulation of the Krebs cycle (Lee, 
1993, Jeppesen et al., 2013), all of which have been previously associated with severe liver 
dysfunction. The perturbation of isobutyrate and pyruvate in ACLF in contrast to 
decompensated cirrhosis, suggest that the acute deterioration of the liver is associated with 
energy metabolism dysfunction and a change in the role of gut microbial metabolism. A 
summary of the metabolite perturbations observed in decompensated cirrhosis and ACLF is 
provided in Figure 6.9. 
In contrast to ACLF and decompensated cirrhosis, the ALF metabolic profiles were 
characterized by additional metabolic perturbations, including higher levels of glutamine 
relative to healthy controls. Patients suffering from a severe liver disease, such as ALF, have 
a reduced capacity of urea synthesis which leads to an accumulation of the ammonium ion 
and a condition known as hyperammonemia (Olde Damink et al., 2002). This is a severe 
condition which can result to encephalopathy and therefore ammonia is removed from the 
system through other metabolic pathways, such as the synthesis of glutamine from glutamate 
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through the addition of a molecule of ammonia (Holecek, 2002). This would result in elevated 
levels of glutamine, as observed in the serum of the ALF patients relative to control.  
 
Figure 6.9: A summary of the proposed underlying mechanisms responsible for the observed 
metabolic effects is shown. Purple, orange and green metabolic changes were associated with 
decompensated cirrhosis, ACLF or both diseases respectively. Crossed-out metabolic pathways have 
been reported to be disrupted by ACLF and decompensated cirrhosis. BCAA – branched chain amino 
acids. DC – decompensated cirrhosis; ACLF – acute on chronic liver failure. 
ALF patients also had higher levels of methionine, a condition known as hypermethioninemia, 
which is considered to be positively correlated with disease severity (Kinsell et al., 1947, 
Marchesini et al., 1992). Higher levels of methionine are thought to be linked a disruption in 
the transsulfuration pathway and S-adenosylmethionine synthesis, as well as reduced blood 
clearance (Horowitz et al., 1981, Marchesini et al., 1992). The transsulfuration pathway is 
important for the regeneration of glutathione, which is depleted in severe liver diseases 
(Yamamoto et al., 1998), through the formation of cysteine from homocysteine (Figure 6.10). 
S-adenosylmethionine, an intermediate in the transsulfuration pathway, has been reported 
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to be depleted through the attenuation of its synthesis by S-adenosylmethionine synthetase 
(Cabrero et al., 1988, Martinez-Chantar et al., 2002) due to a modification of the enzyme’s 
sulfhydryl groups (Corrales et al., 1990).  
 
Figure 6:10: Inter-connectivity of methionine and hypotaurine metabolisms with cysteine metabolism. 
Other metabolic perturbations unique to ALF, relative to decompensated cirrhosis and ACLF, 
included higher levels of glycerol and acetate (by-products of lipolysis) (Lind and Lithell, 1994) 
which have been previously linked to cirrhosis and ACLF (Gao et al., 2009, Amathieu et al., 
2014). This observation suggests a greater degree of lipid catabolism in ALF, in comparison to 
decompensated cirrhosis and ACLF. Finally, higher levels of citrate were also observed which 
are considered to be a consequence of hepatic citrate metabolism dysfunction and the 
release of citrate by peripheral organs (Record et al., 1975, Apsner et al., 1997), revealing a 
greater hepatic dysfunction in ALF.  
The role of bacteria in the development and deterioration of liver conditions such as ALF and 
ACLF is also considered to be very important and is additionally further discussed later on. 
Higher levels of formate, which can be formed by bacteria through the metabolism of short 
chain fatty acids (Zhang et al., 2009), were observed in the 1H-NMR metabolic profiles of ALF 
patients, while elevated isobutyrate was also observed in the ACLF patients. Perturbed levels 
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of these metabolites could be indicative of a change in the composition of gut bacteria, 
bacterial translocation or bacterial overgrowth (Antharam et al., 2013). 
A summary of the metabolic effects induced by ALF in the serum is shown below in Figure 
6.11.  
 
Figure 6.11: A summary of the proposed underlying mechanisms responsible for the observed 
metabolic perturbations in ALF is shown. Crossed-out metabolic pathways have been reported to be 
disrupted by ALF. AA – aromatic amino acids.  
Overall the metabolic perturbations observed in ALF are indicative of a more severe metabolic 
imbalance and dysfunction, relative to decompensated cirrhosis and ACLF, where an 
enhanced disturbance in detoxification mechanisms and energy metabolism was observed. 
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Finally, there was no sign of depletion in the levels of branched chain amino acids in ACLF and 
ALF, which suggests that these conditions were more strongly associated with other 
metabolic perturbations.  
APAP-induced ALF 
APAP-induced ALF had more marked elevations in the levels of tyrosine, citrate and 
methionine, relative to the ALF metabolic profiles of other aetiologies. The relatively higher 
elevation of tyrosine and methionine levels could be reflective of a more advanced ALF 
condition in the APAP overdose patients. Higher levels of tyrosine and methionine are 
considered to be correlated with disease severity (Soeters and Fischer, 1976, Kinsell et al., 
1947, Marchesini et al., 1992). The higher  positive correlation observed in the citrate levels 
observed in the APAP-induced ALF subgroup could due to an enhanced disruption of citrate 
metabolism as a result of APAP-induced mitochondrial dysfunction (McGill et al., 2012a, 
Jaeschke et al., 2012), as well as the higher release of citrate by peripheral organs (Record et 
al., 1975).  
This comparative metabonomic analysis also found that the non-APAP induced ALF sub-group 
had a greater perturbation of serum lactate levels than the APAP-induced ALF sub-group. 
Higher levels of lactate lead to a condition known as lactic acidosis (Mizock and Falk, 1992, 
Bernal et al., 2002) but the exact underlying mechanism responsible for this condition in the 
liver has not yet been elucidated. Potential mechanisms include a pH-induced or hypoxia 
mediated up-regulation of glycolysis (Zborowska-Sluis and Dossetor, 1967), as well as a 
reduced lactate uptake by the liver (Record et al., 1981), but further investigations are 
required (Bernal et al., 2002). Since APAP is thought to cause the upregulation of glycolysis, 
as shown in Chapter 3, lactic acidosis would have been an expected clinical feature of APAP 
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overdose (Shah et al., 2011). It is however, important to clarify that a significant rise in lactate 
levels was predicted by the O-PLS-DA in the APAP-induced ALF patients but the associated 
correlation was lower than the arbitrary heatmap cut-off value (set at |0.5|). The difference 
observed in the correlation levels between the O-PLS-DA models of the two sub-groups could 
be due to differences in intra-group lactate level variance and it essentially reveals that lactate 
was more discriminatory in the non-APAP induced ALF model. 
Survival rate PLS analysis 
The PLS analysis revealed that glutamine, phenylalanine, pyruvate, isobutyrate, lactate, 
creatine and lysine levels were negatively correlated with short term survival rates (30 and 90 
day). As previously explained, higher levels of phenylalanine are potentially linked to impaired 
aromatic amino acid catabolism, higher levels of pyruvate and lactate are related to energetic 
stress, isobutyrate levels are linked to bacterial overgrowth and higher levels of glutamine 
could be indicative of a disruption in the urea cycle. Finally, even though the mechanism by 
which lysine is elevated in liver cirrhosis has not yet been identified, higher levels have been 
previously associated with a poor prognosis (Qi et al., 2012). 
Blood creatine was not previously detected to be associated with any of the three liver 
conditions relative to healthy controls, but it was discovered to be negatively correlated with 
short term survival as well. Creatine is found at high concentrations in muscles and can be 
produced de-novo in the pancreas, kidney and liver by a process which depends on the urea 
cycle; therefore a disruption in the urea cycle would affect the capability of the liver to 
synthesize creatine (Brosnan and Brosnan, 2010). Muscle wasting, a condition associated with 
a poor prognosis in liver cirrhosis (Tessari, 2003), could also lead to a reduced demand and 
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release of creatine and could therefore be responsible for the relatively higher levels of 
creatine observed in the patients who did not survive. 
The levels of these aforementioned metabolites are directly representative of the extent of 
disruption of endocellular processes caused by the deteriorating liver. A greater perturbation 
is indicative of a greater disruption of homeostasis and therefore reveals a greater extent of 
deterioration, which is ultimately linked to a lower patient survival rate. The levels of 
glutamine, glycine, phenylalanine, histidine and alanine were not predicted to be correlated 
as strongly with long term survival which is suggestive that they are not strong predictive 
markers of the long term state of liver deterioration. 
“Cross liver” metabonomic analysis 
The metabolic characterization and subsequent comparison of the metabolic profiles of the 
hepatic portal vein, hepatic vein and peripheral artery provided a rare insight into subtle 
hepatic metabolic phenotype differences. The metabolic compositions of the hepatic vein and 
peripheral artery reflect the metabolic state of the liver and system in general respectively, 
while the hepatic portal vein metabolic profiles show the contribution of the GI tract to the 
liver, which is thought to be vital in the development and deterioration of liver disease (Ilan, 
2012, Schnabl and Brenner, 2014). Intestinal overgrowth of bacteria, changes in bacterial 
populations (Wu et al., 2012, Bajaj et al., 2012) and a higher rate of bacterial translocation 
from the GI tract through the alteration of tight junctions between epithelial cells (Ilan, 2012), 
can lead to the development of sepsis (Wiest and Garcia-Tsao, 2005, Wiest et al., 2014). 
Furthermore, overgrowth and translocation of bacteria can cause an increase in the systemic 
levels of lipopolysaccharide (LPS) which can lead to an activation of proinflammatory 
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signalling cascades and a subsequent “over activation” of the immune system (Wang et al., 
2010). 
The majority of the metabolic differences of three blood vessels, comprised of elevations of 
metabolites in the hepatic vein relative to the peripheral artery and hepatic portal vein. The 
only exception was the higher levels of unidentified DRC molecules in the peripheral artery, 
relative to the hepatic vein, which could be due to the intra-venous administration of 
anaesthetic medication during the surgical operation. The fasted state of the patients during 
the procedure would have affected the metabolic profiles of the hepatic portal vein and could 
have contributed to the observed pattern of consistently higher levels of endogenous 
metabolites in the hepatic vein because of the absence of digestion products. Furthermore, 
the metabolic profiles of the hepatic vein reveal the immediate metabolic perturbations 
resulting from the metabolism of the most metabolically active organ which could also explain 
why it was consistently observed to have the highest concentration of metabolites relative to 
the other two blood vessels. Finally, it is also important to note the potential effect of the 
administered drugs which could further skew the observed effect. Noradrenaline, has been 
reported to cause a fasting effect (Froberg et al., 1975), while propofol (general anaesthetic) 
has been previously linked to affect the mitochondrial function (Cray et al., 1998, Fodale and 
La Monaca, 2008). 
The univariate analysis results revealed that the levels of valine and isoleucine were higher in 
the serum of the hepatic vein, when compared to the peripheral artery, and are therefore 
seemingly contradictory to the literature, which suggests that the metabolism of these 
compounds is impaired during disease. This discrepancy could be explained through the up-
regulation of protein breakdown as a response to a fasted state. Fasting would cause the 
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concomitant down-regulation of insulin and up-regulation of glucagon, which would result in 
hepatic protein catabolism and higher levels of various essential amino acids, such as lysine, 
histidine, valine and isoleucine (Bergamini et al., 1995, Tom and Nair, 2006, Holecek, 2002). 
Furthermore, an in-vivo rat study investigating the effect of SIRS on leucine metabolism found 
that serum branched chain amino acid levels were decreased, but there was an up-regulation 
of hepatic branched chain amino acid synthesis from the reamination of branched chain 
ketoacids and the majority of which was excreted by the liver, which would result to higher 
concentrations in the hepatic vein (Holecek et al., 1998). Therefore, there are many factors 
which can influence the levels of valine, leucine and isoleucine and it was not possible to 
estimate the contribution of each factor in the observed cumulative metabolic effect.  
Other elevated metabolites in the hepatic vein include lactate and glycine. Higher levels of 
lactate were observed relative to the hepatic portal vein and peripheral artery revealing lactic 
acidosis. Higher levels of glycine could be linked to a decrease in the expression of glycine N-
methyltransferase, an enzyme which converts glycine to sarcosine, and has been previously 
associated with the development of severe liver diseases such as hepatocarcinomas (Mato et 
al., 2008). Finally, N-acetyl and alanine resonances were also observed to be elevated in the 
hepatic vein relative to the peripheral artery and have been previously described as blood 
markers of liver deterioration in cirrhosis (Gao et al., 2009, Qi et al., 2012). However, the 
underlying mechanism has yet to be elucidated therefore the relevance of these results is 
unclear. A summary of the potential mechanisms affecting the levels of the discriminatory 
metabolites is shown in Figure 6.12. 
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Figure 6.12: A summary of the proposed underlying mechanisms responsible for the observed 
elevation of some metabolites in the hepatic vein is shown above. Please note that the depletion of 
S-adenosylmethionine (SAMe) was not observed in the metabonomic analysis. 
The univariate comparison of metabolites between decompensated cirrhosis and ACLF with 
ALF samples in the three blood vessels revealed that histidine and lysine were consistently 
elevated in the ALF patients in all blood vessels. The decompensated cirrhosis and ACLF 
patients were grouped together in order to increase group sample numbers and because they 
are similarly characterized by background cirrhosis (Jalan and Williams, 2002, Schuppan and 
Afdhal, 2008). The rise of histidine in the ALF patient blood vessels was the only statistically 
significant result after the Bonferonni multiple test correction and could be indicative of 
protein breakdown or a general dysfunction of liver metabolism. A previous investigation has 
reported higher levels of histidine in decompensated cirrhosis patients, relative to 
compensated cirrhosis, so it could be considered as a marker of liver deterioration and could 
therefore be even further elevated in ALF (Qi et al., 2012).  
Study limitations and future work 
Metabonomic studies of clinical samples usually have several limitations associated with a 
significant genetic variation between individuals, different causes of disease aetiology and 
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differences in background health/diet/environmental influences/microbiome, but low group 
numbers are especially problematic. The “cross liver” study was especaially affected by 
relatively low numbers since it comprised of only fourteen patients due to the difficulty of 
collecting such samples. Furthermore, the sample numbers per disease group were even 
smaller which rendered disease comparisons difficult and it was therefore necessary to group 
the ACLF and decompensated cirrhosis groups together in order to achieve greater sample 
numbers for that aspect of the analysis. Ideally, a comparison between each disease group 
and healthy controls would have facilitated the interpretation of the metabolic pattern 
associated with each disease but that was not possible due to the special circumstances under 
which these samples are collected. Another complication that affected the “cross liver” 
analysis was the general anaesthesia medication which led to extensive resonance overlap in 
the NMR spectra. The quantity and combination of medication varied in each patient, while 
it was also not possible to account for the potential metabolic effect of each xenobiotic. 
The metabonomic comparison of the metabolic profiles of the serum collected from patients 
on the day of hospital admission was also compromised by several factors. Firstly, the time 
period between the development of the disease and when the patient was admitted to 
hospital naturally varied and was not possible to account for. Secondly, the exact aetiology of 
disease development, such as the exact medication mixture in the development of DILI, was 
not determined for all cases. This was especially problematic in the separation of the APAP 
overdose patients who were usually affected by a condition induced by the overdose of APAP 
and a mixture of other medications, both at variable quantities, and it was therefore difficult 
to deduce the contribution of each xenobiotic to the subsequent development of ALF.  
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The proposed future work for this study involves suggested improvements of study design, 
including sample collection. The continuation of the “cross liver” study should include greater 
sample numbers which would improve statistical power and permit the direct comparison of 
different liver diseases. The analysis of liver tissue samples could also complement the serum 
metabolic profiles and reveal the correlation between the metabolic profiles of the liver and 
hepatic vein.  
In terms of obtaining a more comprehensive picture of the metabolome of decompensated 
cirrhosis, ACLF and ALF, existing literature suggests that bile acid (Neale et al., 1971, Barnes 
et al., 1975), lipid (McIntyre, 1978, Reddy and Rao, 2006) and carnitine (Krahenbuhl, 1996) 
levels are affected in liver disease and should therefore be investigated by a more targeted 
approach by UPLC-MS. The complementary use of metabolic profiles revealing different 
classes of metabolites will provide a better overview of the effect of the disease and would 
be beneficial in our attempts to further understanding the underlying mechanisms of disease 
development. Furthermore, future work should also involve the measurement of blood 
miRNA levels (Wang et al., 2012, Szabo and Bala, 2013) and bacterial DNA (Fujita, 2009, 
Garcia-Alvarez et al., 2012) in order to determine how these markers correlate with the 
metabolic profiles which could further facilitate the identification of the underlying 
mechanisms of disease development. Finally, the collection of serum samples at multiple 
time-points per person would permit the identification of metabolites associated with the 
improvement or deterioration of each disease. 
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Chapter 7: Concluding thoughts 
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Metabonomics can identify either diagnostic panels of metabolites or provide temporal 
mechanistic insight into a pathological state through the characterization of disease 
progression or patient recovery. In reality, metabonomics analyses have to deal with vast and 
complex data, the majority of which is often beyond our understanding. The development of 
chemometric tools is important for our efforts of dealing with such data but further analytical 
advancements are required before we can fully take advantage of this approach. It is also 
important to integrate the data derived from metabonomic analyses with that of other –
omics techniques, such as transcriptomics or proteomics. The observed metabolic 
perturbations are the consequence of a potentially large cascade of endocellular processes 
that can be further understood through integration with data representing the differential 
layers of biological organisation. The complementary use of different approaches will 
facilitate the mechanistic interpretation of the observed metabolic effects and will provide a 
better understanding of the biological processes associated with disease development. 
In-vivo pre-clinical investigations are very important in our efforts to improve our mechanistic 
understanding of a disease. In the case of DILI investigations, the ability to study hepatic tissue 
samples in particular is very valuable because it can reveal the immediate effect of drug 
toxicity on endocellular metabolism. The study presented in Chapter 3 presented novel 
metabolic evidence which corroborates previous investigations concerning APAP-induced 
mitochondrial dysfunction and oxidative stress. The metabonomic analysis revealed a 
previously uncharacterized broad metabolic effect in response to mitochondrial toxicity, 
including changes in energy metabolites and the up-regulation of glycolysis. These findings 
are directly translatable to clinical studies since they provide mechanistic clues of the 
endocellular consequences of energetic and oxidative stress. Furthermore, the study also 
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revealed that, even at a comparable dose, AMAP-induced toxicity would not have been 
mediated through mitochondrial dysfunction due to the lack of common effects with APAP. 
Chapter 5 presented the second in-vivo DILI study which demonstrated the risk of ADR 
occurrence in the presence of a background liver disease. The previously uncharacterized 
hepatic and systemic effect of MTX was studied in healthy rats, while the influence of a 
background disease on the metabolic and toxic effect of MTX was also demonstrated in the 
NASH model. MTX in the context of NASH resulted in increased liver toxicity and was 
associated with unique metabolic perturbations in comparison to MTX exposure in the 
healthy rat, including an elevation in phenylalanine levels in particular. This was an interesting 
result because phenylalanine metabolism has been extensively reported to be associated 
with the deterioration of liver function and was consistently observed to be elevated in the 
serum of the decompensated cirrhosis, ACLF and ALF patients, as shown in Chapter 6. Even 
though these studies involved different species and were performed under different 
conditions, the observed similarities reveal a certain degree of translatability inter-species 
conservation in some metabolic processes or disease related adaptations. 
In addition to the investigations of the metabolic perturbations associated with DILI, the study 
presented in Chapter 4 described the metabolic state of a chronic liver disease, NASH, as 
modelled by the MCD diet. This novel systemic characterization enables the contextualization 
of studies performed with this dietary model of NASH, while it also raised questions 
concerning other models which attempt to mimic the metabolic syndrome. Unfortunately it 
was not possible to conduct a metabonomic analysis of NASH clinical samples in order to 
further evaluate the strengths and weaknesses of the MCD diet as a model of clinical NASH. 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
204 
PhD thesis  Michael Kyriakides 
The three aforementioned in-vivo investigations focused at looking at different concepts of 
liver disease in animal models. Following these studies, the clinical study of Chapter 6 
provided the opportunity to characterize three important liver diseases (decompensated 
cirrhosis, ACLF and ALF), as well as to potentially identify common metabolic perturbations 
with the animal studies. The preliminary “cross liver” study provided the unique opportunity 
of studying the local metabolic environment of the liver in a diseased state, as mirrored by 
the surrounding blood vessels. It had however proven difficult to contextualize the results 
due to the limitations associated with the special circumstances under which these samples 
were collected, as well as the low numbers per group. The metabonomic analysis of the three 
liver conditions (decompensated cirrhosis, ACLF and ALF) revealed both common and unique 
metabolic perturbations associated with each disease and revealed that the acute nature of 
ALF was responsible for a greater disturbance of homeostasis. Furthermore, the novel 
metabolic characterization of the ACLF patients is a valuable step towards an improved 
biological classification of this condition, while it was also interesting to observe that the 
pattern of its metabolic perturbations lay in between that of decompensated cirrhosis and 
ALF. Finally, regressing against the different survival rates was of particular interest because 
it facilitated the identification of the mechanistic markers which are more closely associated 
with disease deterioration and patient survival. 
Even though the individual studies presented in this thesis involve different species, drugs, 
and sample collection time-points, and are therefore difficult to directly compare, useful 
conclusions concerning the translatability of in-vivo models to study hepatic dysfunction can 
still be drawn. At the beginning, any observed metabolic profile changes will be more closely 
associated with the toxicity mechanism of the inducer. Providing there is a large enough toxic 
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insult and sample collection was performed after a sufficient time period, the latter metabolic 
perturbations will be more closely associated with universal liver dysfunction. This hypothesis 
can be applied to the drug toxicity associated metabolic perturbations identified in the two 
in-vivo animal studies. The hepatic metabolic changes identified after APAP toxicity are more 
likely to be APAP specific due to the short time-period between dosage and sample collection 
(1, 3 and 6 hours), while the MTX-induced hepatic metabolic changes could be representative 
of markers of universal hepatic dysfunction due to the longer time period between dosage 
and sample collection (96 hours).  
Overall, the work presented in this thesis illustrates the power of a metabonomics approach 
in our efforts to improve our understanding of particular biological conditions such as liver 
diseases. Although a direct metabolic comparison of the clinical and animal studies was not 
entirely possible due to the focus of the latter on hepatic tissue analysis, the characterization 
of animal models of and DILI and NASH led to the elucidation of important mechanistic 
information concerning hepatic metabolism and adaptation to toxic insults, which was then 
applied to the clinical study. 
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Figure 8.1: TOCSY and COSY of urine spectra post-APAP administration. The TOCSY and COSY spectra 
are superimposed. The dotted lines reveal the correlated peaks, while the assignments of the 
metabolites can be seen in the 1D spectrum at the top. APAP-G – APAP glucuronide conjugate; APAP-
S – APAP sulphate conjugate; APAP-Cys – APAP cysteinyl conjugate; 
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Chapter 3 Chapter 4 & 5 Chapter 6 
Sample matrix 
NMR parameters Liver Urine Serum Liver Urine Faeces Serum 
standard 1D 
solvent 
suppression 
pulse 
sequence 
Scans 256 256 158 64 320 128 128 
Spectral width (kHz) 12 12 12 12 12 12 12 
Data-points (k) 64 64 64 64 64 64 74 
Acquisition time (s) 4.56 4.56 2.72 2.72 2.72 3.06 3.06 
Relaxation delay (s) 4.0 4.00 2.00 4.00 4.00 4.00 4.00 
Mixing time (ms) 100 100 100 100 100 100 100 
Line broadening (Hz) 0.3 
Temperature (K) 300 310 
 
CPMG 
Scans 
 
158 384 
 
128 128 
Spectral width (kHz) 12 12 12 12 
Data-points (k) 64 64 74 74 
Acquisition time (s) 2.72 2.72 3.06 3.06 
Relaxation delay (µs) 2.00 4.00 4.00 4.00 
CPMG delay (µs) 160 400  300 300 
Number of loops 200 300 128 128 
Line broadening (Hz) 0.3 
Temperature (K) 300 310 
Table 8.1: Summary of 1H-NMR experiment acquisition parameters. Please note that all experiments 
were performed at a frequency of 600 MHz.  
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1H shift (δ) multiplicity molecule Sample matrix Method of ID 
0.93 t isoleucine urine, liver, serum, faeces literature1 
0.95 d leucine urine, liver, serum, faeces spike-in 
0.97 d leucine urine, liver, serum, faeces spike-in 
0.97 d valine  urine, liver, serum, faeces spike-in 
1.00 d isoleucine urine, liver, serum, faeces literature1 
1.02 d valine urine, liver, serum, faeces spike-in 
1.06 t propionate faeces spike-in 
1.13 d isobutyrate serum literature1 
1.19 t ethanol urine software 
1.20 d 3-hydroxybutyrate urine, serum, liver literature1 
1.21 d fucose urine, serum, faeces spike-in 
1.25 d fucose urine, serum, faeces spike-in 
1.29 s 3-hydroxyisovalerate urine spike-in 
1.32 d threonine urine, liver, serum literature1 
1.33 d lactate urine, liver, serum, faeces literature1 
1.36 s 2-hydroxyisobutyrate urine spike-in 
1.48 d alanine urine, liver, serum, faeces literature1 
1.48 m lysine urine, serum, faeces spike-in 
1.66 m 5-aminovalerate faeces spike-in 
1.75 m lysine urine, serum, faeces spike-in 
1.78 m putrescine urine, faeces spike-in 
1.91 m lysine urine, serum, faeces spike-in 
1.92 s acetate urine, liver, serum, faeces literature1 
2.00 m glutamate urine, liver, serum, faeces literature1 
2.00 m proline serum spike-in 
2.01 s glycoprotein serum literature1 
2.07 m proline serum spike-in 
2.08 m glutamine urine, serum, liver, faeces literature1 
2.13 s methionine serum, faeces spike-in 
2.15 m glutamate urine, liver, serum, faeces iterature1 
2.17 m reduced glutathione liver spike-in 
2.19 q propionate faeces spike-in 
2.23 t 2-aminoadipate urine, faeces spike-in 
2.24 t 5-aminovalerate faeces spike-in 
2.31 m 3-hydroxybutyrate urine, serum, liver literature1 
2.35 m proline serum spike-in 
2.36 m glutamate urine, liver, serum, faeces literature1 
2.37 s pyruvate serum literature1 
2.38 m 3-hydroxybutyrate urine, serum, liver literature1 
2.39 s 3-hydroxyisovalerate urine spike-in 
2.40 s succinate urine, liver, serum, faeces spike-in 
2.41 m glutamine urine, serum, liver, faeces literature1 
2.52 d citrate urine, liver, serum, faeces literature1/software 
2.54 s methylamine urine, liver spike-in 
2.54 m oxidized glutathione liver database 
2.56 m reduced glutathione liver spike-in 
2.65 t methionine serum, faeces spike-in 
2.69 d citrate urine, liver, serum, faeces literature1/software 
2.71 s sarcosine urine, faeces spike-in 
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1H shift (δ) multiplicity molecule Sample matrix Method of ID 
2.72 d dimethylamine urine, liver spike-in 
2.83 s trimethylamine urine spike-in 
2.97 dd reduced glutathione liver spike-in 
2.98 m oxidized glutathione liver database 
3.01 t 5-aminovalerate faeces spike-in 
3.04 s creatine urine, liver, serum, faeces spike-in 
3.05 s creatinine urine, serum spike-in 
3.05 t lysine urine, serum, faeces spike-in 
3.06 t putrescine urine, faeces spike-in 
3.13 dd phenylalanine liver, serum spike-in 
3.21 s choline liver, serum, faeces spike-in 
3.22 s phosphocholine liver, serum, faeces spike-in 
3.23 s G-phosphocholine liver, serum, faeces software 
3.24 dd β-glucose urine, liver, serum, faeces literature1/software 
3.25 t taurine urine spike-in 
3.25 s betaine serum software/database 
3.26 s TMAO urine, liver spike-in 
3.29 dd maltose liver spike-in 
3.32 dd oxidized glutathione liver database 
3.35 m proline serum spike-in 
3.36 s methanol urine, liver, serum, faeces literature1/software 
3.40 t β-glucose urine, liver, serum, faeces literature1/software 
3.41 t taurine urine spike-in 
3.42 t α-glucose urine, liver, serum, faeces literature1/software 
3.45 m proline serum spike-in 
3.47 ddd β-glucose urine, liver, serum, faeces literature1/software 
3.48 t β-glucose urine, liver, serum, faeces literature1/software 
3.54 dd α-glucose urine, liver, serum, faeces literature1/software 
3.56 s glycine liver, serum, faeces spike-in 
3.57 m fructose faeces spike-in 
3.59 s sarcosine urine, faeces spike-in 
3.61 d threonine urine, liver, serum literature1 
3.65 q ethanol urine software 
3.69 s phenylacetylglycine urine spike-in 
3.70 m fructose faeces spike-in 
3.71 t α-glucose urine, liver, serum, faeces literature1/software 
3.72 dd α-glucose urine, liver, serum, faeces literature1/software 
3.75 m phenylacetylglycine urine spike-in 
3.76 m α-glucose urine, liver, serum, faeces literature1/software 
3.78 m glutathione liver spike-in 
3.79 s guanidinoacetate urine spike-in 
3.81 m fructose faeces spike-in 
3.86 ddd α-glucose urine, liver, serum, faeces literature1/software 
3.87 m α-glucose urine, liver, serum, faeces literature1/software 
3.90 s betaine serum software/database 
3.90 dd β-glucose urine, liver, serum, faeces literature1/software 
3.90 dd fructose faeces spike-in 
3.94 s creatine urine spike-in 
4.01 m fructose faeces spike-in 
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1H shift (δ) multiplicity molecule Sample matrix Method of ID 
4.01 dd AMP liver spike-in 
4.02 dd fructose faeces spike-in 
4.02 s creatinine urine, serum spike-in 
4.11 q lactate urine, liver, serum, faeces literature1/software 
4.11 dd glucosan urine, liver spike-in 
4.12 m proline serum spike-in 
4.12 m fructose faeces spike-in 
4.14 m formiminoglutamate liver, urine database 
4.25 t uridine liver spike-in 
4.26 m threonine liver, serum literature1/software 
4.29 m inosine liver spike-in 
4.34 s tartrate urine, liver, serum, faeces spike-in 
4.37 t uridine liver spike-in 
4.37 m AMP liver spike-in 
4.41 s 1,3-Dihydroxyacetone faeces software 
4.45 dd inosine liver spike-in 
4.51 dd AMP liver spike-in 
4.56 m reduced glutathione liver spike-in 
4.64 d β-glucose urine, liver, serum, faeces literature1/software 
4.64 m glucosan urine, liver spike-in 
4.67 d maltose liver spike-in 
5.19 d mannose liver spike-in 
5.23 d α-glucose urine, liver, serum, faeces literature1/software 
5.23 d maltose liver spike-in 
5.41 d maltose liver spike-in 
5.42  m glycogen liver software 
5.47 s glucosan urine, liver spike-in 
5.79 s urea urine software 
5.89 d uracil urine, liver, faeces spike-in 
5.90 d uridine liver spike-in 
5.93 d uridine liver spike-in 
6.11 d inosine liver spike-in 
6.15 d AMP liver spike-in 
6.39 d urocanate urine, liver, faeces literature2/software 
6.53 s fumarate urine, liver, serum, faeces software 
6.94 d tyrosine urine, liver, serum, faeces literature1/software 
7.08 s histidine liver, serum spike-n 
7.19 d tyrosine urine, liver, serum, faeces literature1/software 
7.20 ddd 3-indoxylsulphate urine spike-in 
7.28 ddd 3-indoxylsulphate urine spike-in 
7.34 m phenylalanine liver, serum, faeces spike-in 
7.36 s 3-indoxylsulphate urine spike-in 
7.37 m phenylacetylglycine urine spike-in 
7.38 m phenylalanine liver, serum, faeces spike-in 
7.42 m phenylacetylglycine urine spike-in 
7.44 m phenylalanine liver, serum, faeces spike-in 
7.50 d 3-indoxylsulphate urine spike-in 
7.56 t hippurate urine software 
7.60 d uracil urine, liver, faeces spike-in 
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1H shift (δ) multiplicity molecule Sample matrix Method of ID 
7.61 dd niacinamide liver software/database 
7.65 t hippurate urine software 
7.70 d 3-indoxylsulphate urine spike-in 
7.79 s histidine liver, serum spike-in 
7.80 s formiminoglutamate liver, urine database 
7.84 s formiminoglutamate liver, urine database 
7.84 d hippurate urine software 
7.89 d uridine liver spike-in 
8.02 s phenylacetylglycine urine spike-in 
8.20 t 1-methylnicotinamide urine software/database 
8.21 s hypoxanthine urine, liver, faeces spike-in 
8.22 s hypoxanthine urine, liver, faeces spike-in 
8.25 s inosine liver spike-in 
8.26 dd niacinamide liver software/database 
8.27 s AMP liver spike-in 
8.36 s inosine liver spike-in 
8.45 s formate urine, liver, serum, faeces literature1/software 
8.61 s AMP liver spike-in 
8.72 dd niacinamide liver software/database 
8.90 d 1-methylnicotinamide urine software/database 
8.95 s niacinamide liver software/database 
8.97 d 1-methylnicotinamide urine software/database 
9.28 s 1-methylnicotinamide urine software/database 
Table 8.2: The assigned compounds from the 1H-NMR spectra in all sample matrices, excluding APAP, 
AMAP and methotrexate resonances, are listed above. Bold letters reveal the sample matrix in which 
the spike-in experiment of the compound was performed. Please note that serum refers to both 
plasma and serum. The database used was the human metabolome database (www.hmdb.ca). The 
software used for Chenomx NMR Suite by Chenomx. AMP – adenosine monophosphate. TMAO – 
trimethylamine-N-oxide. s – singlet; d – doublet; ss – split singlet; d – double doublet; ddd – double 
double doublet; t- triplet; m – multiplet; ppm – parts per million. 
literature1 – Nicholson, J.K. and Foxall, P.J.D. (1995) 750 MHz 1H and 1H-13C NMR Spectroscopy of 
Human Blood Plasma. Analytical Chemistry 
literature2 – Saric, J., Wang, Y., Li, J. et al. (2007) Species Variation in the Fecal Metabolome Gives 
Insight into Differential Gastrointestinal Function. Journal of proteome research  
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Diet Comparison R2Y Q2Y 
Statistical 
significance 
Control 
0 vs 12 hours 0.9879 0.7963  p < 0.05 
0 vs 24 hours 0.9968 0.7222 p < 0.05 
0 vs 48 hours 0.8863 0.6925 p < 0.05 
MCD diet 
0 vs 12 hours 0.9371 0.6008 p > 0.05 
0 vs 24 hours 0.9508 0.7566 p < 0.05 
0 vs 48 hours 0.9469 0.8012 p < 0.05 
Table 8.3:  Summary of O-PLS-DA model parameters derived from the comparison of the metabolic 
profiles post MTX administration (100 mg/kg) at 12 hours, 24 hours and 48 hours, relative to the pre-
dose baseline (0 hour) in both diets. 
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Abstract  
Adverse drug reactions (ADRs) represent a significant clinical challenge with respect to patient 
morbidity and mortality. We investigated the hepatotoxicity and systems level metabolic 
phenotype of methotrexate (MTX) in the context of a prevalent liver disease; non-alcoholic 
steatohepatitis (NASH). An NMR spectroscopic based metabonomic approach was employed 
to analyze the metabolic consequences of MTX (0, 10, 40, 100 mg/kg) in urine and liver of 
healthy rats (control diet) and in a model of NASH (methionine-choline deficient diet).  
Histopathological analysis confirmed baseline (0 mg/kg) liver necrosis, liver inflammation and 
lipid accumulation in the NASH model. Administration of MTX (40 and 100 mg/kg) led to liver 
necrosis in the control cohort, whilst the NASH cohort also displayed biliary hyperplasia and 
liver fibrosis (100 mg/kg), providing evidence of the synergistic effect of MTX and NASH. The 
complementary hepatic and urinary metabolic phenotypes of the NASH model, at baseline, 
revealed perturbation of multiple metabolites associated with oxidative and energetic stress, 
and folate homeostasis. Administration of MTX in both diet cohorts showed dose-dependent 
metabolic consequences affecting gut microbial, energy, nucleobase, nucleoside and folate 
metabolism. Furthermore, a unique panel of metabolic changes reflective of the synergistic 
effect of MTX and NASH were identified, including the elevation of hepatic phenylalanine, 
urocanate, acetate and both urinary and hepatic formiminoglutamic acid. This systems level 
metabonomic analysis of the hepatotoxicity of MTX in the context of NASH provided novel 
mechanistic insight of potential wider clinical relevance for further understanding the role of 
liver pathology as a risk factor for ADRs. 
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Introduction 
Adverse drug reactions (ADRs) are estimated to be responsible for approximately 7 % of 
hospital admissions in the USA and UK (Lazarou et al., 1998;  Pirmohamed et al., 2004). 
Methotrexate (MTX), a folate analogue originally designed to inhibit dihydrofolate reductase 
for leukaemia treatment (Farber et al., 1956), can cause ADRs including nephrotoxicity and 
hepatotoxicity (West, 1997;  Widemann and Adamson, 2006). The risk of MTX-induced 
hepatotoxicity has been shown to increase in the presence of conditions such as diabetes 
mellitus or non-alcoholic steatohepatitis, with MTX alone also reported to cause a NASH-like 
injury (Langman et al., 2001;  Rosenberg et al., 2007). 
NASH is an advanced form of non-alcoholic fatty liver disease characterized by inflammation, 
macrovesicular steatosis, oxidative stress and insulin resistance (Brunt, 2004). It is estimated 
to affect approximately 12 % of USA adults, and approximately 20 % of NASH sufferers 
develop liver cirrhosis (Williams et al., 2011). The development of NASH is believed to involve 
a first hit, which is the result of imbalanced fat metabolism, and a second hit that involves 
metabolic and oxidative stress (Day and James, 1998). NASH has also been shown to influence 
hepatic drug metabolism by affecting CYP 450 enzyme activity (Fisher et al., 2009) and ATP-
binding cassette transporters (Hardwick et al., 2011) and could therefore increase the risk of 
ADR occurrence.  
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NASH is modelled in-vivo using several methods that include the use of specific diets or 
genetic models (Larter and Yeh, 2008). The methionine-choline deficient (MCD) diet has been 
widely employed to model NASH as it leads to a condition characterized by steatosis, 
mitochondrial dysfunction, inflammation and oxidative stress (Rinella et al., 2008;  Rizki et al., 
2006). Moreover, increased CYP 2E1 expression (Leclercq et al., 2000) and down-regulation 
of stearoyl-CoA desaturase-1 (SCD-1) (Rizki, et al., 2006) have also been reported, all of which 
reflect the clinical NASH phenotype. However, the MCD model fails to recapitulate the 
metabolic syndrome component of NASH as it does not induce obesity, insulin resistance or 
hyperglycaemia (Larter and Yeh, 2008). 
Metabonomics is a top-down untargeted systems approach that has been widely applied to 
characterize metabolic profiles of biofluids or tissues in disease states or in response to toxic 
interventions (Nicholson et al., 1999). Metabonomic analysis typically relies on nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry to generate high-resolution 
metabolic profiles. Statistical pattern recognition tools including principal components 
analysis (PCA) and orthogonal partial least squares discriminant analysis (O-PLS-DA) are 
applied to model the multivariate data (Fonville et al., 2010). Metabonomics has been 
previously employed to investigate the serum metabolic effects of MTX in rheumatoid 
arthritis patients, where endogenous metabolic markers capable of predicting response to 
MTX treatment were identified, which included amino acids, taurine and uracil  (Wang et al., 
2012). It has also been applied to characterize the clinical NASH lipidomic plasma signature 
(Puri et al., 2009), together with the serum metabolic phenotype of the MCD model of NASH 
in mice (Tanaka et al., 2012), which found disruption of phospholipid and bile acid 
homeostasis.  
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In the present study we employed a metabonomic approach to investigate the dose and time-
dependent systemic endogenous and xenobiotic metabolic phenotype of MTX in the urine 
and liver of healthy animals and in the context of NASH, as modelled by the MCD diet.  
Materials and Methods 
Animal Husbandry and MTX administration 
This study was approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Arizona, and is in accordance with NIH guidelines for the care and use of 
experimental animals. Male Sprague-Dawley rats (weighing 200-250 g prior to induction of 
NASH, ca. 8-weeks old, n = 44, Harlan Laboratories; Indianapolis, IN) were rats were split 
randomly into two groups (n = 22), which were either fed ad libitum a choline sufficient and 
amino-acid defined diet or the equivalent methionine-choline deficient diet (Dyets Inc; 
Bethlehem, PA), and tap water, for a period of 8 weeks. The rats were acclimated to 12-hour 
light and dark cycles in an AAALAC-accredited animal facility for one week prior to the 
initiation of experiments. The rats in each diet group were then randomly assigned to be 
administered 10, 40 and 100 mg/kg of MTX dissolved in 0.3 M sodium bicarbonate (Toronto 
Chemicals; Toronto, Canada) or vehicle (0.3 M sodium bicarbonate) via a single intra-
peritoneal injection. 
Sample collection 
Urine samples were collected at 0 hours (pre-dose, -6 to 0 hour collection; 0hr) and across 
the following time periods 6-12 (12hr), 18-24 (24hr) and 36-48 (48hr) hours post-dose via 
metabolism cages into 50 mL tubes on ice containing sodium azide (1 mL, 1% w/v in water). 
At each time-point the urine was transferred to a clean 50 mL conical tube and immediately 
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stored at -80 °C. At 96 hours post-dose (96hr), animals were euthanized via CO2 asphyxiation 
and livers were immediately snap-frozen in liquid nitrogen and stored at -80 °C until analysis.  
Liver histopathology and imaging 
Liver tissue for histomorphologic examination was taken from the medial lobe of each animal, 
fixed in 10% neutral-buffered formalin for 24 hours then placed in 70% ethanol until paraffin 
embedding and hematoxylin and eosin (H&E) staining. Masson Trichrome staining was also 
performed using the Masson Trichrome Kit from Sigma-Aldrich (St. Louis, MO) per 
manufacturer’s instructions. All slides were imaged with a Leica DM4000B microscope, 
DFC450 camera, and Leica Application Suite software (Leica Microsystems, Wetzlar, 
Germany). Sections were examined by light microscopy by a board certified blinded 
veterinary pathologist (Burkhardt et al., 2011). Liver necrosis, inflammation, fibrosis, lipid 
accumulation and biliary hyperplasia were scored. The scoring criteria were as follows: 0 (no 
lesion), 1 (<10% lesion; minimal), 2 (10-25 % lesion; mild), 3 (25-40 % lesion; moderate), 4 (40-
50 % lesion; marked) and 5 (>50 % lesion; severe). Representative histology images were 
acquired with a Leica DM4000B microscope, DFC450 camera, and Leica Application Suite 
software (Leica Microsystems; Wetzlar, Germany).  
Sample preparation and 1H-NMR spectroscopy of hepatic aqueous-soluble extracts 
Liver metabolite extraction and 1H-NMR spectroscopy of the hepatic aqueous-soluble extracts 
was performed as previously described (Beckonert et al., 2007). Briefly, liver tissue samples 
(mean 52.5 mg, STD ± 0.73) were added to acetonitrile/water (1.5 mL, 1:1). The samples were 
homogenized with zirconia beads in a homogenizer (Qiagen Tissue Lyser, Retsch GmBH, Haan, 
Germany) at 6500 Hz for two 45 seconds periods, with an intermediate 5 minute cooling 
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period on dry ice. The samples were then kept on ice for 45 minutes prior to centrifugation at 
17,000 g for 15 minutes at 4 oC. The supernatants were concentrated and dried overnight in 
a centrifugal evaporator (SpeedVac, Thermoscientific, Waltham, Massachusetts, United 
States) at room temperature. The dried supernatants were reconstituted in phosphate buffer 
(600 μL of a 0.2 M solution) containing 100% D2O, sodium azide (NaN3, 3 mM) and 3-
(trimethylsilyl)-[2,2,3,3-2H4]-propionic acid sodium salt (TSP; 1mM)), vortexed for 30 seconds 
and then centrifuged at 17,000 g for 15 minutes at 4 oC. The supernatants (550 μL) were 
transferred to 5 mm NMR tubes (NMR Precision tube 507-HP-7, Norell, Landisville, New 
Jersey, United States). NMR spectral data were acquired on a Bruker Avance-600 
spectrometer (Bruker Biopsin, Rheinstetten, Germany)  operating at 600.13 MHz (14.1 T) 1H 
frequency and at a temperature of 300 K, using a Bruker TXI probe and an automated sample 
handling carousel (Bruker). A standard one-dimensional solvent suppression pulse sequence 
was used to acquire the FID (relaxation delay - 90° pulse- 4 μs delay - 90° pulse - mixing time 
- 90° pulse - acquire FID) (Beckonert, et al., 2007). For each experiment, 64 transients were 
collected into 64k data points using a spectral width of 12 000 Hz, with a relaxation delay of 
4 seconds,  an acquisition time of 2.7 seconds and a mixing time of 100 ms. A Carr-Purcell-
Meiboom-Gill (CPMG) spin-echo pulse sequence, with a fixed spin-spin relaxation delay 2nτ 
of 240 ms (n = 300, τ = 400 μs), was also used to acquire the FID (relaxation delay - 90° pulse 
- (t - 180° - t)n – acquire FID).(Beckonert, et al., 2007) The CPMG pulse sequence is used to 
attenuate signals from large macromolecules such as lipids and proteins. 384 transients were 
collected into 64k data points using a spectral width of 12 000 Hz, with a relaxation delay of 
4 seconds and an acquisition time of 2.7 seconds. The D2O present in the buffer provided a 
field frequency lock, whilst TSP served as the chemical shift reference. A line-broadening 
factor of 0.3 Hz was applied to all spectra prior to Fourier Transformation (FT). 
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1H-NMR spectroscopy of urine 
1H-NMR spectroscopy of urine was performed as previously described (Beckonert, et al., 
2007). Briefly, urine was mixed with phosphate buffer (2:1; 600 μL total volume; 0.2 M as 
above) and vortexed for 1 minute. The samples were then centrifuged at 17,000 g for 15 
minutes at 4 oC. The resulting supernatants (550 μL) were then transferred to 5 mm NMR 
tubes (507-HP-7). NMR spectral data were acquired on a Bruker Avance-600 spectrometer 
operating at 600.13 MHz (14.1 T) 1H frequency and at a temperature of 300 K using a Bruker 
TXI probe and an automated sample handling carousel (Bruker). A standard one-dimensional 
solvent suppression pulse sequence was used to acquire the FID as described above. For each 
experiment, 320 transients were collected into 64k data points using a spectral width of 12 
000 Hz, with a relaxation delay of 4 seconds, an acquisition time of 2.7 seconds and mixing 
time of 100 ms. A line-broadening factor of 0.3 Hz was applied to all spectra prior to FT. 
The NMR spectra were initially processed using TopSpin 3.0 NMR software (Bruker), where 
they were manually phased, baseline adjusted and referenced to the TSP resonance at 0 ppm. 
Full-resolution NMR data were imported into MATLAB (R2012, Mathworks Inc, Natick, 
Massachusetts, United States), using an in-house script, for further processing. This included 
the removal of the TSP, MTX related and water resonances in the hepatic aqueous-soluble 
component spectra and the TSP, MTX related, urea and water resonances from the urine 
spectra. Probabilistic quotient normalization and spectral alignment were performed in each 
diet cohort dataset separately, apart from when performing the diet baseline comparison 
(using an in-house script developed by Dr. Kirill Veselkov) (Dieterle et al., 2006). Spectral 
assignments were performed using Statistical TOtal Correlation Spectroscopy (STOCSY) 
(Cloarec et al., 2005), spectral databases (in-house, Human Metabolome Database and 
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Biological Magnetic Resonance Bank), Chenomx NMR Suite (Chenomx, Edmonton, Alberta, 
Canada) and previously published assignments (Nicholson et al., 1995;  Waters et al., 2005). 
The assignments of uracil, hypoxanthine, inosine, uridine, maltose, mannose, choline, 
phosphocholine and glycine in the hepatic aqueous-soluble extracts and dimethylamine, 
methylamine, phenylacetylglycine, putrescine, 3-indoxylsulphate, tartrate, glucosan and 
taurine in the urine were confirmed by addition of the pure standard compounds. Please note 
that glutathione refers to total glutathione (sum of oxidized and reduced glutathione). The 
CPMG spectra of the hepatic aqueous-soluble extracts were acquired and modelled in order 
to minimize the contribution from lipids that arose from the MCD diet cohort. 
The urinary excretion of MTX following administration of 100 mg/kg in both diet cohorts was 
calculated by performing local baseline correction prior to integration of the MTX resonance 
at 8.63 ppm in TopSpin. The integral of TSP (which was of known concentration) and the 
excreted urine volumes per rat at each time-point were used to calculate the urinary amount 
of MTX (in micrograms). The results were verified independently by mass spectrometry (R > 
0.99). 
Statistical analysis  
Multivariate statistical tools were employed to analyze the 1H-NMR data from both the urine 
and hepatic extracts. PCA was initially applied to investigate the baseline diet comparison and 
the effect of MTX by characterizing the inherent clustering of the data and the presence of 
potential outliers (Fonville, et al., 2010). O-PLS-DA was subsequently performed, which 
discriminated the pre-dose and post-dose groups. O-PLS-DA filters out variation that is 
orthogonal to class membership and hence improves model interpretability. In order to avoid 
over-fitting the data, a 7-fold cross-validation was used and statistical parameters (R2Y and 
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Q2Y representing the goodness of fit and predictive ability) were calculated (Fonville, et al., 
2010). Permutation tests (n = 1000 permutations of the class membership) were also used to 
test the validity of each model. Heatmaps based on the Pearson correlation coefficient values 
(R) of the identified discriminatory resonances from the O-PLS-DA models were also 
constructed with a cut off R value of |0.5|. Prism 5.0 (Graphpad; La Jolla, CA) was used for 
non-parametric univariate analysis (Kruskal-Wallis with Dunn’s multiple correction test). A 
significance threshold value of p < 0.05 was set throughout. 
Results  
Liver histopathology 
Histopathological assessment of the control diet cohort revealed hepatic necrosis following 
MTX treatment (40 and 100 mg/kg; Figure 1A, Figure 2). In the control diet cohort, one animal 
also developed liver inflammation and another biliary hyperplasia following MTX treatment 
(40 and 100 mg/kg respectively, Figure 1C and 1E respectively). In contrast, the MCD diet 
cohort had a background (vehicle group) characterized by liver necrosis, lipid accumulation 
and liver inflammation (Figure 1A-C respectively, Figure 2). Following treatment of the MCD 
diet cohort with MTX (40 mg/kg), a statistically significant reduction in lipid accumulation and 
liver inflammation was observed (Figure 1B and 1C respectively, Figure 2). The MCD diet 
cohort rats also developed minimal liver fibrosis and mild biliary hyperplasia (black arrow, 
Figure 2) following treatment with the highest dose of MTX (100 mg/kg; Figure 1D and 1E 
respectively).  
Body weight was monitored at the beginning and end of the study. The average baseline 
weight of the control diet cohort animals was 390 g (± 57 g) whereas that of the MCD diet 
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cohort was 200 g (± 46 g). In the control diet cohort, weight loss was observed following 
administration of MTX with an average percentage weight loss of 7 %, 16 % and 26 % for the 
cohorts administered 10, 40 and 100 mg/kg MTX respectively. The MCD diet cohort also 
experienced weight loss with an average percentage weight loss of 18 %, 20 % and 20 % for 
the cohorts administered 10, 40 and 100 mg/kg MTX respectively (Figure S1).  
Hepatic and urinary metabolic phenotype of the NASH model (MCD diet cohort baseline) 
Pair-wise O-PLS-DA models were computed to identify the discriminatory metabolites 
between the two diet cohorts for each biological matrix. A robust O-PLS-DA model (Figure 3A; 
R2Y = 0.9913, Q2Y = 0.9315 and p = 0.009) revealed complete differentiation between the 
hepatic aqueous-soluble extract baseline (vehicle) metabolic profiles of the two diet cohorts 
as evidenced from the cross-validated predictive component of the scores plot (Tcv, cross-
validated predictive scores, Figure 3A1). The corresponding coefficient plot (Figure 3A2) 
showed that the metabolic signature of the MCD diet cohort included depleted levels of 
glucose, glycogen, mannose, maltose, glutathione, lactate, niacinamide, choline, 
phosphocholine, trimethylamine, tyrosine, 1-methylhistidine, inosine and uridine, together 
with elevated levels of glycine, lipids, fumarate and formiminoglutamic acid (FIGLU), with 
respect to the baseline control diet cohort.  
The O-PLS-DA model comparing the urinary baseline (pre-dose, 0hr) metabolic profiles of the 
two diet cohorts (Figure 3B; R2Y = 0.9519, Q2Y = 0.9040 and p = 0.001) indicated complete 
discrimination as evidenced from the scores plot (Tcv, Figure 3B1). The corresponding 
coefficient plot (Figure 3B2) indicated that, relative to the control diet, the MCD diet cohorts 
had elevated levels of citrate, urocanate, guanidinoacetate, methylamine, taurine, formate 
and FIGLU, and depleted levels of trimethylamine-N-oxide (TMAO) and dimethylamine. 
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Hepatic metabolic phenotype following MTX administration in the control diet cohort 
O-PLS-DA pair-wise models were employed to characterize the metabolic consequences of 
MTX administration on the hepatic aqueous-soluble extract metabolic profiles of the control 
diet cohort, relative to the vehicle cohort. The statistically robust O-PLS-DA model 
characterizing the effect of 100 mg/kg MTX administration (Figure 4A; R2Y = 0.9985, Q2Y = 
0.8485 and p = 0.009) achieved complete separation between the two groups in the scores 
plot (Tcv, Figure 4A1). The corresponding coefficient plot (Figure 4A2) found that the 
administration of 100 mg/kg MTX led to the depletion of lactate, glucose, maltose, mannose, 
glycogen, betaine, inosine, dimethylamine and glutathione. It also led to the concomitant rise 
in the levels of valine, glutamate, leucine, isoleucine, glycerophosphocholine, D-3-
hydroxybutyrate, formate, uracil, hypoxanthine, creatine and choline following MTX 
administration relative to the vehicle cohort.  
The O-PLS-DA models comparing the hepatic metabolic profiles of the vehicle with the 10 and 
40 mg/kg MTX administration groups (Figure S2) were statistically robust and identified a 
panel of discriminatory metabolites for each dose group, including an elevation of glutamate, 
valine, isoleucine, leucine and uracil, together with depletion of betaine, glutathione, 
dimethylamine, glycogen and glucose, relative to the control cohort. The scale of metabolic 
perturbations induced by MTX administration was progressive and was maximal at the 
highest dose (100 mg/kg). Hepatic changes reflective of a dose response included elevation 
of valine, isoleucine, leucine and depletion of glucose, dimethylamine, glycogen and 
glutathione. Furthermore, a number of unique metabolic changes were observed specific to 
the administration of 100 mg/kg MTX relative to the vehicle, which included increased levels 
of hypoxanthine, formate and creatine. A summary of the hepatic metabolic effects induced 
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by MTX administration at all doses in the control diet cohort is presented in Figure 5A in the 
form of a heatmap, which displays the given Pearson correlation coefficient (R) for each 
discriminatory metabolite obtained from the O-PLS-DA coefficients. 
Hepatic metabolic phenotype following MTX administration in the MCD diet cohort 
O-PLS-DA pair-wise models were computed to identify the discriminatory metabolites related 
to the effect of MTX administration at each dose level (10 mg/kg, 40 mg/kg and 100 mg/kg) 
relative to the vehicle group in the MCD diet cohort. The statistically robust O-PLS-DA model 
of the vehicle and 100 mg/kg MTX administration group of the MCD diet cohort (Figure 4B1; 
R2Y = 0.9957, Q2Y = 0.9155 and p = 0.001) differentiated completely between the two groups 
(Tcv, Figure 4B1). The corresponding coefficient plot (Figure 4B2) indicated that the 
administration of 100 mg/kg MTX led to the rise of the levels of uracil, fumarate, D-3-
hydroxybutyrate, valine, leucine, phenylalanine, glutamate, creatine, choline, urocanate, 
FIGLU, formate and niacinamide while inosine, phosphocholine, lactate, glycogen, maltose 
and glucose were depleted. The increase in fumarate was unique to the model characterizing 
the effect of high dose MTX administration (100 mg/kg) in the MCD diet cohort.  
Significant hepatic metabolic perturbations were also identified following administration of 
both 10 and 40 mg/kg MTX including the depletion of glucose, maltose and glycogen, and the 
elevation of leucine, isoleucine, glutamate, uracil and FIGLU. The scale of metabolic change 
was reflective of the dose response with respect to an increase in phenylalanine, acetate, 
glutamate and FIGLU and decrease in lactate levels. A summary of the hepatic metabolic 
effects induced by MTX administration at all doses for the MCD diet cohort is presented in 
Figure 5B. 
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Elevation of phenylalanine was also observed to be statistically significant in a regression 
analysis of the hepatic aqueous-soluble extract metabolic profiles from both diet cohorts with 
the biliary hyperplasia and fibrosis scores (R2Y = 0.5218, Q2Y = 0.2423 and p = 0.020, and R2Y 
= 0.5406, Q2Y = 0.2542 and p = 0.014 respectively). Integration of the phenylalanine 
resonance showed a statistically significant elevation following administration of 100 mg/kg 
MTX in the MCD diet cohort, when compared to the vehicle cohort, confirming the O-PLS 
regression results (p = 0.02; Figure S3).  
Urinary metabolic phenotype following MTX administration in the control diet 
The collection of urine samples at sequential time-points facilitated the characterization of 
the temporal metabolic consequences of MTX at each dose level for each diet cohort. O-PLS-
DA pair-wise models were constructed to investigate the differentiation of pre-dose urinary 
baseline metabolic profiles (0hr) and post-treatment metabolic profiles (12hr, 24hr and 48hr). 
The O-PLS-DA models that discriminated the metabolic effect of the 100 mg/kg dose of MTX 
from baseline had the highest statistical significance and greatest predictive ability and will 
be further discussed.  
The O-PLS-DA models characterizing the comparison of the urine pre-dose (0hr) metabolic 
profiles with each of the post-dose (100mg/kg MTX) time-points (12hr, 24hr and 48hr) in the 
control diet cohort showed that as time progressed, the effect of MTX became more 
pronounced (for a summary of the statistical parameters for each model please see Table S1). 
The statistically robust model comparing the metabolic profiles of the control diet 0hr and 
48hr time-points (Figure 6A; R2Y = 0.9859, Q2Y = 0.7608, p = 0.034) achieved complete 
separation between the two groups in the scores plot (Tcv; Figure 6A1). The corresponding 
coefficient plot (Figure 6A2) reported a depletion of alanine, methylamine, dimethylamine, 
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hippurate, TMAO and 3-indoxylsulphate, together with an elevation of the levels of succinate, 
creatine, phenylacetylglycine and formate.  
Urinary metabolic phenotype following MTX administration in the MCD diet 
The corresponding urinary analysis of the metabolic effect of MTX administration (100 mg/kg) 
in the MCD diet cohort also indicated a time-dependent progressive effect of MTX that was 
maximal at 48hr post-treatment (Table S1 provides a summary of the statistical parameters 
of the models). The statistically robust model comparing the metabolic profiles of the MCD 
diet 0hr and 48hr time-points (Figure 6B; R2Y = 0.9985, Q2Y = 0.8485, p = 0.001) achieved 
complete differentiation between the two groups in the scores plot (Tcv, Figure 6B1). The 
coefficient plot (Figure 6B2) indicated that MTX administration led to an elevation in the levels 
of FIGLU and formate, and the depletion of methylamine, alanine and hippurate.  
Following administration of MTX (100 mg/kg) the urinary metabolic phenotype showed a 
progressive depletion from 12hr to 48hr of methylamine and hippurate and elevation of 
formate and FIGLU. The depletion of alanine at 48hr was a unique metabolic effect that was 
specific for this time-point. Depletions in the levels of 3-indoxylsulphate and 
phenylacetylglycine were also observed but these were restricted to the 24hr time-point, 
whilst TMAO was depleted in both 12hr and 24hr but had returned to baseline levels by 48hr. 
With respect to the models characterizing the metabolic effect of the 10 mg/kg and 40 mg/kg 
doses of MTX, elevation of FIGLU and formate was also observed at 48hr post-dose. However, 
at that time-point, both of the lower doses of MTX also led to the depletion of methylamine 
and 3-indoxylsulphate, together with the elevation of dimethylamine, all of which were not 
observed at the corresponding time-point after 100 mg/kg MTX administration. 
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The comparison of the effects of administration of MTX (100 mg/kg) in the two diet cohorts 
showed several diet specific MTX-induced metabolic effects. At 48hr post-dose, elevations of 
phenylacetylglycine, creatine, citrate and succinate were specific only to the control diet 
cohort, whilst elevated levels of FIGLU were specific only to the MCD diet cohort (Figure 7 
illustrates a heatmap summary of the urinary metabolic effect of MTX administration 
(100mg/kg) in both diet cohorts).  
Finally, temporal urinary levels of the MTX parent compound following administration of the 
100 mg/kg dose were also compared between the two diet cohorts at the 12hr, 24hr and 48hr 
time-points. The levels of MTX were greater in the control diet cohort than the MCD cohort 
at all time-points, reaching statistical significance at the 48hr time-point (p = 0.0025, Figure 
S4). 
Discussion 
Characterization of the MCD diet model of NASH 
The MCD diet had liver histopathology consistent with a phenotype reflective of clinical NASH 
(Brunt, 2004). Metabonomic analysis of the hepatic extracts and urine from the MCD diet 
cohort indicated a general impairment of energy and choline metabolism, coupled with 
glutathione depletion. The depletion of energy metabolites such as hepatic glucose and 
glycogen, relative to the control diet cohort, is indicative of energetic stress and could be 
related to the previously reported NASH-induced mitochondrial stress (Perez-Carreras et al., 
2003) or the inhibition of stearoyl-CoA desaturase-1 (Rizki, et al., 2006). Glutathione depletion 
is a marker of oxidative stress which is also characteristic of the NASH background (Merrell 
and Cherrington, 2011). Its hepatic depletion was also potentially exacerbated by the 
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methionine deficient nature of the MCD diet. Finally, the choline deficient nature of the diet 
was also likely to be directly linked to the depletion of choline related metabolites such as 
hepatic trimethylamine and choline and urinary TMAO. 
The choline and methionine deficient nature of this dietary model would have also directly 
impaired the folate cycle and one-carbon metabolism (Figure 8). Impairment of the folate 
cycle would lead to reduced tetrahydrofolate (THF) production, which may explain the 
observed accumulation of urinary and hepatic FIGLU and urocanate and urinary formate. THF 
is required for the conversion of FIGLU to glutamate and FIGLU is a previously described 
urinary marker of folate deficiency (Rabinowitz and Tabor, 1958). Accumulation of urinary 
formate would arise from THF depletion and the subsequent impairment of formyl-THF 
production. Finally, the depleted levels of hepatic inosine and the elevated levels of hepatic 
glycine and urinary guanidinoacetate (a glycine metabolite) may also be linked to a general 
inhibition of the folate cycle (Fowler, 2001). 
It is important to be aware of the limitations associated with the MCD diet as a model of 
NASH. Creation of a model that accurately reflects the clinical condition of NASH has proven 
difficult, since it would require replication of both the liver pathology and the systemic 
metabolic environment (Larter and Yeh, 2008). The MCD diet is believed to induce 
steatohepatitis and oxidative stress through the inhibition of phosphatidylcholine synthesis 
and impairment of hepatic lipid transport (Rinella, et al., 2008), but it is not thought to be an 
accurate reflection of the metabolic syndrome component of NASH since it does not induce 
obesity, insulin resistance or hyperglycaemia. Furthermore, the MCD diet induces significant 
weight loss as was also observed in our study (Larter and Yeh, 2008;  Rinella, et al., 2008). 
Effect of MTX in the context of the control diet cohort 
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Minimal liver necrosis was observed following administration of MTX (40 and 100 mg/kg) in 
the control diet cohort. Metabonomic analysis showed dose-related metabolic consequences 
in both sample matrices, together with a temporal effect in the case of urinary metabolic 
profiles.  
The MTX-induced elevation of the levels of hepatic uracil, is potentially due to the inhibition 
of thymidylate synthetase, while the observed depletion of hepatic inosine could result from 
the inhibition of phosphoribosylaminoimidazolecarboxamide formyltransferase (Genestier et 
al., 2000). MTX could also affect the levels of nucleobases and nucleosides indirectly through 
the disruption of the folate cycle and its inhibition of THF formation, which could have other 
down-stream consequences such as the observed elevation of urinary formate.  
The observed effect of MTX, consistent at all doses, on hepatic energy metabolism, including 
the depletion of lactate, glucose and glycogen could be attributed to the previously reported 
inhibition of oxidative phosphorylation, which would lead to a higher utilization of glucose 
through other pathways (Yamamoto et al., 1988). Furthermore, the depletion of the 
aforementioned metabolites could lead to lipid breakdown, as indicated by the elevated 
levels of hepatic D-3-hydroxybutyrate. This observed disturbance of energy metabolism could 
also be linked to a reduced caloric intake through the previously reported MTX-induced 
weight loss, which is linked to a disruption of gut absorption and mucositis (Naruhashi et al., 
2000). A reduction of caloric intake could also be linked to the observed depletion of hepatic 
glutathione (Szkudelski et al., 2004) and choline related moieties, such as hepatic 
phosphocholine and dimethylamine. However, a previous metabolic profiling investigation of 
caloric restriction observed a different panel of discriminatory urinary metabolites to that of 
our investigation (Connor et al., 2004). Nevertheless, it is recommended that future studies 
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should also record food consumption and employ an experimental design that would 
incorporate a pair feeding system in order to be able to easily identify any metabolic changes 
linked to fasting. 
Effect of MTX in the context of the NASH background (MCD diet model) 
We hypothesized that the presence of the NASH background, which can induce changes in 
drug metabolizing enzymes and hepatic transporters (Fisher, et al., 2009;  Hardwick, et al., 
2011), would alter MTX-induced metabolic consequences and toxic outcome. The 
administration of MTX (40 mg/kg) in the context of NASH resulted in a statistically significant 
histomorphologic reduction of lipid accumulation and inflammation. These observed 
reductions are suggestive of a protective effect due to the anti-inflammatory properties of 
MTX, while MTX has previously been reported to affect cholesterol transport  (Coomes et al., 
2011). However, administration of the highest dose caused minimal liver fibrosis and biliary 
hyperplasia suggesting enhanced toxicity of MTX in the context of NASH. 
Metabonomic analysis of the hepatic aqueous-soluble extracts found that, in part, the 
metabolic effect of MTX in the NASH model had a similar progressive pattern to the control 
diet cohort. Interestingly, MTX-induced metabolic effects specific to the NASH model were 
also observed, suggesting that the NASH baseline influenced the metabolic consequences of 
MTX administration. These included increased levels of hepatic FIGLU, urocanate, 
phenylalanine, acetate, niacinamide and fumarate. The progressive dose-dependent 
elevations of fumarate, phenylalanine and niacinamide did not follow the same pattern as the 
observed weight loss in the MCD diet cohort and therefore are more likely to be 
mechanistically indicative of MTX toxicity and not a direct consequence of either MTX or 
MCD-diet induced weight loss. The elevations of hepatic metabolites associated with the 
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folate cycle, such as FIGLU and urocanate, following MTX administration in the NASH model 
are signs of a significant inhibition of the folate cycle, greater than that observed in the MCD 
diet at baseline and greater than that observed after MTX administration in the control diet 
cohort. This combined effect of MTX and NASH, coupled to previous clinical reports of NASH 
induced methionine cycle disruption triggered through glutathione depletion (Kalhan et al., 
2011), suggest a clinically relevant synergistic effect of NASH and MTX on folate metabolism 
(Figure 8). 
Hepatic phenylalanine was also identified by regression analyses as the sole endogenous 
metabolite associated with the development of biliary hyperplasia and liver fibrosis. Levels of 
hepatic phenylalanine are used as a liver function test because they are related to the activity 
of the phenylalanine hydroxylase enzyme, an important enzyme for phenylalanine 
degradation (Burke et al., 1997). Higher levels of serum phenylalanine have been previously 
reported clinically following treatment with MTX and were linked to the inhibition of 
dihydropteridine reductase (Hilton et al., 1989). However, the observed elevation of hepatic 
phenylalanine in our study is likely to be influenced by additional mechanisms since the levels 
of hepatic tyrosine remained unperturbed. Furthermore the levels of urinary 
phenylacetylglycine following administration of 100 mg/kg MTX in the MCD diet cohort were 
largerly unperturbed during the time-course of the study. 
The parallel study of the xenobiotic metabolic profile enabled characterization of the effect 
of NASH on the disposition of MTX and showed increased urinary excretion of MTX in the 
control cohort at the 12hr, 24hr and 48hr time-points. This is explained by the greater urinary 
excretion of MTX that was observed for the MCD diet cohort relative to the control diet cohort 
within the first six hours post-dose (Hardwick et al., recently submitted for publication). The 
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observed higher early urinary excretion of MTX in the MCD diet cohort could be due to the 
reported downregulation of canalicular transporters in the NASH model, and the relatively 
lower quantity of MTX in the feces, which indicate a shift in the excretion pathway of MTX, 
towards urinary excretion (Hardwick et al., recently submitted for publication).  Furthermore, 
a previous study has also reported the down–regulation of uptake transporter genes in 
disease–compromised livers as a hepatoprotective mechanism, indicating another potential 
mechanism behind the observed difference of urinary MTX excretion (Lake et al., 2011). 
Effect of MTX on gut microbial co-metabolites 
High dose MTX can cause intestinal toxicity and it has also been shown to affect the intestinal 
microbial composition (Naruhashi, et al., 2000). Both MTX (100 mg/kg) diet cohorts displayed 
mild inflammation and minimal apoptosis in the small intestine (Hardwick et al., recently 
submitted for publication). Metabonomic analysis indicated that gut microbial co-
metabolites, including urinary methylamine, TMAO and 3-indoxylsulphate, were depleted in 
both diet cohorts following administration of 100 mg/kg MTX suggesting a potential 
perturbation of the gut microfloral balance (Nicholson et al., 2012). 
Summary 
This systems level data analysis provided enhanced mechanistic phenotyping of a widely used 
model of NASH, revealing a metabolic phenotype characterized by energetic and oxidative 
stress, and further contextualized its application in experimental studies. Metabolic profiling 
of the hepatic and urinary dose and temporal response to MTX administration revealed a 
wide panel of metabolic consequences that provided novel mechanistic insight. Finally, the 
administration of MTX (100 mg/kg) in the context of NASH led to enhanced hepatotoxicity 
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and the identification of a unique panel of metabolites which reflected this synergistic effect, 
providing mechanistic insight of potential translatable relevance for the clinical setting.  
Supplementary data description 
The figures displaying the percentage weight loss and phenylalanine integrals of each 
diet/dose cohort (Figure S1 and Figure S3), the O-PLS-DA models of the hepatic aqueous-
soluble extract metabolic profiles after the administration of 10 and 40 mg/kg MTX in both 
diet cohorts (Figure S2) and the temporal quantity of urinary excreted MTX after the 
administration of 100 mg/kg MTX are provided in the supplementary data (Figure S4). 
Furthermore, a summary of the statistical parameters of the urine O-PLS-DA models of the 
metabolic effects after the administration of 100 mg/kg MTX in both diet cohorts is also 
provided (Table S1). 
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Figures 
 
Figure 1: Histopathology scores representing liver necrosis (A), lipid accumulation (B), liver 
inflammation (C), liver fibrosis (D) and biliary hyperplasia (E) (mean and standard deviation) following 
administration of MTX (vehicle, 10, 40 and 100 mg/kg) in both the control and MCD diet cohorts. 
Statistical significance is indicated by one or two asterisks representing p < 0.05 and p < 0.01 
respectively. There are five animals per group apart from the 100 mg/kg dose in the MCD diet cohort 
which has six. The scoring criteria are: 0 = no significant lesions, 1 = minimal, 2 = mild, 3 = moderate, 
4 = marked and 5 = severe. Veh – Vehicle 
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Figure 2: (A) Representative histology images of H&E-stained control and MCD liver sections following 
vehicle or 10, 40, or 100 mg/kg MTX and (B) Masson Trichrome stained liver sections following 100 
mg/kg administration in both diets (20X magnification). White and cyan arrows indicate inflammation 
and single cell necrosis respectively in the MCD diet cohort baseline. Black and red arrows indicate 
biliary hyperplasia and liver fibrosis respectively in the MCD cohort following administration of MTX 
(100 mg/kg). 
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Figure 3: Hepatic aqueous-soluble extracts (A1, A2) and urinary (B1, B2) O-PLS-DA models 
distinguishing between the baseline of the control and MCD diet cohort. The scores plots (A1 and B1) 
depict the separation of the MCD (red; n = 5 in the liver and n = 20 in the urine) and control diet cohort 
(black; n = 5 in the liver and n = 20 in the urine) in multivariate space. Tcv is the predictive component, 
whilst TYosc is the orthogonal component. The loadings coefficient plots (A2 and B2) illustrate the 
discriminatory spectral resonances with the height of spectral peaks representing covariance. The 
color-scale corresponds to the coefficient of determination (R2) ranging from low (0; blue) to high (red; 
1). Resonances pointing upwards indicate an increase in that specific resonance in the control cohort 
and vice versa. FIGLU – formiminoglutamic acid; Choline-NMe3 – NMe3 resonance of choline, 
phosphocholines and glycerophosphocholines; TMAO – trimethylamine-N-oxide.  
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Figure 4: Hepatic extract O-PLS-DA models comparing the vehicle cohorts and 100 mg/kg MTX 
administration cohorts in the control diet (A1 and A2; n = 5 for the vehicle group and n = 5 for the MTX 
dosed group) and MCD diet (B1 and B2; n = 5 for the vehicle group and n = 6 for the MTX doses group). 
The scores plots (A1 and B1) depict the separation of the MTX dose (red) and vehicle (black) cohorts 
in multivariate space. See Legend for Figure 3. Asterisks - formiminoglutamic acid (FIGLU); DMA – 
dimethylamine; D-3-HB – D-3-hydroxybutyrate.  
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Figure 5: Heatmap describing the hepatic metabolic effects of MTX administration in the control diet 
(A) and MCD diet (B). The heatmap was constructed using the maximum Pearson correlation 
coefficient values (R) for each metabolite from the hepatic extract O-PLS-DA models distinguishing the 
metabolic profiles of MTX treated (10, 40, 100 mg/kg) and the vehicle cohort, in the control diet (A) 
and MCD diet (B). The scale shown on the right has a range from -1 (perfect negative correlation; blue 
colour) to 1 perfect positive correlation; red colour), whilst a cut-off value of |0.5| was set. Key: see 
legend above.  
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Figure 6: Urinary O-PLS-DA models comparing the pre-dose time point and the 48 hour post-dose 
time-point after 100 mg/kg MTX administration in the normal diet (A1 and A2; n = 4 at 0hr and n = 5 
at 48hr) and MCD diet (B1 and B2; n = 6 at 0hr and n = 7 at 48hr). See Legend for Figure 3.  
 
 
 
 
Metabolic phenotyping applied to pre-clinical drug induced liver injury and acute liver failure 
273 
PhD thesis  Michael Kyriakides 
 
Figure 7: Heatmap describing the urinary metabolic effects of MTX administration in the control diet 
(A) and MCD diet (B) . Based on O-PLS-DA models that discriminated between the metabolic profiles 
of the post-dose time-points (12hr, 24hr and 48hr) of MTX administration (100 mg/kg) and the pre-
dose time-point (0hr), in both diets. Phenylacetyl-G – phenylacetylglycine.  
 
Figure 8: A simplified diagrammatic representation of the interaction of the methionine cycle (blue), 
folate cycle (black), choline catabolism (red) and histidine catabolism (orange) pathways, are depicted 
above. (1) reveals where the choline catabolism pathway interacts with the methionine cycle, (2) 
indicates the point at which the methionine and folate cycles interact, (3) shows the metabolic 
reaction inhibited by methotrexate and (4) indicates how the folate cycle can directly influence the 
histidine catabolism pathway. THF; tetrahydroflate; DHF – dihydrofolate; FIGLU – formiminoglutamic 
acid. 
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Supplementary information 
 
Supplementary figure 1: Average percentage body weight loss and standard deviation (as calculated 
from the body weights at the beginning and end of the study) of all dose groups in both diet groups 
is depicted above. Statistical significant at p < 0.05 and p < 0.01 are indicated by a single asterisk (*) 
and double asterisk (**) respectively. The vehicle and three doses of MTX are indicated at the 
horizontal axis (Veh, 10, 40 and 100). Veh – Vehicle 
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Supplementary figure 2: Aqueous liver extract O-PLS-DA discriminating the vehicle cohort and MTX 
administration (10 mg/kg) in the normal diet (A1 and A2) and MCD diet (C1 and C2), and between the 
vehicle cohort and 40 mg/kg MTX administration cohorts in the normal diet (B1 and B2) and MCD diet 
(D1 and D2). The scores plots (A1, B1, C1 and D1) depict the separation of the MTX dose (red) and 
vehicle (black) cohorts in multivariate space and the loadings coefficient plots (A2, B2, C2 and D2) 
illustrate the spectral comparison between control and treated. FIGLU – formiminoglutamic acid; DMA 
– dimethylamine; D-3-HB - D-3-Hydroxybutyrate. 
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Supplementary figure 3: Hepatic extract phenylalanine relative integrals of all the dosage groups in 
both diet groups. Please note that the integrals cannot be directly compared between the two diet 
cohorts due to individual pre-processing of each diet cohort which included normalisation. Statistical 
significance was set at p < 0.05 and is indicated by the asterisk. 
 
 
Supplementary figure 4: Quantity of urinary MTX (µg) following the administration of 100 mg/kg MTX 
at 6-12 hours, 18-24 hours and 36-48 hours. Statistical significance is indicated by the asterisks, 
indicating p < 0.01.  
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MTX dose Comparison (model) R2Y Q2Y Statistical sig. 
100 mg/kg 
0 vs. 12 hours (control 
diet) 
0.9011 0.5907 p < 0.05 
0 vs. 24 hours (control 
diet) 
0.9404 0.7675 p < 0.05 
0 vs. 48 hours (control 
diet) 
0.9344 0.8225 p < 0.05 
100 mg/kg 
0 vs. 12 hours (MCD diet) 0.9833 0.8135 p < 0.05 
0 vs. 24 hours (MCD diet) 0.9958 0.7317 p < 0.05 
0 vs. 48 hours (MCD diet) 0.9859 0.7602 p < 0.05 
Supplementary table 1: Summary of urinary O-PLS-DA models following administration of MTX (100 
mg/kg) in both diet cohorts at the defined time collection periods.  
 
